

[illegible]

[illegible]

securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company's common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the "SEC") on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the offering, before deducting the Placement Agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, was approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. 8 Table of Contents Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services. The Board recently authorized the restoration of the Company 401k match effective October 1, 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the "Series I Warrants") and Series II common stock purchase warrants (the "Series II Warrants") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. The Company believes that its existing capital resources will be sufficient to support its operating plan through May 31, 2025. However, the Company will seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof. There can be no assurance we will be successful in raising additional capital. Revenue Recognition: The Company recognizes revenue in accordance with Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 "Revenue Recognition below for additional disclosures. For the three months ended September 30, 2024, two customers represented 12% and 10% of net sales. For the nine months ended September 30, 2024, one customer represented 16% of net sales. For the three months ended September 30, 2023, two customers represented 21% and 11% of net sales. For the nine months ended September 30, 2023, two customers each represented 17% and 12% of net sales. Accounts Receivable: Accounts receivables are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management's evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers' financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date, the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of September 30, 2024, or December 31, 2023. As of September 30, 2024, two customers represented 16% and 11% of the accounts receivable balance. As of December 31, 2023, two customers represented 14% and 15% of the total accounts receivable balance. 9 Table of Contents Inventories: Inventories represent finished goods purchased from the Company's suppliers and are recorded as the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company's production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. Inventories consisted of the following: (in thousands) As of September 30, 2024 As of December 31, 2023 Finished Goods \$ 538.4 \$ 393.4 Work in Process \$ 220.4 \$ 207.4 Raw Materials \$ 1,150.4 \$ 1,472.4 Inventory Reserves \$ (44.4) \$ (75.4) Total \$ 1,864.4 \$ 1,997.4 Loss per Share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. See Note 3 "Stockholders' Equity below for additional disclosures. Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: As of September 30, 2024 As of December 30, 2023 As of September 30, 2023 As of December 30, 2022 As of September 30, 2022 As of December 30, 2021 As of September 30, 2021 As of December 30, 2020 As of September 30, 2020 As of December 30, 2019 As of September 30, 2019 As of December 30, 2018 As of September 30, 2018 As of December 30, 2017 As of September 30, 2017 As of December 30, 2016 As of September 30, 2016 As of December 30, 2015 As of September 30, 2015 As of December 30, 2014 As of September 30, 2014 As of December 30, 2013 As of September 30, 2013 As of December 30, 2012 As of September 30, 2012 As of December 30, 2011 As of September 30, 2011 As of December 30, 2010 As of September 30, 2010 As of December 30, 2009 As of September 30, 2009 As of December 30, 2008 As of September 30, 2008 As of December 30, 2007 As of September 30, 2007 As of December 30, 2006 As of September 30, 2006 As of December 30, 2005 As of September 30, 2005 As of December 30, 2004 As of September 30, 2004 As of December 30, 2003 As of September 30, 2003 As of December 30, 2002 As of September 30, 2002 As of December 30, 2001 As of September 30, 2001 As of December 30, 2000 As of September 30, 2000 As of December 30, 1999 As of September 30, 1999 As of December 30, 1998 As of September 30, 1998 As of December 30, 1997 As of September 30, 1997 As of December 30, 1996 As of September 30, 1996 As of December 30, 1995 As of September 30, 1995 As of December 30, 1994 As of September 30, 1994 As of December 30, 1993 As of September 30, 1993 As of December 30, 1992 As of September 30, 1992 As of December 30, 1991 As of September 30, 1991 As of December 30, 1990 As of September 30, 1990 As of December 30, 1989 As of September 30, 1989 As of December 30, 1988 As of September 30, 1988 As of December 30, 1987 As of September 30, 1987 As of December 30, 1986 As of September 30, 1986 As of December 30, 1985 As of September 30, 1985 As of December 30, 1984 As of September 30, 1984 As of December 30, 1983 As of September 30, 1983 As of December 30, 1982 As of September 30, 1982 As of December 30, 1981 As of September 30, 1981 As of December 30, 1980 As of September 30, 1980 As of December 30, 1979 As of September 30, 1979 As of December 30, 1978 As of September 30, 1978 As of December 30, 1977 As of September 30, 1977 As of December 30, 1976 As of September 30, 1976 As of December 30, 1975 As of September 30, 1975 As of December 30, 1974 As of September 30, 1974 As of December 30, 1973 As of September 30, 1973 As of December 30, 1972 As of September 30, 1972 As of December 30, 1971 As of September 30, 1971 As of December 30, 1970 As of September 30, 1970 As of December 30, 1969 As of September 30, 1969 As of December 30, 1968 As of September 30, 1968 As of December 30, 1967 As of September 30, 1967 As of December 30, 1966 As of September 30, 1966 As of December 30, 1965 As of September 30, 1965 As of December 30, 1964 As of September 30, 1964 As of December 30, 1963 As of September 30, 1963 As of December 30, 1962 As of September 30, 1962 As of December 30, 1961 As of September 30, 1961 As of December 30, 1960 As of September 30, 1960 As of December 30, 1959 As of September 30, 1959 As of December 30, 1958 As of September 30, 1958 As of December 30, 1957 As of September 30, 1957 As of December 30, 1956 As of September 30, 1956 As of December 30, 1955 As of September 30, 1955 As of December 30, 1954 As of September 30, 1954 As of December 30, 1953 As of September 30, 1953 As of December 30, 1952 As of September 30, 1952 As of December 30, 1951 As of September 30, 1951 As of December 30, 1950 As of September 30, 1950 As of December 30, 1949 As of September 30, 1949 As of December 30, 1948 As of September 30, 1948 As of December 30, 1947 As of September 30, 1947 As of December 30, 1946 As of September 30, 1946 As of December 30, 1945 As of September 30, 1945 As of December 30, 1944 As of September 30, 1944 As of December 30, 1943 As of September 30, 1943 As of December 30, 1942 As of September 30, 1942 As of December 30, 1941 As of September 30, 1941 As of December 30, 1940 As of September 30, 1940 As of December 30, 1939 As of September 30, 1939 As of December 30, 1938 As of September 30, 1938 As of December 30, 1937 As of September 30, 1937 As of December 30, 1936 As of September 30, 1936 As of December 30, 1935 As of September 30, 1935 As of December 30, 1934 As of September 30, 1934 As of December 30, 1933 As of September 30, 1933 As of December 30, 1932 As of September 30, 1932 As of December 30, 1931 As of September 30, 1931 As of December 30, 1930 As of September 30, 1930 As of December 30, 1929 As of September 30, 1929 As of December 30, 1928 As of September 30, 1928 As of December 30, 1927 As of September 30, 1927 As of December 30, 1926 As of September 30, 1926 As of December 30, 1925 As of September 30, 1925 As of December 30, 1924 As of September 30, 1924 As of December 30, 1923 As of September 30, 1923 As of December 30, 1922 As of September 30, 1922 As of December 30, 1921 As of September 30, 1921 As of December 30, 1920 As of September 30, 1920 As of December 30, 1919 As of September 30, 1919 As of December 30, 1918 As of September 30, 1918 As of December 30, 1917 As of September 30, 1917 As of December 30, 1916 As of September 30, 1916 As of December 30, 1915 As of September 30, 1915 As of December 30, 1914 As of September 30, 1914 As of December 30, 1913 As of September 30, 1913 As of December 30, 1912 As of September 30, 1912 As of December 30, 1911 As of September 30, 1911 As of December 30, 1910 As of September 30, 1910 As of December 30, 1909 As of September 30, 1909 As of December 30, 1908 As of September 30, 1908 As of December 30, 1907 As of September 30, 1907 As of December 30, 1906 As of September 30, 1906 As of December 30, 1905 As of September 30, 1905 As of December 30, 1904 As of September 30, 1904 As of December 30, 1903 As of September 30, 1903 As of December 30, 1902 As of September 30, 1902 As of December 30, 1901 As of September 30, 1901 As of December 30, 1900 As of September 30, 1900 As of December 30, 1999 As of September 30, 1999 As of December 30, 1998 As of September 30, 1998 As of December 30, 1997 As of September 30, 1997 As of December 30, 1996 As of September 30, 1996 As of December 30, 1995 As of September 30, 1995 As of December 30, 1994 As of September 30, 1994 As of December 30, 1993 As of September 30, 1993 As of December 30, 1992 As of September 30, 1992 As of December 30, 1991 As of September 30, 1991 As of December 30, 1990 As of September 30, 1990 As of December 30, 1989 As of September 30, 1989 As of December 30, 1988 As of September 30, 1988 As of December 30, 1987 As of September 30, 1987 As of December 30, 1986 As of September 30, 1986 As of December 30, 1985 As of September 30, 1985 As of December 30, 1984 As of September 30, 1984 As of December 30, 1983 As of September 30, 1983 As of December 30, 1982 As of September 30, 1982 As of December 30, 1981 As of September 30, 1981 As of December 30, 1980 As of September 30, 1980 As of December 30, 1979 As of September 30, 1979 As of December 30, 1978 As of September 30, 1978 As of December 30, 1977 As of September 30, 1977 As of December 30, 1976 As of September 30, 1976 As of December 30, 1975 As of September 30, 1975 As of December 30, 1974 As of September 30, 1974 As of December 30, 1973 As of September 30, 1973 As of December 30, 1972 As of September 30, 1972 As of December 30, 1971 As of September 30, 1971 As of December 30, 1970 As of September 30, 1970 As of December 30, 1969 As of September 30, 1969 As of December 30, 1968 As of September 30, 1968 As of December 30, 1967 As of September 30, 1967 As of December 30, 1966 As of September 30, 1966 As of December 30, 1965 As of September 30, 1965 As of December 30, 1964 As of September 30, 1964 As of December 30, 1963 As of September 30, 1963 As of December 30, 1962 As of September 30, 1962 As of December 30, 1961 As of September 30, 1961 As of December 30, 1960 As of September 30, 1960 As of December 30, 1959 As of September 30, 1959 As of December 30, 1958 As of September 30, 1958 As of December 30, 1957 As of September 30, 1957 As of December 30, 1956 As of September 30, 1956 As of December 30, 1955 As of September 30, 1955 As of December 30, 1954 As of September 30, 1954 As of December 30, 1953 As of September 30, 1953 As of December 30, 1952 As of September 30, 1952 As of December 30, 1951 As of September 30, 1951 As of December 30, 1950 As of September 30, 1950 As of December 30, 1949 As of September 30, 1949 As of December 30, 1948 As of September 30, 1948 As of December 30, 1947 As of September 30, 1947 As of December 30, 1946 As of September 30, 1946 As of December 30, 1945 As of September 30, 1945 As of December 30, 1944 As of September 30, 1944 As of December 30, 1943 As of September 30, 1943 As of December 30, 1942 As of September 30, 1942 As of December 30, 1941 As of September 30, 1941 As of December 30, 1940 As of September 30, 1940 As of December 30, 1939 As of September 30, 1939 As of December 30, 1938 As of September 30, 1938 As of December 30, 1937 As of September 30, 1937 As of December 30, 1936 As of September 30, 1936 As of December 30, 1935 As of September 30, 1935 As of December 30, 1934 As of September 30, 1934 As of December 30, 1933 As of September 30, 1933 As of December 30, 1932 As of September 30, 1932 As of December 30, 1931 As of September 30, 1931 As of December 30, 1930 As of September 30, 1930 As of December 30, 1929 As of September 30, 1929 As of December 30, 1928 As of September 30, 1928 As of December 30, 1927 As of September 30, 1927 As of December 30, 1926 As of September 30, 1926 As of December 30, 1925 As of September 30, 1925 As of December 30, 1924 As of September 30, 1924 As of December 30, 1923 As of September 30, 1923 As of December 30, 1922 As of September 30, 1922 As of December 30, 1921 As of September 30, 1921 As of December 30, 1920 As of September 30, 1920 As of December 30, 1919 As of September 30, 1919 As of December 30, 1918 As of September 30, 1918 As of December 30, 1917 As of September 30, 1917 As of December 30, 1916 As of September 30, 1916 As of December 30, 1915 As of September 30, 1915 As of December 30, 1914 As of September 30, 1914 As of December 30, 1913 As of September 30, 1913 As of December 30, 1912 As of September 30, 1912 As of December 30, 1911 As of September 30, 1911 As of December 30, 1910 As of September 30, 1910 As of December 30, 1909 As of September 30, 1909 As of December 30, 1908 As of September 30, 1908 As of December 30, 1907 As of September 30, 1907 As of December 30, 1906 As of September 30, 1906 As of December 30, 1905 As of September 30, 1905 As of December 30, 1904 As of September 30, 1904 As of December 30, 1903 As of September 30, 1903 As of December 30, 1902 As of September 30, 1902 As of December 30, 1901 As of September 30, 1901 As of December 30, 1900 As of September 30, 1900 As of December 30, 1999 As of September 30, 1999 As of December 30, 1998 As of September 30, 1998 As of December 30, 1997 As of September 30, 1997 As of December 30, 1996 As of September 30, 1996 As of December 30, 1995 As of September 30, 1995 As of December 30, 1994 As of September 30, 1994 As of December 30, 1993 As of September 30, 1993 As of December 30, 1992 As of September 30, 1992 As of December 30, 1991 As of September 30, 1991 As of December 30, 1990 As of September 30, 1990 As of December 30, 1989 As of September 30, 1989 As of December 30, 1988 As of September 30, 1988 As of December 30, 1987 As of September 30, 1987 As of December 30, 1986 As of September 30, 1986 As of December 30, 1985 As of September 30, 1985 As of December 30, 1984 As of September 30, 1984 As of December 30, 1983 As of September 30, 1983 As of December 30, 1982 As of September 30, 1982 As of December 30, 1981 As of September 30, 1981 As of December 30, 1980 As of September 30, 1980 As of December 30, 1979 As of September 30, 1979 As of December 30, 1978 As of September 30, 1978 As of December 30, 1977 As of September 30, 1977 As of December 30, 1976 As of September 30, 1976 As of December 30, 1975 As of September 30, 1975 As of December 30, 1974 As of September 30, 1974 As of December 30, 1973 As of September 30, 1973 As of December 30, 1972 As of September 30, 1972 As of December 30, 1971 As of September 30, 1971 As of December 30, 1970 As of September 30, 1970 As of December 30, 1969 As of September 30, 1969 As of December 30, 1968 As of September 30, 1968 As of December 30, 1967 As of September 30, 1967 As of December 30, 1966 As of September 30, 1966 As of December 30, 1965 As of September 30, 1965 As of December 30, 1964 As of September 30, 1964 As of December 30, 1963 As of September 30, 1963 As of December 30, 1962 As of September 30, 1962 As of December 30, 1961 As of September 30, 1961 As of December 30, 1960 As of September 30, 1960 As of December 30, 1959 As of September 30, 1959 As of December 30, 1958 As of September 30, 1958 As of December 30, 1957 As of September 30, 1957 As of December 30, 1956 As of September 30, 1956 As of December 30, 1955 As of September 30, 1955 As of December 30, 1954 As of September 30, 1954 As of December 30, 1953 As of September 30, 1953 As of December 30, 1952 As of September 30, 1952 As of December 30, 1951 As of September 30, 1951 As of December 30, 1950 As of September 30, 1950 As of December 30, 1949 As of September 30, 1949 As of December 30, 1948 As of September 30, 1948 As of December 30, 1947 As of September 30, 1947 As of December 30, 1946 As of September 30, 1946 As of December 30, 1945 As of September 30, 1945 As of December 30, 1944 As of September 30, 1944 As of December 30, 1943 As of September 30, 1943 As of December 30, 1942 As of September 30, 1942 As of December 30, 1941 As of September 30, 1941 As of December 30, 1940 As of September 30, 1940 As of December 30, 1939 As of September 30, 1939 As of December 30, 1938 As of September 30, 1938 As of December 30, 1937 As of September 30, 1937 As of December 30, 1936 As of September 30, 1936 As of December 30, 1935 As of September 30, 1935 As of December 30, 1934 As of September 30, 1934 As of December 30, 1933 As of September 30, 1933 As of December 30, 1932 As of September 30, 1932 As of December 30, 1931 As of September 30, 1931 As of December 30, 1930 As of September 30, 1930 As of December 30, 1929 As of September 30, 1929 As of December 30, 1928 As of September 30, 1928 As of December 30, 1927 As of September 30, 1927 As of December 30, 1926 As of September 30, 1926 As of December 30, 1925 As of September 30, 1925 As of December 30, 1924 As of September 30, 1924 As of December 30, 1923 As of September 30, 1923 As of December 30, 1922 As of September 30, 1922 As of December 30, 1921 As of September 30, 1921 As of December 30, 1920 As of September 30, 1920 As of December 30, 1919 As of September 30, 1919 As of December 30, 1918 As of September 30, 1918 As of December 30, 1917 As of September 30, 1917 As of December 30, 1916 As of September 30, 1916 As of December 30, 1915 As of September 30, 1915 As of December 30, 1914 As of September 30, 1914 As of December 30, 1913 As of September 30, 1913 As of December 30, 1912 As of September 30, 1912 As of December 30, 1911 As of September 30, 1911 As of December 30, 1910 As of September 30, 1910 As of December 30, 1909 As of September 30, 1909 As of December 30, 1908 As of September 30, 1908 As of December 30, 1907 As of September 30, 1907 As of December 30, 1906 As of September 30, 1906 As of December 30, 1905 As of September 30, 1905 As of December 30, 1904 As of September 30, 1904 As of December 30, 1903 As of September 30, 1903 As of December 30, 1902 As of September 30, 1902 As of December 30, 1901 As of September 30, 1901 As of December 30, 1900 As of September 30, 1900 As of December 30, 1999 As of September 30, 1999 As of December 30, 1998 As of September 30, 1998 As of December 30, 1997 As of September 30, 1997 As of December 30, 1996 As of September 30, 1996 As of December 30, 1995 As of September 30, 1995 As of December 30, 1994 As of September 30, 1994 As of December 30, 1993 As of September 30, 1993 As of December 30, 1992 As of September 30, 1992 As of December 30, 1991 As of September 30, 1991 As of December 30, 1990 As of September 30, 1990 As of December 30, 1989 As of September 30, 1989 As of December 30, 1988 As of September 30, 1988 As of December 30, 1987 As of September 30, 1987 As of December 30, 1986 As of September 30, 1986 As of December 30, 1985 As of September 30, 1985 As of December 30, 1984 As of September 30, 1984 As of December 30, 1983 As of September 30, 1983 As of December 30, 1982 As of September 30, 1982 As of December 30, 1981 As of September 30, 1981 As of December 30, 1980 As of September 30, 1980 As of December 30, 1979 As of September 30, 1979 As of December 30, 1978 As of September 30, 1978 As of December 30, 1977 As of September 30, 1977 As of December 30, 1976 As of September 30, 1976 As of December 30, 1975 As of September 30, 1975 As of December 30, 1974 As of September 30, 1974 As of December 30, 1973 As of September 30, 1973 As of December 30, 1972 As of September 30, 1972 As of December 30, 1971 As of September 30, 1971 As of December 30, 1970 As of September 30, 1970 As of December 30, 1969 As of September 30, 1969 As of December 30, 1968 As of September 30, 1968 As of December 30, 1967 As of September 30, 1967 As of December 30, 1966 As of September 30, 1966 As of December 30, 1965 As of September 30, 1965 As of December 30, 1964 As of September 30, 1964 As of December 30, 1963 As of September 30, 1963 As of December 30, 1962 As of September 30, 1962 As of December 30, 1961 As of September 30, 1961 As of December 30, 1960 As of September 30, 1960 As of December 30, 1959 As of September 30, 1959 As of December 30, 1958 As of September 30, 1958 As of December 30, 1957 As of September 30, 1957 As of December 30, 1956 As of September 30, 1956 As of December 30, 1955 As of September 30, 1955 As of December 30, 1954 As of September 30, 1954 As of December 30, 1953 As of September 30, 1953 As of December 30, 1952 As of September 30, 1952 As of December 30, 1951 As of September 30, 1951 As of December 30, 1950 As of September 30, 1950 As of December 30, 1949 As of September 30, 1949 As of December 30, 1948 As of September 30, 1948 As of December 30, 1947 As of September 30, 1947 As of December 30, 1946 As of September 30, 1946 As of December 30, 1945 As of September 30, 1945 As of December 30, 1944 As of September 30, 1944 As of December 30, 1943 As of September 30, 1943 As of December 30, 1942 As of September 30, 1942 As of December 30, 1941 As of September 30, 1941 As of December 30, 1940 As of September 30, 1940 As of December 30, 1939 As of September 30, 1939 As of December 30, 1938 As of September 30, 1938 As of December 30, 1937 As of September 30, 1937 As of December 30, 1936 As of September 30, 1936 As of December 30, 1935 As of September 30, 1935 As of December 30, 1934 As of September 30, 1934 As of December 30, 1933 As of September 30, 1933 As of December 30, 1932 As of September 30, 1932 As of December 30, 1931 As of September 30, 1931 As of December 30, 1930 As of September 30, 1930 As of December 30, 1929 As of September 30, 1929 As of December 30, 1928 As of September 30, 1928 As of December 30, 1927 As of September 30, 1927 As of December 30, 1926 As of September 30, 1926 As of December 30, 1925 As of September 30, 1925 As of December 30, 1924 As of September 30, 1924 As of December 30, 1923 As of September 30, 1923 As of December 30, 1922 As of September 30, 1922 As of December 30, 1921 As of September 30, 1921 As of December 30, 1920 As of September 30, 1920 As of December 30, 1919 As of September 30, 1919 As of December 30, 1918 As of September 30, 1918 As of December 30, 1917 As of September 30, 1917 As of December 30, 1916 As of September 30, 1916 As of December 30, 1915 As of September 30, 1915 As of December 30, 1914 As of September 30, 1914 As of December 30, 1913 As of September 30, 1913 As of December 30, 1912 As of September 30, 1912 As of December 30, 1911 As of September 30, 1911 As of December 30, 1910 As of September 30, 1910 As of December 30, 1909 As of September 30, 1909 As of December 30, 1908 As of September 30, 1908 As of December 30, 1907 As of September 30, 1907 As of December 30, 1906 As of September 30, 1906 As of December 30, 1905 As of September 30, 1905 As of December 30, 1904 As of September 30, 1904 As of December 30, 1903 As of September 30, 1903 As of December 30, 1902 As of September 30, 1902 As of December 30, 1901 As of September 30, 1901 As of December 30, 1900 As of September 30, 1900 As of December 30, 1999 As of September 30, 1999 As of December 30, 1998 As of September 30, 1998 As of December 30, 1997 As of September 30

registered public offering by the Company, 150,000 units, with each Unit consisting of (A) one share of the Company’s Series J Convertible Redeemable Preferred Stock, par value \$0.0001 per share, and (B) one warrant to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock, at a price to the public of \$15.00 per Unit, less placement agent fees and commissions. The public offering price of \$15.00 per Unit reflects the issuance of the Series J Convertible Preferred Stock with an original issue discount of 40%. The Company also registered under the Registration Statement (as defined below) an additional 362,933 shares of Series J Convertible Preferred Stock that will be issued, if and when the Company’s Board of Directors declares such dividends, as paid in-kind dividends and the shares of Common Stock issuable upon conversion of the Series J Convertible Preferred Stock issued as PIK dividends. 12 Table of Contents The Units, the shares of Series J Convertible Preferred Stock, the Warrants, the PIK Dividend Shares, the PIK Conversion Shares as well as the shares of Series J Convertible Preferred Stock issuable upon exercise of the Warrants and the shares of the Company’s common stock, par value \$0.0001 per share, issuable upon conversion of the Series J Convertible Preferred Stock, were offered and sold by the Company pursuant to an effective registration statement on Form S-1. The closing of the Offering contemplated by the Placement Agency Agreement occurred on October 17, 2023. On October 17, 2023, the Company also entered into a warrant agency agreement with the Company’s transfer agent, Equiniti Trust Company, LLC, who acts as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in this Offering. Each Warrant has an exercise price of \$262.50 per one-half of one (0.5) share of Series J Convertible Preferred Stock, is immediately exercisable and will expire three (3) years from the date of issuance. There is no established trading market for the Series J Convertible Preferred Stock or the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Series J Convertible Preferred Stock or the Warrants on The Nasdaq Capital Market or any other national securities exchange or any other nationally recognized trading system. The gross proceeds to the Company from the October 17, 2023, Offering were \$2.25 million. Net proceeds were approximately \$1.5 million after deducting placement agent fees and commissions and Offering expenses payable by the Company. The Company used the net proceeds from the Offering for working capital and for general corporate purposes. The Series J Convertible Preferred Stock is classified as mezzanine equity and accreted to reflect its redemption value as of each reporting date. The accretion will be reflected as a deemed dividend adjustment to arrive at net loss attributed to common stockholders for earnings per share calculations. The Warrants are recorded as a liability and re-measured at fair value as of each reporting date with fair value changes being recorded as non-operating income or expense. The Warrants were valued on day 1 and exceeded the gross proceeds of the offering. This resulted in a day 1 financing expense of \$2.7 million. April 2024 Offering: On April 30, the Company closed on a best efforts public offering of 240,571 shares of its common stock, 80,854 shares of its common stock for pre-funded warrants and warrants to purchase up to an aggregate of 3,214,288 shares of its common stock at a combined public offering price \$8.40 per share. All pre-funded warrants were exercised on the date of the offering. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of \$2.10 per share, were exercisable immediately upon issuance, and will expire five years following the date of issuance. Each whole common warrant entitles the holder thereof to purchase one share of common stock. The common warrants contain a reset of the exercise price, effective upon the Warrant Stockholder Approval, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the five trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the five trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024. Subsequent to June 30 2024, the number of shares underlying the common warrants were adjusted to 2,710,734 shares and the exercise price was adjusted to \$2.49 per share. In addition, the common warrants provided for full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$2.10. The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million. The warrants offered in this financing were originally classified as a liability on the balance sheet. An independent valuation of the warrants was performed and reviewed with management, and the valuation at issuance was \$7.8 million. The warrants had down-round protection and the price was reset from the July 2024 and the August 2024 offerings. At the August 2024 offering, the exercise price of these warrants were adjusted to \$2.10, which represented the floor price on these warrants. As the price floor was hit, there was no further down-round protection. The warrants were re-evaluated and classified as equity as of September 30, 2024. During the quarter, there were 398,488 of warrants exercised at a weighted average exercise price of \$2.97. The warrants are fair valued on the date of exercise and the adjustment to fair value is recorded to Additional Paid in Capital. There were 2,651,426 of warrants converted to equity resulting in \$4.2 million to Additional Paid in Capital. 13 Table of Contents July 2024 Offering: On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company’s common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, will be exercisable immediately following the date of issuance and have a term of five years from the date of issuance. The warrants issued in this offering were concluded to be equity classified. The closing of the registered direct offering and the concurrent private placement occurred on July 25, 2024. The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately \$2.0 million. After deducting placement agent fees and other offering expenses payable by the Company, net proceeds were approximately \$1.5 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. August 2024 Offering: On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company’s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the SEC) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The warrants issued in this offering were concluded to be equity classified. The gross proceeds of the Offering, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, will be approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. Underwriter and Placement Agent Fees: In connection with the offerings described above, the Company paid the underwriter or placement agent, as applicable, an aggregate cash fee of either 7% or 8% of the aggregate gross proceeds raised in each of the offerings, except with respect to the issuances made pursuant to the At-the-Market Program, for which the placement fee was equal to 3% of the aggregate gross proceeds. At the Company’s annual meeting of stockholders on June 6, 2024, its stockholders approved a proposal to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a reverse split of the Company’s outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-70 to be determined at the discretion of our Board of Directors. On June 26, 2024, the Company’s board of directors approved a one-for-thirty-five reverse stock split of the Company’s issued and outstanding shares of common stock (the Reverse Stock Split). On June 27, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the Certificate of Amendment) to affect the Reverse Stock Split. The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on June 27, 2024, and the Company’s common stock began trading on a split-adjusted basis when the market opened on June 28, 2024. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock splits for all periods presented. 14 Table of Contents Note 4 - Stock-Based Compensation Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The following table presents the classification of stock-based compensation expense recognized for the periods below: Three months ended September 30 Nine months ended September 30 (in thousands) 2024 2023 2024 2023 Selling, general and administrative expense \$ 99 \$ 133 \$ 363 \$ 484 Research and development expense \$ 2 \$ 2 \$ 11 \$ 29 Total stock-based compensation expense \$ 101 \$ 135 \$ 374 \$ 513 During the three months ended September 30, 2024, and 2023, under the 2017 Equity Incentive Plan, and the 2021 Inducement Plan, the Company granted zero and 532 stock options, respectively, to its directors, officers and employees. During the nine months ended September 30, 2024 and 2023, the Company granted 1,264 and 3,544 stock options, respectively, to its directors, officers and employees. Vesting generally occurs over an immediate to 48-month period based on a time-of-service condition. The weighted-average grant date fair value of the stock options issued during the three months ended September 30, 2024 and 2023 was zero and \$62.65 per share, respectively. The weighted-average grant date fair value of the stock options issued during the nine months ended September 30, 2024 and 2023 was \$24.14 and \$226.26 per share, respectively. The total number of stock options outstanding as of September 30, 2024 and September 30, 2023 was 3,890 and 3,101, respectively. The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended September 30, 2024 and 2023: Three months ended Nine months ended September 30 September 30 2024 2023 Expected volatility 138.70 % 131.06 % 138.70 % 152.59 % Expected Life of options (years) 5.51 6.25 5.51 6.19 Expected dividend yield 0 % 0 % 0 % Risk-free interest rate 3.94 % 4.29 % 3.94 % 4.16 % During the three months ended September 30, 2024 and 2023, 420 and 69 stock options vested, respectively, and 102 and 595 stock options were expired or forfeited during these periods, respectively. During the nine months ended September 30, 2024 and 2023, 1,767 and 129 stock options vested, respectively, and 465 and 680 stock options were expired or forfeited during these periods, respectively. During the three and nine months ended September 30, 2024 and 2023, no options were exercised. Note 5 “Fair Value of Financial Instruments” Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges. 15 Table of Contents Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over-the-counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques. The fair value of the Company’s common and preferred stock warrant liabilities related to the investor warrants issued in the October 2023, October 2022 and April 2024 public offerings was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. The following is a roll-forward of the fair value of the Level 3 warrants: (in thousands) Balance at December 31, 2022 \$ 6,868 Change in fair value \$ 755 Issuance of Common Stock for exercise of Series I warrants \$ (7,623) October 17, 2023, issuance of Series J warrants \$ 4,965 Exercise of Series J warrants \$ (536) Change in fair value \$ (1,586) Balance at December 31, 2023 \$ 2,843 Exercise of Series J warrants \$ (1,357) April 30, 2024, issuance of common warrants \$ 7,813 Exercise of April 2024 warrants \$ (1,373) Reclassification of April 2024 warrants to equity \$ (2,844) Change in fair value \$ (4,602) Balance at September 30, 2024 \$ 480 Note 6 “Income Taxes” The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of its deferred tax assets. The Company has established a full valuation allowance for its U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements. As of September 30, 2024, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2023. Note 7 “Operating Leases” The Company leases a 23,000 square foot facility located in Eden Prairie, Minnesota for office and manufacturing space under a non-cancelable operating lease that expires in March 2027. In November 2021, the Company entered into a fourth amendment to the lease, extending the term of the lease from March 31, 2022 to March 31, 2027. This facility serves as our corporate headquarters and houses substantially all our functional departments. Monthly rent and common area maintenance charges, including estimated property tax for our headquarters, total approximately \$34,000. The lease contains provisions for annual inflationary adjustments. Rent expense is being recorded on a straight-line basis over the term of the lease. Beginning on April 1, 2022, the annual base rent was \$10.50 per square foot, subject to future annual increases of \$0.32 to \$0.34 per square foot. Note 8 “Commitments and Contingencies” Employee Retirement Plan: The Company has a 401(k) retirement plan that provides retirement benefits to all eligible U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employees’ contributions at the discretion of the Company. 16 Table of Contents Note 9 - Subsequent Events On October 20, 2024 (the Effective Date), Nuwellis, Inc. (the Company) and SeaStar Medical Holding Corporation (the SeaStar) entered into a Confidential Settlement Agreement and Release (the Settlement Agreement), which terminated the License and Distribution Agreement entered into by the Company and SeaStar, dated as of December 27, 2022 (the Distribution Agreement) and the Supplier and Distributor Quality Agreement dated as of March 5, 2024 (the Supply Agreement), and together with the Distribution Agreement, the SeaStar Agreements pursuant to which SeaStar appointed the Company as its exclusive distributor for the sale and distribution of SeaStar’s product, QUELIMMUNE, with SeaStar agreeing to pay the Company \$900,000 before December 31, 2024. The Company is accounting for the settlement as a gain contingency and will record the gain at the earlier of when the contingency is realized or realizable. The Company received payment of \$500,000 on October 22, 2024 and was recognized in October 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the Existing Warrants) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the Series I Warrants) and Series II common stock purchase warrants (the Series II Warrants) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the Securities Act), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the SEC) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. 17 Table of Contents ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The

following discussion and analysis of our financial condition and results of operations should be read in conjunction with our interim condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and the audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the year ended December 31, 2023. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a variety of factors, including those discussed in Part I, Item 1A of our Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent filings with the Securities and Exchange Commission (the “SEC”). Unless otherwise specified or indicated by the context, Nuwellis, the Company, we, us, our, and our subsidiaries refer to Nuwellis, Inc. and its subsidiary.

OVERVIEW About Nuwellis We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy. The Aquadex SmartFlow system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. 18 Table of Contents Prior to July 2016, we were focused on developing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. In August 2016, we acquired the Aquadex Business from a subsidiary of Baxter, a global leader in the hospital products and dialysis markets. In September 2016, we announced a refocus of our strategy that included halting all clinical evaluations of the C-Pulse System related technology to fully focus our resources on our recently acquired Aquadex Business. On May 23, 2017, we announced that we were changing our name from Sunshine Heart, Inc. to CHF Solutions, Inc. to more appropriately reflect the direction of our business. On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to reflect the expansion of its customer base from treating fluid imbalance resulting from congestive heart failure to also include critical care and pediatrics applications. A Recent Developments Nasdaq Compliance As previously disclosed on May 29, 2024 and June 10, 2024, the Company was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) that the Company did not satisfy Nasdaq Listing Rules 5550(b)(1) (the “Stockholder’s Equity” Requirement) and 5550(a)(2) (the “Minimum Bid Price Requirement”), respectively, and was therefore subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). On July 18, 2024, Nasdaq notified the Company that it had regained compliance with the Minimum Bid Price Requirement. At a hearing before the Panel on July 23, 2024, the Company presented its plan of compliance to regain compliance with the Stockholder’s Equity Requirement. On August 8, 2024, the Company was notified by Nasdaq that the Panel had granted the Company’s request for continued listing, subject to, among other things, the Company’s filing of its Quarterly Report on Form 10-Q for the period ending September 30, 2024, evidencing compliance with the Stockholder’s Equity Requirement. Public Offering conforming changes from above On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company’s common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued warrants to the investors to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, are exercisable immediately following the date of issuance and will have a term of five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement occurred on or about July 25, 2024. The gross proceeds to Nuwellis from the registered direct offering and the concurrent private placement, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately \$2.0 million. Nuwellis intends to use the net proceeds from the offering for working capital and for general corporate purposes. On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company’s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares are being sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the Offering, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, will be approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. 19 Table of Contents Reverse Stock Split At the Company’s annual meeting of stockholders on June 6, 2024, its stockholders approved a proposal to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to effect such a reverse split of the Company’s outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-70 to be determined at the discretion of our Board of Directors. On June 26, 2024, the Company’s board of directors approved a one-for-thirty-five reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”). On June 27, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to affect the Reverse Stock Split. The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on June 27, 2024, and the Company’s common stock began trading on a split-adjusted basis when the market opened on June 28, 2024. CRITICAL ACCOUNTING POLICIES AND ESTIMATES We have adopted various accounting policies to prepare the condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (the “GAAP”). Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. The preparation of the condensed consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to stock-based compensation, valuation of equity and debt securities, and income tax reserves are updated as appropriate, which in most cases is quarterly. We base our estimates on historical experience, valuations, or various assumptions that are believed to be reasonable under the circumstances. There have been no material changes to our critical accounting policies and estimates from the information provided in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023. Revenue Recognition: We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Accordingly, we recognize revenue when our customers obtain control of their products or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods and services. See Note 2 of our Revenue Recognition, included in Part I, Item 1 of this Quarterly Report on Form 10-Q, for additional disclosures. Accounts Receivable: Our accounts receivables generally have terms that require payment within 30 days. We did not establish an allowance for credit losses as of September 30, 2024, as we have not incurred any write-offs or experienced a deterioration in the aging of our receivables, and we do not expect to experience write-offs in the future. The Company provides reserves against accounts receivable for estimated credit losses that may result from a customer’s inability to pay based on a combination of factors, such as the aging of accounts receivable, the customer’s financial strength and payment history. To date there the Company has not experienced any write offs. Inventories: Inventories consist of finished goods, raw materials and subassemblies and are recorded at the lower of cost or net realizable value using the first-in, first-out method. Stock-Based Compensation: We recognize all share-based payments to employees, directors, and consultants, including grants of stock options and common stock awards, in the consolidated statement of operations and comprehensive loss as an operating expense based on their fair values as established at the grant date. Other equity instruments issued to non-employees consist of warrants to purchase shares of our common stock. These warrants are either fully vested and exercisable at the date of grant or vest over a certain period during which services are provided. We compute the estimated fair values of stock options and warrants using the Black-Scholes option pricing model and market-based warrants using a Monte Carlo valuation model. Market price at the date of grant is used to calculate the fair value of any restricted stock units and common stock awards. 20 Table of Contents We expense the fair market value of fully vested awards at the time of grant, and of unvested awards over the period in which the related services are received. Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for estimated forfeitures, except for market-based warrants, which are expensed based on the grant date fair value regardless of whether the award vests. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Accounting for Warrants: We have issued and may continue to issue warrants to purchase shares of common stock through our public and private offerings and in conjunction with the Supply Agreement executed with DaVita in June 2023. We account for such warrants in accordance with ASC 480, Distinguishing Liabilities from Equity, which identifies three categories of freestanding financial instruments that are required to be accounted for as a liability. If determined to be classified as a liability, we will remeasure the fair value of the warrants at each balance sheet date. If determined to be classified as equity, the fair value of the warrants will be measured as of the date of issuance and will not be subject to remeasurement at each subsequent balance sheet date. The fair value of the warrant liability is estimated using a Monte Carlo simulation model using relevant inputs and assumptions based upon the terms of the warrants. Loss per Share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. See Note 3 of our Stockholders’ Equity below for additional disclosures. Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. Impairment of Long-Lived Assets: Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group is exceeded by its carrying amount. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates. The Company continues to report operating losses and negative cash flows from operations, both of which it considers to be indicators of potential impairment. Therefore, the Company evaluates its long-lived assets for potential impairment at each reporting period. The Company has concluded that its cash flows from the various long-lived assets are highly interrelated and, as a result, the Company consists of a single asset group. As the Company expects to continue incurring losses in the foreseeable future, the undiscounted cash flow step was bypassed, and the Company proceeded to measure fair value of the asset group. The Company has determined the fair value of the asset group associated with its loaner units by using expected cash flows estimating future discounted cash flows expected from the rental of these units. For recently acquired assets within the asset group, primarily equipment, the Company determined the fair value based on the replacement cost. There have been no impairment losses recognized for the three and nine-month periods ended September 30, 2024 or the year ended December 31, 2023. Going Concern: Our consolidated financial statements have been prepared and presented on a basis assuming we continue as a going concern. During the years ended December 31, 2023, and 2022, and through September 30, 2024, we incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. Since the company’s inception and as of September 30, 2024, we had an accumulated deficit of \$297.3 million, and we expect to incur losses for the foreseeable future. To date, we have been funded by debt and equity financings, and although we believe that we will be able to successfully fund our operations into the future, there can be no assurance that we will be able to do so or that we will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through at least twelve months from the report date. We became a revenue-generating company after acquiring the Aquadex Business in August 2016. We expect to incur additional losses in the near-term as we grow the Aquadex Business, including investments in our sales and marketing capabilities, product development, purchasing inventory and manufacturing components, generating additional clinical evidence supporting the efficacy of the Aquadex System, and complying with the requirements related to being a U.S. public company. To become and remain profitable, we must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require us to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing, and distributing the Aquadex System and related components. There can be no assurance that we will succeed in these activities, and we may never generate revenues sufficient to achieve profitability. 21 Table of Contents Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services. The Board recently reauthorized the Company 401k match effective as of October 1, 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the “Series I Warrants”) and Series II common stock purchase warrants (the “Series II Warrants”) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. We believe that our existing capital resources will be sufficient to support our operating plan through May 31, 2025; however, there can be no assurance of this. We will likely seek to raise additional capital to support our growth or other strategic initiatives through debt, equity, or a combination thereof. There can be no assurance the Company will be successful in raising additional capital. A NEW ACCOUNTING PRONOUNCEMENTS The Company has considered all recent accounting pronouncements issued and their potential effects on its financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s condensed financial statements. FINANCIAL OVERVIEW We are a medical device company focused on commercializing the Aquadex System for ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy. Activities since inception have consisted

principally of raising capital, performing research and development, and conducting pre-clinical and clinical studies. During 2016, we acquired the Aquadex Business and announced that we were halting all clinical evaluations of our prior technology, the C-Pulse System. Since then, our activities have consisted mainly of expanding our sales and marketing capabilities, performing clinical research, and engaging in new product development. Since the companyâ€™s inception and as of September 30, 2024, we had an accumulated deficit of \$297.3 million, and we expect to incur losses for the foreseeable future. To date, we have been funded by public and private equity financings and debt. Although we believe that we will be able to continue to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably. 22 Table of Contents Results of Operations Comparison of three months ended September 30, 2024 to three months ended September 30, 2023 Net Sales (in thousands) Three months ended September 30, 2024 Â Â Three months ended September 30, 2023 Â Â Â Increase (Decrease) Â Â Â % Change Â Â \$ 2,367.4 Â Â \$ 2,412.4 Â Â \$ (45.0) Â Â (1.9) % Revenue is generated mainly from the sale of disposable blood filters and catheters used in conjunction with the Aquadex System consoles. We sell primarily in the United States to hospitals and clinics through our direct salesforce. We sell outside of the United States to independent specialty distributors, who in turn sell to hospitals and clinics in their geographic regions. The decrease in sales in the current year period is due to a decrease in circuit and console sales offset by a one-time increase in SeaStar Medical Quellimmune sales in the current year quarter. Costs and Expenses Our costs and expenses were as follows: (in thousands) Â Three months ended September 30, 2024 Â Three months ended September 30, 2023 Â Â Increase (Decrease) Â Â Â % Change Â Â Cost of goods sold Â \$ 711.4 Â \$ 1,031.4 Â \$ (320.0) Â Â (31.0) % Selling, general and administrative Â \$ 2,702.4 Â \$ 3,428.4 Â \$ (726.0) Â Â (21.2) % Research and development Â \$ 486.4 Â \$ 1,117.4 Â \$ (631.0) Â Â (56.5) % Cost of Goods Sold The decrease in cost of goods sold for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, was due primarily to higher manufacturing volumes of circuits in the current year period and lower fixed overhead manufacturing expenses. Selling, General and Administrative The decrease in selling, general and administrative expense was primarily realized through efficiency initiatives enacted in the second half of 2023. Research and Development The decrease in R&D expenses was primarily driven by reduced consulting fees and compensation-related expenses. Â Comparison of nine months ended September 30, 2024 to nine months ended September 30, 2023 Net Sales (in thousands) Nine months ended September 30, 2024 Â Â Nine months ended September 30, 2023 Â Â Â Increase (Decrease) Â Â Â % Change Â Â \$ 6,418.4 Â Â \$ 6,313.4 Â Â \$ 105.0 Â Â 1.7 % Revenue is generated mainly from the sale of disposable blood filters and catheters used in conjunction with the Aquadex system consoles. We sell primarily in the United States to hospitals and clinics through our direct salesforce. We sell outside of the United States to independent specialty distributors who in turn sell to hospitals and clinics in their geographic regions. The increase in sales in the current year period is due to a 3% increase in circuit sales, reflecting continued increases in the number of patients treated with the Aquadex therapy, and a one-time increase in SeaStar Medical Quellimmune sales offset by a decrease in console sales. 23 Table of Contents Costs and Expenses Our costs and expenses were as follows: (in thousands) Â Nine months ended September 30, 2024 Â Â Nine months ended September 30, 2023 Â Â Â Increase (Decrease) Â Â Â % Change Â Â Cost of goods sold Â \$ 2,097.4 Â Â \$ 2,718.4 Â Â \$ (621.0) Â Â (22.8) % Selling, general and administrative Â \$ 10,544.4 Â Â \$ 13,582.4 Â Â \$ (3,038.0) Â Â (22.4) % Research and development Â \$ 2,378.4 Â Â \$ 4,050.4 Â Â \$ (1,672.0) Â Â (41.3) % Cost of Goods Sold The decrease in cost of goods sold for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, was primarily due to higher manufacturing volumes of circuits in the current year period and lower fixed overhead manufacturing expenses. Selling, General and Administrative The decrease in selling, general and administrative expense was primarily realized through efficiency initiatives enacted in the second half of 2023. Research and Development The decrease in R&D expense versus the prior year was primarily driven by reduced consulting fees and compensation-related expenses. Liquidity and Capital Resources Sources of Liquidity We have funded our operations primarily through cash on hand and a series of equity issuances. In March 2023, the Company filed a Prospectus Supplement to its Registration Statement on Form S-3 with the SEC in connection with a proposed At-the-Market Securities offering (the â€œAt-the-Market Programâ€). During 2023, the Company issued 18,781 shares of common stock under the At-the-Market Program for gross proceeds of approximately \$2.3 million.Â Net proceeds totaled approximately \$2.1 million after deducting the underwriting discounts and commissions and other costs associated with the offering.Â The Company terminated its At-the-Market Program inÂ July of 2024. On October 17, 2023, the Company closed on a public offering of 4,286 Units, with each Unit consisting of one share of the Companyâ€™s Series J Convertible Redeemable Preferred Stock, par value \$0.0001 per share, with a liquidation preference of \$25.00 per share (the â€œSeries J Convertible Preferred Stockâ€), and one October 2023 Warrant to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock. The purchase price for one Unit was \$15.00, which reflects the issuance of the Series J Convertible Preferred Stock with an original issue discount. The Series J Convertible Preferred Stock has a term of three (3) years and is convertible at the option of the holder at any time into shares of the Companyâ€™s common stock at a conversion price of \$1.01. If any shares of our Series J Convertible Preferred Stock are outstanding at the end of the three-year term, then the Company will promptly redeem all of such outstanding shares of Series J Convertible Preferred Stock on a pro rata basis among all of the holders of Series J Convertible Preferred Stock commencing on the Mandatory Redemption Date in cash, to the extent legally permissible under Delaware law, or, if redemption for cash is not legally permissible in duly authorized, validly issued, fully paid and non-assessable shares of the Companyâ€™s common stock equal in number to the quotient obtained by dividing such unpaid amount by the closing price of the Companyâ€™s common stock on the Nasdaq on the Mandatory Redemption Date. Dividends on the Series J Convertible Preferred Stock will be paid, if and when declared by the Companyâ€™s board of directors, in-kind (â€œPIK dividendsâ€) in additional shares of Series J Convertible Preferred Stock based on the stated value of \$25.00 per share at a dividend rate of 5.0%. The PIK dividends will be paid on a quarterly basis for three (3) years following the closing date to holders of the Series J Convertible Preferred Stock of record at the close of business on October 31, January 31, April 30, and July 31 of each year. The October 2023 Warrants have a term of three (3) years. Each October 2023 Warrant has an exercise price of \$262.50 (50.0% of the public offering price per Unit) per one-half of one share (0.5) of Series J Convertible Preferred Stock and is immediately exercisable. 24 Table of Contents The gross proceeds before underwriting discounts and commissions and offering expenses, were approximately \$2.25 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. On April 30, 2024, the Company closed on an underwritten public offering of 321,417 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 482,146 shares of its common stock at a combined public offering price \$0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of \$14.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. Each whole common warrant entitles the holder thereof to purchase one share of common stock. The common warrants contain a reset of the exercise price, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the five trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the five trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024.Â Upon such a reset, there will be a proportionate adjustment to the number of shares underlying the common warrants. In addition, the common warrants will provide for full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$0.06. The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million. On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued warrants to the investors to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, are exercisable immediately following the date of issuance and will have a term of five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement occurred on or about July 25, 2024. The gross proceeds to Nuwellis from the registered direct offering and the concurrent private placement, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately \$2.0 million. Nuwellis intends to use the net proceeds from the offering for working capital and for general corporate purposes. On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Companyâ€™s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Companyâ€™s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the â€œSECâ€) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock.Â The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the Offering, before deducting the Placement Agentâ€™s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, were approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. 25 Table of Contents As of September 30, 2024 and December 31, 2023, cash and cash equivalents were \$1.9 million and \$3.8 million, respectively. Our business strategy and ability to fund our operations in the future depend in part on our ability to grow the Aquadex Business by expanding our salesforce, selling our products to hospitals and other healthcare facilities, and controlling costs. We will need to seek additional financing in the future, which, to date, has been primarily through offerings of our equity securities. Cash Flows used in Operating Activities Net cash used in operating activities was \$8.1 million and \$15.2 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The net cash used in each of these periods primarily reflects the net loss for those periods, partially offset by non-cash charges for stock-based compensation, depreciation and amortization, and revaluation of the warrant liability, and the effects of changes in operating assets and liabilities, including working capital. Cash Flows provided by (used in) Investing Activities Net cash provided by (used in) investing activities was (\$37,000) and \$294,000 for the nine months ended September 30, 2024, and 2023, respectively. The cash used in investing activities was for legal costs related to new patent applications in the prior year and for the purchase of manufacturing, laboratory, and office equipment, respectively, in those periods. Cash Flows provided by Financing Activities Net cash provided by financing activities was \$6.2 million and \$2.1 million for the nine months ended September 30, 2024, and 2023, respectively. The cash provided by financing activities in the current year period was the result of proceeds received from the April 2024, July 2024, and August 2024 financings and from the exercise of warrants from the October 2023 and April 2024 financings. The cash provided by financing activities in the prior year period was the result of proceeds received from our 2023 At-The-Market program. Capital Resource Requirements As of September 30, 2024, we did not have any material commitments for capital expenditures. Forward-Looking Statements and Risk Factors Certain statements in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€), that are based on managementâ€™s beliefs, assumptions and expectations and information currently available to management.Â All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, business development, and employees, our ability to execute on our strategic realignments, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, intellectual property protection, and other risks and uncertainties described in our filings with the SEC. In some cases, you can identify forward-looking statements by the following words: â€œanticipate,â€ â€œbelieve,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œongoing,â€ â€œplan,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.Â Forward-looking statements are subject to a number of risks and uncertainties that could cause actual events to adversely differ from the expectations indicated in these forward-looking statements, including without limitation, the risks and uncertainties described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, in other reports filed thereafter with the SEC, which risk factors may be updated from time to time, and in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. We operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our products, the possibility we may be unable to raise the funds necessary for the development and commercialization of our products, and those described in our filings with the SEC. 26 Table of Contents ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Not applicable. ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer (together, the â€œCertifying Officersâ€), as appropriate to allow for timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. As of September 30, 2024, the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of management, including the Certifying Officers, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their stated objectives. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2024. The Certifying Officers based their conclusion on the fact that the Company has identified two material weaknesses in controls over financial reporting, as detailed in the 2023 Annual Report on Form 10-K. In light of this fact, management expects to perform additional analyses, reconciliations, and remediations. Changes in Internal Controls over Financial Reporting There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, as a result of the identified material weaknesses, changes in our internal control over financial reporting will occur. PART IIâ€œOTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS None. ITEM 1A. RISK FACTORS You should carefully consider the risks and uncertainties we describe in our Annual Report on Form 10-K for the year ended December 31,

2023, and in other reports filed thereafter with the SEC, before deciding to invest in or retain shares of our common stock. Other than set forth below, there have been no material changes to the Risk Factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023. Risk Related to our Common Stock Nasdaq may delist our common stock from its exchange which could limit your ability to make transactions in our securities and subject us to additional trading restrictions. 27 Table of Contents Our common stock is listed on the Nasdaq Capital Market under the symbol “NUVE”. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, the minimum stockholders’ equity requirement and the minimum bid price requirement. There can be no assurances that we will be successful in maintaining, or if we fall out of compliance, in regaining compliance with the continued listing requirements and maintaining the listing of our common stock on the NASDAQ Capital Market. On December 7, 2023, we received a notice from Nasdaq (the “Notice”) informing us that because the closing bid price for our Common Stock was below \$1.00 for 30 consecutive trading days, we were not in compliance with the minimum bid price requirement for continued listing on Nasdaq, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), we were granted a period of 180 calendar days from December 7, 2023, or until June 4, 2024, to regain compliance with the Minimum Bid Price Requirement. Subsequently, on May 23, 2024, we received a letter from the Listing Qualifications Staff (the “Staff”) informing the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq, under Listing Rule 5550(b)(1) (the “Stockholder’s Equity Requirement”), because the Company’s stockholders’ equity of \$885,000, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, was below the required minimum of \$2.5 million, and because, as of May 23, 2024, the Company did not meet the alternative compliance standards, relating to the market value of listed securities of \$35 million or net income from continuing operations of \$500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. As a result, on June 5, 2024, we received a letter from Nasdaq indicating the Company’s continued non-compliance with Nasdaq Marketplace Rule 5550(a)(2) (the “Letter”). The Letter further informed the Company that the Common Stock would be delisted from Nasdaq unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company’s requested a hearing to request additional time to meet the Stockholder Equity Requirement which stayed any further delisting action by the Staff pending the ultimate outcome of the hearing. The Common Stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. On June 27, 2024, we effected a 1-for-35 reverse stock split of our outstanding Common Stock. Additionally, in 2020, the SEC approved a Nasdaq rule change to expedite delisting of securities of companies that have had one or more reverse stock splits with a cumulative ratio of one for 250 or more shares over the prior two-year period. Under the new rules, if a company falls out of compliance with the \$1.00 minimum bid price after completing reverse stock splits over the immediately preceding two years that cumulatively result in a ratio one for 250 shares, the company will not be able to avail itself of any compliance periods and Nasdaq will instead request the issuance of a Staff delisting determination, which is appealable to a hearings panel. Our ability to remain listed on Nasdaq may be negatively impacted by this Nasdaq rule. On July 18, 2024, the Company received a letter from the Staff informing the Company that it had regained compliance with the Minimum Bid Price Requirement, but that because it was still non-compliant with the Stockholder’s Equity Requirement the hearing would continue as scheduled as to the matter of the Stockholder’s Equity Requirement. On July 23, 2024, the Company addressed the Panel and presented its plan of compliance for the Stockholder’s Equity Requirement. On August 8, 2024, the Company was notified by Nasdaq that the Panel had granted the Company’s request for continued listing, subject to, among other things, the Company’s filing of its Quarterly Report on Form 10-Q for the period ending September 30, 2024, evidencing compliance with the Stockholder’s Equity Requirement. There can be no assurance the Panel will grant any request for continued listing or that the Company will be able to regain compliance with the applicable listing criteria within the period of time that may be granted by the Panel. If our Common Stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our Common Stock and could harm our business and future prospects. In addition, we believe that, if our Common Stock is delisted, our stockholders would likely find it more difficult to obtain accurate quotations as to the price of the Common Stock and it may be more difficult for stockholders to buy or sell our Common Stock at competitive market prices, or at all. 28 Table of Contents If our Common Stock is delisted, our Common Stock would likely then trade only in the over-the-counter market. If our Common Stock were to trade on the over-the-counter market, selling our Common Stock could be more difficult because smaller quantities of shares would likely be bought and sold, transactions could be delayed, and we could face significant material adverse consequences, including: a limited availability of market quotations for our securities; reduced liquidity with respect to our securities; a determination that our shares are a “penny stock,” which will require brokers trading in our securities to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our securities; a reduced amount of news and analyst coverage for us; and a decreased ability to issue additional securities or obtain additional financing in the future. These factors could result in lower prices and larger spreads in the bid and ask prices for our Common Stock and would substantially impair our ability to raise additional funds and could result in a loss of institutional investor interest and fewer development opportunities for us. In addition to the foregoing, if our Common Stock is delisted from Nasdaq and it trades on the over-the-counter market, the application of the “penny stock” rules could adversely affect the market price of our Common Stock and increase the transaction costs to sell those shares. The SEC has adopted regulations which generally define a “penny stock” as an equity security that has a market price of less than \$5.00 per share, subject to specific exemptions. If our Common Stock is delisted from Nasdaq and it trades on the over-the-counter market at a price of less than \$5.00 per share, our Common Stock would be considered a penny stock. The SEC’s penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and the salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules generally require that before a transaction in a penny stock occurs, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s agreement to the transaction. If applicable in the future, these rules may restrict the ability of brokers-dealers to sell our Common Stock and may affect the ability of investors to sell their shares, until our Common Stock no longer is considered a penny stock. We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. There can be no assurance that we will be able to maintain compliance or, if we fall out of compliance, regain compliance with any deficiency, or if we implement an option that regains our compliance, maintain compliance thereafter. If we fail to comply with federal and state laws regarding off-label use of our products, we could face substantial civil and criminal penalties and our business, financial condition, results of operations, and prospects could be adversely affected. Healthcare professionals may choose to use and prescribe medical devices for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical trials and approved or authorized by the regulatory authorities. Medical device companies, however, are prohibited from marketing and promoting products for indications and uses that are not specifically approved or authorized by FDA. Such “off-label” uses are common on the medical world and often are appropriate treatments for some patients. Regulatory authorities in the U.S. generally do not restrict or regulate the treatment choices of healthcare professionals. Regulatory authorities do, however, restrict communications by companies concerning off-label uses of their products. Any FDA approval or marketing authorization that we have or may obtain in the future permits us to promote the subject medical device only for the specific use(s) cleared, approved, certified or otherwise authorized. We are prohibited from marketing or promoting any medical devices for off-label use. Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional speech concerning their products. Accordingly, we engage in medical education activities and communicate with healthcare professionals about many aspects of our products and clinical trials. In addition, we are aware that the Aquadex System, which is cleared by FDA solely for use in adults and pediatric patients weighing 20 kg or more, is being used off-label uses to treat patients who weigh under 20 kg, including being modified by children’s hospitals so that it can provide dialysis to neonates and other premature infants who were born either without kidneys or without normal kidney function. These patients typically have very few other treatment options given the large extracorporeal blood volume required by standard dialysis machines, the need for blood priming of the dialysis circuit and the use of large catheters. Although we believe that all of our communications regarding off-label uses are in compliance with the relevant regulatory requirements, the FDA or another regulatory authority may disagree, and characterize such communications as marketing and promotion of an off-label use. If the FDA determines that we have marketed or promoted our products for off-label use by us or our commercial partners, it could request that we or our commercial partners modify those promotional materials. We also could be subject to regulatory or enforcement actions, including the issuance of an untitled letters or warning letters, injunctions, seizures, civil fines and criminal penalties. 29 Table of Contents In addition to FDA, we may be subject to significant enforcement actions from other federal and state enforcement authorities, such as the Department of Justice and the Office of the Inspector General of the Department of Health and Human Services, if they consider our communications, including promotional and training materials, to constitute promotion of an unclear, uncertified or unapproved use of a medical device. In the U.S., engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and debarment from government contracts and refusal of future orders under existing contracts. These laws include the federal False Claims Act, which allows any individual to bring a lawsuit against a company on behalf of the federal government alleging submission of false or fraudulent claims or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. Many False Claims Act lawsuits against, and preceding investigations of, manufacturers of healthcare products are brought every year, leading to several substantial civil and criminal settlements related to off-label uses. In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we or our collaborators do not lawfully promote our approved products, we may become subject to such investigations and litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, we must have adequate substantiation for the claims we make for our products and services. If any of our claims are determined to be false, misleading or deceptive, our products and services could be considered misbranded under the FDCA or in violation of the Federal Trade Commission Act. We could also face lawsuits from our competitors under the Lanham Act alleging that our marketing materials are false or misleading. Foreign jurisdictions have their own laws and regulations concerning medical devices, including marketing authorizations and certifications, communications about off-label uses, and substantiation of advertising and promotional claims. Failure to comply with those laws and regulations could result in actions against us, including fines, penalties and exclusion from the market. Any such actions could adversely affect our ability to market new products and services or continue to market existing products and services in those jurisdictions. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company’s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the Offering, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, were approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. 30 Table of Contents ITEM 3. DEFAULTS UPON SENIOR SECURITIES Not applicable. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS The exhibits filed as part of this Quarterly Report on Form 10-Q are listed in the Exhibit Index below. 31 Table of Contents Exhibit Index Nuwellis, Inc. Form 10-Q for the Quarterly Period Ended September 30, 2024 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847. 848. 849. 850. 851. 852. 853. 854. 855. 856. 857. 858. 859. 860. 861. 862. 863. 864. 865. 866. 867. 868. 869. 870. 871. 872. 873. 874. 875. 876. 877. 878. 879. 880. 881. 882. 883. 884. 885. 886. 887. 888. 889. 890. 891. 892. 893. 894. 895. 896. 897. 898. 899. 900. 901. 902. 903. 904. 905. 906. 907. 908. 909. 910. 911. 912. 913. 914. 915. 916. 917. 918. 919. 920. 921. 922. 923. 924. 925. 926. 927. 928. 929. 930. 931. 932. 933. 934. 935. 936. 937. 938. 939. 940. 941. 942. 943. 944. 945. 946. 947. 948. 949. 950. 951. 952. 953. 954. 955. 956. 957. 958. 959. 960. 961. 962. 963. 964. 965. 966. 967. 968. 969. 970. 971. 972. 973. 974. 975. 976. 977. 978. 979. 980. 981. 982. 983. 984. 985. 986. 987. 988. 989. 990. 991. 992. 993. 994. 995. 996. 997. 998. 999. 1000. 1001. 1002. 1003. 1004. 1005. 1006. 1007. 1008. 1009. 1010. 1011. 1012. 1013. 1014. 1015. 1016. 1017. 1018. 1019. 1020. 1021. 1022. 1023. 1024. 1025. 1026. 1027. 1028. 1029. 1030. 1031. 1032. 1033. 1034. 1035. 1036. 1037. 1038. 1039. 1040. 1041. 1042. 1043. 1044. 1045. 1046. 1047. 1048. 1049. 1050. 1051. 1052. 1053. 1054. 1055. 1056. 1057. 1058. 1059. 1060. 1061. 1062. 1063. 1064. 1065. 1066. 1067. 1068. 1069. 1070. 1071. 1072. 1073. 1074. 1075. 1076. 1077. 1078. 1079. 1080. 1081. 1082. 1083. 1084. 1085. 1086. 1087. 1088. 1089. 1090. 1091. 1092. 1093. 1094. 1095. 1096. 1097. 1098. 1099. 1100. 1101. 1102. 1103. 1104. 1105. 1106. 1107. 1108. 1109. 1110. 1111. 1112. 1113. 1114. 1115. 1116. 1117. 1118. 1119. 1120. 1121. 1122. 1123. 1124. 1125. 1126. 1127. 1128. 1129. 1130. 1131. 1132. 1133. 1134. 1135. 1136. 1137. 1138. 1139. 1140. 1141. 1142. 1143. 1144. 1145. 1146. 1147. 1148. 1149. 1150. 1151. 1152. 1153. 1154. 1155. 1156. 1157. 1158. 1159. 1160. 1161. 1162. 1163. 1164. 1165. 1166. 1167. 1168. 1169. 1170. 1171. 1172. 1173. 1174. 1175. 1176. 1177. 1178. 1179. 1180. 1181. 1182. 1183. 1184. 1185. 1186. 1187. 1188. 1189. 1190. 1191. 1192. 1193. 1194. 1195. 1196. 1197. 1198. 1199. 1200. 1201. 1202. 1203. 1204. 1205. 1206. 1207. 1208. 1209. 1210. 1211. 1212. 1213. 1214. 1215. 1216. 1217. 1218. 1219. 1220. 1221. 1222. 1223. 1224. 1225. 1226. 1227. 1228. 1229. 1230. 1231. 1232. 1233. 1234. 1235. 1236. 1237. 1238. 1239. 1240. 1241. 1242. 1243. 1244. 1245. 1246. 1247. 1248. 1249. 1250. 1251. 1252. 1253. 1254. 1255. 1256. 1257. 1258. 1259. 1260. 1261. 1262. 1263. 1264. 1265. 1266. 1267. 1268. 1269. 1270. 1271. 1272. 1273. 1274. 1275. 1276. 1277. 1278. 1279. 1280. 1281. 1282. 1283. 1284. 1285. 1286. 1287. 1288. 1289. 1290. 1291. 1292. 1293. 1294. 1295. 1296. 1297. 1298. 1299. 1300. 1301. 1302. 1303. 1304. 1305. 1306. 1307. 1308. 1309. 1310. 1311. 1312. 1313. 1314. 1315. 1316. 1317. 1318. 1319. 1320. 1321. 1322. 1323. 1324. 1325. 1326. 1327. 1328. 1329. 1330. 1331. 1332. 1333. 1334. 1335. 1336. 1337. 1338. 1339. 1340. 1341. 1342. 1343. 1344. 1345. 1346. 1347. 1348. 1349. 1350. 1351. 1352. 1353. 1354. 1355. 1356. 1357. 1358. 1359. 1360. 1361. 1362. 1363. 1364. 1365. 1366. 1367. 1368. 1369. 1370. 1371. 1372. 1373. 1374. 1375. 1376. 1377. 1378. 1379. 1380. 1381. 1382. 1383. 1384. 1385. 1386. 1387. 1388. 1389. 1390. 1391. 1392. 1393. 1394. 1395. 1396. 1397. 1398. 1399. 1400. 1401. 1402. 1403. 1404. 1405. 1406. 1407. 1408. 1409. 1410. 1411. 1412. 1413. 1414. 1415. 1416. 1417. 1418. 1419. 1420. 1421. 1422. 1423. 1424. 1425. 1426. 1427. 1428. 1429. 1430. 1431. 1432. 1433. 1434. 1435. 1436. 1437. 1438. 1439. 1440. 1441. 1442. 1443. 1444. 1445. 1446. 1447. 1448. 1449. 1450. 1451. 1452. 1453. 1454. 1455. 1456. 1457. 1458. 1459. 1460. 1461. 1462. 1463. 1464. 1465. 1466. 1467. 1468. 1469. 1470. 1471. 1472. 1473. 1474. 1475. 1476. 1477. 1478. 1479. 1480. 1481. 1482. 1483. 1484. 1485. 1486. 1487. 1488. 1489. 1490. 1491. 1492. 1493. 1494. 1495. 1496. 1497. 1498. 1499. 1500. 1501. 1502. 1503. 1504. 1505. 1506. 1507. 1508. 1509. 1510. 1511. 1512. 1513. 1514. 1515. 1516. 1517. 1518. 1519. 1520. 1521. 1522. 1523. 1524. 1525. 1526. 1527. 1528. 1529. 1530. 1531. 1532. 1533. 1534. 1535. 1536. 1537. 1538. 1539. 1540. 1541. 1542. 1543. 1544. 1545. 1546. 1547. 1548. 1549. 1550. 1551. 1552. 1553. 1554. 1555. 1556. 1557. 1558. 1559. 1560. 1561. 1562. 1563. 1564. 1565. 1566. 1567. 1568. 1569. 1570. 1571. 1572. 1573. 1574. 1575. 1576. 1577. 1578. 1579. 1580. 1581. 1582. 1583. 1584. 1585. 1586. 1587. 1588. 1589. 1590. 1591. 1592. 1593. 1594. 1595. 1596. 1597. 1598. 1599. 1600. 1601. 1602. 1603. 1604. 1605. 1606. 1607. 1608. 1609. 1610. 1611. 1612. 1613. 1614. 1615. 1616. 1617. 1618. 1619. 1620. 1621. 1622. 1623. 1624. 1625. 1626. 1627. 1628. 1629. 1630. 163

[illegible]

(c)A A A A A A A A A A Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section 5(b)(i). In the event the corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporationâ€™s notice of meeting, if written notice setting forth the information required by Section 5(b) (i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the later of the nineteenth (90th) day prior to such meeting or the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under Section 5(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholderâ€™s notice as described above. 6.(d)A A A A A A A A A A Notwithstanding the foregoing provisions of this Section 6, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section 6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporationâ€™s proxy statement pursuant to Rule 14a-8 under the 1934 Act; provided, however, that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to Section 6(c) of these Bylaws. 7.A A A A A A A A A A NOTICE OF MEETINGS. Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholderâ€™s address as it appears on the records of the corporation. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. 8.A A A A A A A A A A QUORUM. At all meetings of stockholders, except where otherwise provided by statute or by the corporationâ€™s Fourth Amended and Restated Certificate of Incorporation, as it may be amended from time to time (the â€œCertificate of Incorporationâ€), or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. 7.9.A A A A A A A A A A ADJOURNMENT AND NOTICE OF ADJOURNED MEETINGS. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. 10.A A A A A A A A A A VOTING RIGHTS. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section 12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3) years from its date of creation unless the proxy provides for a longer period. 11.A A A A A A A A A A JOINT OWNERS OF STOCK. If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a) if only one (1) vote, his act binds all; (b) if more than one (1) votes, the act of the majority so voting binds all; (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section 217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection (c) shall be a majority or even-split in interest. 12.A A A A A A A A A A LIST OF STOCKHOLDERS. The Secretary shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided by law. 13.A A A A A A A A A A ACTION WITHOUT MEETING. No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent or by electronic transmission. 8.14.A A A A A A A A A A ORGANIZATION. (a)A A A A A A A A A A At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. (b)A A A A A A A A A A The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. ARTICLE IV DIRECTORS 15.A A A A A A A A A A NUMBER AND TERM OF OFFICE. The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. 16.A A A A A A A A A A POWERS. The powers of the corporation shall be exercised, its business conducted and its property controlled by the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. 17.A A A A A A A A A A CLASSES OF DIRECTORS. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class I directors shall expire and the Class I directors shall be elected for a term of that will expire at the fourth annual meeting of stockholders following the initial classification of the Board of Directors. At the second annual meeting of stockholders following such initial classification, the term of office of the Class II directors shall expire and the Class II directors shall be elected for a term of that will expire at the fifth annual meeting of stockholders following the initial classification of the Board of Directors. At the third annual meeting of stockholders following such initial classification, the term of office of the Class III directors shall expire and the Class III directors shall be elected for a term of that will expire at the sixth annual meeting of stockholders following the initial classification of the Board of Directors. At each succeeding annual meeting of stockholders, directors shall be elected for a term that will expire at the third annual meeting of stockholders following such annual meeting to succeed the directors of the class whose terms expire at such annual meeting. 9 Notwithstanding the foregoing provisions of this Section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. 18.A A A A A A A A A A VACANCIES. Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders; provided, however, that whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such directorâ€™s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Section in the case of the death, removal or resignation of any director. 19.A A A A A A A A A A RESIGNATION. Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, such resignation shall be deemed effective at the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the unexpired portion of the term of the Director whose place shall be vacated and until his successor shall have been duly elected and qualified. 20.A A A A A A A A A A REMOVAL. (a)A A A A A A A A A A Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances, neither the Board of Directors nor any individual director may be removed without cause. (b)A A A A A A A A A A Subject to any limitation imposed by law, any individual director or directors may be removed only with cause by the affirmative vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy at a meeting of stockholders and entitled to vote generally on the election of directors, voting together as a single class. 21.A A A A A A A A A A MEETINGS. (a)A A A A A A A A A A Regular Meetings. Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors. (b)A A A A A A A A A A Special Meetings. Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by any member of the Board of Directors. 10 (c)A A A A A A A A A A Meetings by Electronic Communications Equipment. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting. (d)A A A A A A A A A A Notice of Special Meetings. Notice of the time and place of all special meetings of the Board of Directors shall be given orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least twenty-four (24) hours before the date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three (3) days before the date of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. (e)A A A A A A A A A A Waiver of Notice. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. 22.A A A A A A A A A A QUORUM AND VOTING. (a)A A A A A A A A A A Unless the Certificate of Incorporation requires a greater number, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. (b)A A A A A A A A A A At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. 23.A A A A A A A A A A ACTION WITHOUT MEETING. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members

of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. 24.Â Â Â Â Â FEES AND COMPENSATION. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor. 11 25.Â Â Â Â Â COMMITTEES. (a)Â Â Â Â Â Executive Committee. The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopting, amending or repealing any Bylaw of the corporation. (b)Â Â Â Â Â Other Committees. The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. (c)Â Â Â Â Â Term. The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections (a) and (b) of this Section 25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. (d)Â Â Â Â Â Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section 25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. 26.Â Â Â Â Â LEAD INDEPENDENT DIRECTOR. The Chairman of the Board of Directors, or if the Chairman is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (the "Lead Independent Director"). The Lead Independent Director will: with the Chairman of the Board of Directors, establish the agenda for regular Board meetings and serve as chairman of Board of Directors meetings in the absence of the Chairman of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is presented or discussed; and perform such other duties as may be established or delegated by the Chairman of the Board of Directors. 12 27.Â Â Â Â Â ORGANIZATION. At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or, if the Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary or other officer or director directed to do so by the President, shall act as secretary of the meeting. 28.Â Â Â Â Â DUTIES OF CHAIRMAN OF THE BOARD OF DIRECTORS. The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. ARTICLE V OFFICERS 29.Â Â Â OFFICERS DESIGNATED. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors. 30.Â Â Â Â Â TENURE AND DUTIES OF OFFICERS. (a)Â Â Â Â Â General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors. (b)Â Â Â Â Â Duties of Chief Executive Officer. The Chief Executive Officer shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an officer has been appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. (c)Â Â Â Â Â Duties of President. The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. 13 (d)Â Â Â Â Â Duties of Vice Presidents. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. (e)Â Â Â Â Â Duties of Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. (f)Â Â Â Â Â Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. (g)Â Â Â Â Â Duties of Treasurer. Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. 31.Â Â Â DELEGATION OF AUTHORITY. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. 32.Â Â Â Â RESIGNATIONS. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. 14 33.Â Â Â Â REMOVAL. Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. ARTICLE VI EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION 34.Â Â Â Â EXECUTION OF CORPORATE INSTRUMENTS. The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. All checks and drafts drawn on banks or other depositories on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. 35.Â Â Â Â VOTING OF SECURITIES OWNED BY THE CORPORATION. All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. ARTICLE VII SHARES OF STOCK 36.Â Â Â Â FORM AND EXECUTION OF CERTIFICATES. The shares of the corporation shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock, if any, shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by certificate in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors or the President or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. 37.Â Â Â Â LOST CERTIFICATES. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner's legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. 15 38.Â Â Â Â TRANSFERS. (a)Â Â Â Â Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. (b)Â Â Â Â The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. 39.Â Â Â Â FIXING RECORD DATES. (a)Â Â Â Â In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. (b)Â Â Â Â In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. 40.Â Â Â Â REGISTERED STOCKHOLDERS. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other

notice thereof, except as otherwise provided by the laws of Delaware. ARTICLE VIII OTHER SECURITIES OF THE CORPORATION 11.Â Â Â Â Â EXECUTION OF OTHER SECURITIES. All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section 36), may be signed by the Chairman of the Board of Directors, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. 16 ARTICLE IX DIVIDENDS 42.Â Â Â Â Â DECLARATION OF DIVIDENDS. Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. 43.Â Â Â Â Â DIVIDEND RESERVE. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created. ARTICLE X FISCAL YEAR 44.Â Â Â Â Â FISCAL YEAR. The fiscal year of the corporation shall be fixed by resolution of the Board of Directors. ARTICLE XI INDEMNIFICATION 45.Â Â Â Â Â INDEMNIFICATION OF DIRECTORS, OFFICERS, EMPLOYEES AND OTHER AGENTS. (a)Â Â Â Â Â Directors and Officers. The corporation shall indemnify its directors and officers to the extent not prohibited by the DGCL or any other applicable law; provided, however, that the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the corporation, (iii) such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or (iv) such indemnification is required to be made under paragraph (d) of this Section. (b)Â Â Â Â Â Employees and Other Agents. The corporation shall have the power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine. (c)Â Â Â Â Â Expenses. The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding; provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an "undertaking"), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a "final adjudication") that such indemnitee is not entitled to be indemnified for such expenses under this Section or otherwise. 17 Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this Section, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. (d)Â Â Â Â Â Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or advances granted by this Section to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because the officer or director has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this Section or otherwise shall be on the corporation. (e)Â Â Â Â Â Non-Exclusivity of Rights. The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law. 18 (f)Â Â Â Â Â Survival of Rights. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director, officer, employee or other agent and shall inure to the benefit of the heirs, executors and administrators of such a person. (g)Â Â Â Â Â Insurance. To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section. (h)Â Â Â Â Â Amendments. Any repeal or modification of this Section shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. (i)Â Â Â Â Â Saving Clause. If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Section that shall not have been invalidated, or by any other applicable law. If this Section shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer to the full extent under any other applicable law. (j)Â Â Â Â Â Certain Definitions. For the purposes of this Bylaw, the following definitions shall apply: (i)Â Â Â Â Â The term "proceeding" shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. (ii)Â Â Â Â Â The term "expenses" shall be broadly construed and shall include, without limitation, court costs, attorneys' fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. (iii)Â Â Â Â The term "corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued. (iv)Â Â Â Â Â References to a "director", "officer", "employee", "trustee or agent of another corporation, partnership, joint venture, trust or other enterprise", "person", "agent of the corporation" or "person" shall include employee benefit plans; references to "officers" shall include any executive taxes assessed on a person with respect to an employee benefit plan; and references to "persons" shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the corporation" as referred to in this Section. 19 ARTICLE XII NOTICES 46.Â Â Â Â Â NOTICES. (a)Â Â Â Â Â Notice to Stockholders. Written notice to stockholders of stockholder meetings shall be given as provided in Section 7 herein. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means. (b)Â Â Â Â Â Notice to Directors. Any notice required to be given to any director may be given by the method stated in subsection (a), as otherwise provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary or, in the absence of such filing, to the last known post office address of such director. (c)Â Â Â Â Â Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. (d)Â Â Â Â Â Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. (e)Â Â Â Â Â Notice to Person With Whom Communication Is Unlawful. Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. (f)Â Â Â Â Â Notice to Stockholders Sharing an Address. Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within sixty (60) days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. 20 ARTICLE XIII AMENDMENTS 47.Â Â Â Â Â AMENDMENTS. Subject to the limitations set forth in Section 45(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. ARTICLE XIV LOANS TO OFFICERS OR EMPLOYEES 48.Â Â Â Â Â LOANS TO OFFICERS OR EMPLOYEES. Except as otherwise prohibited by applicable law, the corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute. ARTICLE XV AUSTRALIAN SECURITIES EXCHANGE LISTING RULES 49.Â Â Â Â Â AUSTRALIAN SECURITIES EXCHANGE LISTING RULES. While the corporation is on the official list of the Australian Securities Exchange, the following rules shall apply: (a)Â Â Â Â Â notwithstanding anything contained in these Bylaws, if the official listing rules of the Australian Securities Exchange (the "Listing Rules") prohibit an act being done, the act shall not be done; (b)Â Â Â Â Â nothing contained in these Bylaws prevents an act being done that the Listing Rules require to be done; (c)Â Â Â Â Â if the Listing Rules require an act to be done or not to be done, authority is given for that act to be done or not to be done (as the case may be); (d)Â Â Â Â Â if the Listing Rules require these Bylaws to contain a provision and these Bylaws do not contain such a provision, these Bylaws shall be treated as containing that provision; (e)Â Â Â Â Â if the Listing Rules require these Bylaws not to contain a provision and these Bylaws contain such a provision, these Bylaws shall be treated as not containing that provision; and (f)Â Â Â Â Â if any provision of these Bylaws is or becomes inconsistent with the Listing Rules, these Bylaws shall be treated as not containing that provision to the extent of such inconsistency. 21 EX-3.14 3 ef20034581 ex3-14.htm EXHIBIT 3.14 AMENDMENT TO THE THIRD AMENDED AND RESTATED BYLAWS OF NUWELLIS, INC. Â The Third Amended and Restated Bylaws (the "Bylaws") of Nuwellis, Inc., a Delaware corporation, are hereby amended as follows, effective as of October 5, 2022. Â 1.Â Â Â Â Â Section 8 of ARTICLE III of the Bylaws is hereby amended and restated in its entirety to read as follows: Â "Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the corporation's Fourth Amended and Restated Certificate of Incorporation, as it may be amended from time to time (the "Certificate of

Incorporationâ€), or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of one-third of the voting power of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the voting power of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of voting power of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, or by applicable stock exchange rules, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute, or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, one-third of the voting power of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute, or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series.â€ 2. A A A A A A A A A A Except as specifically amended herein, the Bylaws shall remain unchanged and in full force and effect. A (Remainder of page intentionally left blank) NUWELLIS, INC. CERTIFICATE OF ADOPTION OF AMENDMENT TO THIRD AMENDED AND RESTATED BYLAWS A The undersigned hereby certifies that he is the duly elected, qualified, and acting Secretary of Nuwellis, Inc., a Delaware corporation, and that the foregoing Amendment to the Third Amended and Restated Bylaws constitutes the entire amendment to the Third Amended and Restated Bylaws, as duly adopted by the Board of Directors on October 5, 2022. A /s/ Neil P. Ayotte A Neil P. Ayotte A Secretary A 2 EX-31.1 4 ef20034581 ex31-1.htm EXHIBIT 31.1 Exhibit 31.1 CHIEF EXECUTIVE OFFICERâ€ S 302 CERTIFICATION I, Nestor Jaramillo, Jr., certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of Nuwellis, Inc. for the quarterly period ended September 30, 2024; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): A a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and A b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 12, 2024 /s/ Nestor Jaramillo, Jr. A Nestor Jaramillo, Jr. A President and Chief Executive Officer EX-31.2 5 ef20034581 ex31-2.htm EXHIBIT 31.2 Exhibit 31.2 CHIEF FINANCIAL OFFICERâ€ S 302 CERTIFICATION I, Robert Scott, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Nuwellis, Inc. for the quarterly period ended September 30, 2024. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 12, 2024 /s/ Robert Scott A Robert Scott A Chief Financial Officer EX-32.1 6 ef20034581 ex32-1.htm EXHIBIT 32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Nuwellis, Inc. (the â€Companyâ€) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€Reportâ€), I, Nestor Jaramillo, Jr., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 12, 2024 /s/ Nestor Jaramillo, Jr. A Nestor Jaramillo, Jr. A President and Chief Executive Officer EX-32.2 7 ef20034581 ex32-2.htm EXHIBIT 32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Nuwellis, Inc. (the â€Companyâ€) on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€Reportâ€), I, Robert Scott, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 12, 2024 /s/ Robert Scott A Robert Scott A Chief Financial Officer EX-101.SCH 8 nvue-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Insider Trading Arrangement link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 080100 - Disclosure - Nature of Business and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090102 - Disclosure - Nature of Business and Basis of Presentation, Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Revenue Recognition (Details)Default link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nvue-20240930.cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 nvue-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 nvue-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accumulated other comprehensive income: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Additional paid-in capital Additional Paid in Capital Allowance for doubtful accounts Warrant financing costs Financing Expense Condensed Consolidated Balance Sheets [Abstract] Basic loss per share (in dollars per share) Basic net income (loss) per share (in dollars per share) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts receivable Increase (Decrease) in Accounts Receivable Inventory, net Increase (Decrease) in Inventories Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock as of September 30, 2024 and December 31, 2023, par value \$0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,866,890 and 162,356, respectively Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk Type [Axis] Concentration Risk Type [Domain] Cost of goods sold Cost of Goods and Services Sold Foreign currency translation adjustment Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Total current liabilities Liabilities, Current Current liabilities Liabilities, Current [Abstract] Customer Concentration Risk [Member] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Diluted loss per share (in dollars per share) Diluted net income (loss) per share (in dollars per share) Principles of Consolidation Stock-based compensation expense Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Gross profit Gross Profit Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] Income Taxes Income Tax Disclosure [Text Block] Finished Goods Inventories, net Total Inventory, Net Inventories [Abstract] Raw Materials Work in Process Inventory Reserves Inventory Valuation Reserves Inventories Stock-Based Compensation Expense Items [Abstract] Income Statement Compensation Expense Items [Abstract] Total liabilities Liabilities TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Liabilities and Equity LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating Activities: Net income (loss) Net loss Net income (loss) Net income (loss) attributable to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Loss from operations Operating Income (Loss) Other current assets Other Assets, Current Other income (expense), net Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Issuance of common stock from offering Gross proceeds from public stock offering Proceeds from ATM stock offerings, net Property, plant and equipment, net Property, Plant and Equipment, Net Additions to intangible assets Payments to Acquire Intangible Assets Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Accounts Receivable Accumulated deficit Sale of Stock [Domain] Common stock offering price per share (in dollars per share) Classification of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Selling, general and administrative Selling, General and Administrative Expense Series F Convertible Preferred Stock [Member] Series A Junior Participating Preferred Stock [Member] Weighted average grant date fair value of stock options issued (in dollars per share) Outstanding stock options (in shares) Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Award Type [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Consolidated Statements of Cash Flows [Abstract] Condensed Consolidated Statements of Stockholders' Equity [Abstract] Stock Options [Member] Equity Option [Member] Stockholders' equity Stockholders' equity [Abstract] Stockholders' Equity Equity [Text Block] Warrants to purchase shares of common stock (in shares) Aggregate purchase of warrants (in shares) Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Supplemental cash flow information Mezzanine Equity Total current assets Assets, Current Current assets Assets, Current [Abstract] Warrants to

Purchase Common Stock [Member] Weighted average shares outstanding - diluted (in shares) Weighted average shares outstanding - basic (in shares) Common Stock [Member] Common Stock [Member] Research and development Research and Development Expense TOTAL ASSETS Assets Other current liabilities Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Financial Instruments [Domain] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Statement [Table] Antidilutive Securities, Name [Domain] ASSETS Assets [Abstract] Statement [Line Items] Roll-Forward of Fair Value of Level 3 Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Stockholders' Equity [Abstract] Fair Value of Financial Instruments Mezzanine equity, shares authorized (in shares) Mezzanine equity, shares issued (in shares) Mezzanine equity, shares outstanding (in shares) Class of Stock [Domain] Proceeds from sale of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Issuance of common stock for pre-funded warrants (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Other assets Other Assets, Noncurrent Operating expenses: Total operating expenses Operating Expenses Reported net loss with reported net loss per share [Abstract] Earnings Per Share Reconciliation [Abstract] Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potential Shares of Common Stock not Included in Diluted Net Loss Per Share Antidilutive Security, Excluded EPS Calculation [Table] Loss per Share Earnings Per Share, Policy [Policy Text Block] Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Earnings Per Share, Diluted, Other Disclosure [Abstract] Class of Stock [Axis] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Unrealized foreign currency translation adjustment Total stockholders' equity Balance Balance Equity, Attributable to Parent Income tax expense Income Tax Expense (Benefit) Preferred stock Accounts Receivable [Member] Equity Components [Axis] Additional Paid in Capital [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Equity Component [Domain] Stock Options [Member] Stock options expired or forfeited (in shares) Issuance of common stock, net Stock-based compensation, net Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Conversion of preferred stock into common stock Issuance of common stock, net (in shares) Stock-based compensation, net (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Exercise of stock options (in shares) No of warrants converted to equity (in shares) Conversion of preferred stock into common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Deemed dividend Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings Issuance of common stock, net Stock Repurchased During Period, Value Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Additional Disclosures [Abstract] Weighted Average Assumptions used in Black-Scholes Option Pricing Model [Abstract] Class of Stock [Line Items] Class of Stock Disclosures [Abstract] Stock, Class of Stock [Table] Operating Leases [Abstract] Commitments and contingencies Commitments and Contingencies Adjustments to reconcile net loss to cash flows used in operating activities: Accounts payable and accrued liabilities Accrued compensation Employee-related Liabilities, Current Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Nature of Business and Basis of Presentation Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Mezzanine equity, par value (in dollars per share) Deemed dividend on Series J Preferred Stock Deemed dividend attributable to Series J Convertible Preferred Stock Temporary Equity, Dividends, Adjustment Collaborative Arrangement, and Arrangement Other than Collaborative [Axis] Gross proceeds received through exercise of warrants Proceeds from the exercise of Series J Convertible Preferred Warrants Issuance Balance (in shares) Balance (in shares) Shares, Outstanding Ending balance Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Inventories Schedule of Inventory, Current [Table Text Block] Commitments and Contingencies [Abstract] Income Taxes [Abstract] Fair Value of Financial Instruments [Abstract] Subsequent Events Weighted Average Assumptions used in Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock-Based Compensation [Abstract] Subsequent Events Subsequent Events, Policy [Policy Text Block] Research and Development Expense [Member] Research and Development Expense [Member] Nature of Business and Basis of Presentation [Abstract] Subsequent Events [Abstract] Other current assets Increase (Decrease) in Other Current Assets Other assets and liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Stock options granted (in shares) Reconciliation of Reported Net Loss with Reported Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Financial Instrument [Axis] Series J Convertible Preferred Stock as of September 30, 2024 and December 31, 2023, par value \$0.0001 per share; authorized 600,000 shares, issued and outstanding 95 and 11,950, respectively Temporary Equity, Carrying Amount, Attributable to Parent Award Type [Axis] Subsequent Event [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Expected Life of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Period of warrants expected to vest Vesting period Selling, General and Administrative Expense [Member] Selling, General and Administrative Expenses [Member] Concentration risk percentage Percentage of net sales Agreement settlement amount receivable Loss Contingency, Receivable Reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Net Sales [Member] Sales Revenue [Member] Change in fair value of warrant liability Change in fair value of warrant liability Vesting [Axis] Vesting [Domain] Percentage of warrants expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock options vested (in shares) Tranche One [Member] Tranche Two [Member] Tranche Three [Member] Exercise price of warrants (in dollars per share) Warrant exercise price per share (in dollars per share) International [Member] Non-US [Member] Agreement settlement amount received Loss Contingency, Receivable, Proceeds Disaggregation of Revenue [Table] Revenue Recognized over Time [Member] Transferred over Time [Member] Disaggregation of Revenue [Line Items] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Revenue Recognition [Abstract] Revenue Recognition Revenue from Contract with Customer [Text Block] Revenue Recognition [Abstract] Revenue, Performance Obligation [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Operating lease right-of-use asset Net sales Revenue from Contract with Customer, Excluding Assessed Tax Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Payments on finance lease liability Finance Lease, Principal Payments Current portion of operating lease liability Operating Lease, Liability, Current Operating lease liability Operating Lease, Liability, Noncurrent Operating Leases Expected timing of satisfaction, period Net realized gain on marketable securities Debt Securities, Available-for-Sale, Gain (Loss) Revenue Recognition Warrants term Warrants and Rights Outstanding, Term Converted warrant Reclassification of warrants to equity Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount Customer [Domain] Geographical [Domain] Geographical [Axis] Customer [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding The amount of issuance of preferred stock for exercise of warrants. Issuance of Preferred Stock for Warrant Exercises Issuance of Series J Preferred Stock for exercise of warrants The amount of issuance of common stock for conversion of preferred stock. Issuance of Common Stock for Conversion of Preferred Stock Issuance of Common Stock for conversion of Series J Preferred Stock The amount of non-cash impact of conversion of warrants to common stock. Non-Cash Impact of Conversion of Warrants to Common Stock Non-cash impact of conversion of warrants to common stock The reclassification of warrants to equity. Reclassification of Warrants to Equity Reclassification of April 2024 warrants to equity The cash inflow associated with the amount received from holders exercising their warrants. Proceeds From Exercise of Warrants Proceeds from the exercise of April 2024 Warrants The cash inflow from issuance of rights to purchase common stock and warrants. Issuance of Common Stock and Warrants Issuance of July and August 2024 Common Stock and Warrants Series j preferred stock. Series j Convertible Preferred Stock [Member] Series j Convertible Preferred Stock [Member] Amount of common stock warrant liability, due after one year or the normal operating cycle, if longer. Common Stock Warrant Liability, Noncurrent Common stock warrant liability Series j preferred stock. Series j Preferred Stock [Member] Series j Convertible Preferred Stock [Member] Series j Convertible Preferred Stock [Member] The agreement entered by the company with certain institutional investors for the purchase and sale of shares. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Going Concern [Abstract] Going Concern [Abstract] The floor price per share represents the lowest price (lowest level) at which an IPO may be bid on. Floor Price Per Share Floor price per share (in dollars per share) Number of warrants included in each unit in a public offering. Number of Warrants in Each Unit Number of warrants included in each unit Number of securities into which the class of warrant or right may be converted. Class of Warrant or Right, Number of Securities Called by Warrants or Rights to Purchase Shares of Common Stock Warrants to purchase common shares (in shares) Amount of merit increases to base salaries of named executive officer or employee during the period. Merit Increases to Base Salaries of Named Executive Officer or Employee Merit increases to base salaries of named executive officer or employee Period warrants expiry , in PnYmMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Warrant Expiry Period Warrant expiry period The amount of gross proceeds before deducting placement agent fees and commissions and offering expenses. Gross Proceeds Before Deducting Placement Agent Fees and Commissions and Offering Expenses Gross proceeds before deducting placement agent fees and commissions and offering expenses Number of major customers of the entity. Number of Major Customers Number of major customers Represents the typical credit period from the invoice date, after which unpaid accounts are individually analyzed for collectability in PnYmMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Accounts Receivables Maximum Credit Period from Invoice Date Accounts receivables maximum credit period from invoice date Amount of cash bonuses paid to any named executive officer or employee during the period. Payment for Cash Bonus Cash bonuses to named executive officer or employee Warrant security classified as series I and series II, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Series I Warrants and Series II Warrants [Member] Series I Warrants and Series II Warrants [Member] Warrant security classified as series I, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Series I Warrants [Member] Series I Warrants [Member] The April 2024 stock offering to the public. April 2024 Offering [Member] April 2024 Offering [Member] Period of time when Warrants becomes exercisable, in PnYmMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Exercisable Warrants or Rights Period Warrants exercisable period The amount of gross proceeds prior deducting inducement agent fees and estimated offering expenses. Gross Proceeds from Offering Prior Deducting Inducement Agent Fees and Estimated Offering Expenses Gross proceeds prior to deducting inducement agent fees and estimated offering expenses Gross proceeds prior to deducting inducement agent fees and estimated offering expenses A major single external customer or group of external customers representing concentration risk. Customer One [Member] Customer One [Member] Refers to percentage of reduction in monthly burn rate balanced against strategic growth initiatives. Percentage of Reduce in Monthly Cash Burn Rate Reduce our monthly cash burn rate The amount of gross proceeds before deducting the placement agent fees and other offering expenses. Gross Proceeds from Offering Before Deducting the Placement Agent Fees and Other Offering Expenses Gross proceeds before deducting the placement agent fees and other offering expenses Warrant security classified as series II, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Series II Warrants [Member] Series II Warrants [Member] 'Number of trading days immediately following the date the Company effects a reverse stock split in the future, in PnYmMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days Number of trading days A major single external customer or group of external customers representing concentration risk. Customer Two [Member] Customer Two [Member] The August 2024 stock offering to the public. August 2024 Offering [Member] August 2024 Offering [Member] Operating Lease [Abstract] Operating Leases [Abstract] Annual increase in the amount of rent expense per square foot for leased assets. Annual base rent Increase per Square Foot Annual increase per square foot (in dollars per square foot) Area of leased property under operating lease. Operating Lease, Area for Lease Area of property leased under operating lease Amount of base rent expense per square foot for leased assets. Annual Base Rent per Square Foot Annual base rent (per square foot) Amount of monthly rent and common area maintenance charges, including estimated property tax for headquarters. Operating Lease, Monthly Rent and Common Area Maintenance Charges Monthly rent and common area maintenance charges Additional paid-in-capital attributable to conversion (for example, stock purchase warrants, detachable call options) or other instrument features (for example, embedded conversion option) that satisfy the conditions for equity classification. Additional Paid-in Capital, Attributable to Convertible Option [Member] Warrants [Member] Amount of exercise value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues, Exercise of Warrants Exercise of warrants Amount of issuance of common stock in equity for warrants measured at fair value on recurring basis using unobservable input (level 3). Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Stock Issued for Conversion of Warrants Issuance of Common Stock for exercise of warrants Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. April 30, 2024 Warrants Issuance [Member] April 30, 2024 Warrants Issuance [Member] Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. October 17, 2023 Warrants Issuance [Member] October 17, 2023 Series J Warrants Issuance [Member] Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. October 18, 2022 Warrants Issuance [Member] October 18, 2022 Series I Warrants Issuance [Member] Amount of reclassification to equity measured at fair value on recurring basis using unobservable input (level 3). Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification to Equity Reclassification to Equity The gross value of stock issued during the period upon the exercise of warrants. Stock Issued During Period, Value, Exercise of Warrants Exercise of common stock warrants Number of shares issued during the period as a result of the conversion of warrants. Stock Issued During Period, Shares, Conversion of Warrants Conversion of warrants into common stock (in shares) Amount of decrease (increase) to additional paid in capital (APIC) resulting from deemed dividend. Adjustments to Additional Paid In Capital, Deemed Dividend Series J convertible preferred stock deemed dividend Number of shares issued during the period as a result of the exercise of warrants. Stock Issued During Period, Shares, Exercise of Warrants Exercise of common stock warrants (in shares) The gross value of stock issued during the period upon the conversion of warrants. Stock Issued During Period, Value, Conversion of Warrants Conversion of warrants into common stock Represents the information pertaining to the securities purchase agreement with an institutional investor. Purchase Agreement [Member] An "at-the-market" offering is an offering of securities into an existing trading market for outstanding shares of the same class at other than a fixed price on, or through the facilities of, a national securities exchange, or to or through a market maker otherwise than on an exchange. At The Market Offering [Member] At-the-Market Program [Member] The October 2023 stock offering to the public. October 2023 Offering [Member] October 2023 Offering [Member] The July 2024 stock offering to the public. July 2024 Offering [Member] July 2024 Offering [Member] The number of tranches in which the warrants/rights will vest. Class of Warrant or Right, Number Of Tranches Number of tranches Amount of financing expense incurred for liability in excess of gross

proceeds of offering on day 1. Financing Expense for Liability in Excess of Gross Proceeds of Offering Financing expense Warrants to be exercised for amount of shares ownership percentage in entity subject to certain vesting milestones. Class of Warrant or Right, Warrants to be Exercised for Amount of Shares Ownership Percentage in Entity Subject to Certain Vesting Milestones Warrants to be exercised for amount of shares ownership percentage in entity Refers to percentage of placement fee paid to underwriter or placement agent, based on aggregate gross proceeds raised in the offering and issued warrants. Percentage of Fees Paid to Underwriter or Placement Agent in Cash Aggregate cash fee paid to underwriter or placement agent Percentage of original issue discount on convertible preferred stock issued. Convertible Preferred Stock Original Issue Discount Percentage Per Unit Original issue discount percentage The amount of net proceeds after deducting placement agent fees and commissions and offering expenses. Net Proceeds After Deducting Placement Agent Fees and Commissions and Offering Expenses Net proceeds after deducting placement agent fees and commissions and offering expenses Number of consecutive trading days in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Consecutive Trading Days Number of consecutive trading days The net cash inflow from the additional capital contribution to the entity. Proceeds From Issuance Of Common Stock, Net Net proceeds from public stock offering Number of consecutive trading days considered for expiration in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Consecutive Trading Days Considered for Expiration Number of consecutive trading days considered for expiration Trading volume for each trading day during the period. Trading Volume for Each Trading Day Trading volume for each trading day The number of shares included in one unit. Number of Share in One Unit Number of shares in one unit (in shares) Percentage of volume weighted average price of the common stock. Percentage of Volume Weighted Average Price of Common Stock Percentage of volume weighted average price of common stock Refers to price per share of the preferred stock at conversion into common stock. Conversion of Stock, Shares Conversion Price Conversion price (in dollars per share) Convertible preferred stock shares issuable upon declaration of dividends. Convertible Preferred Stock Issuable Upon Declaration of Dividends Paid In Kind Additional shares issuable upon declaration of dividends (in shares) Name of Supply and Collaboration agreement. Supply and Collaboration Agreement [Member] Supply Agreement [Member] The aggregate offering price of shares offer or sold in the stock transaction. Sale of Stock Aggregate Offering Price Term of continued provision of both inpatient and outpatient ultrafiltration services, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Period for Ultrafiltration Services Period for ultrafiltration services Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. DaVita Warrant [Member] DaVita Warrant [Member] Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share Based Compensation Award Tranche Four [Member] Tranche Four [Member] SeaStar Medical Holding Corporation, (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune responses including hyperinflammation on vital organs ("SeaStar"). SeaStar Medical Holding Corporation [Member] SeaStar Medical Holding Corporation [Member] Disclosure of accounting policy for the going concern when substantial doubt is raised about the ability to continue as a going concern. Going Concern [Policy Text Block] Going Concern Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract] EX-101.PRE 12 nuwe-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep 30, 2024 Nov 08, 2024 Cover [Abstract] Á Á Document Type 10-Q Á Amendment Flag false Á Document Quarterly Report true Á Document Period End Date Sep. 30, 2024 Á Current Fiscal Year End Date -12-31 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q3 Á Document Transition Report false Á Entity File Number 001-35312 Á Entity Registrant Name NUWELLIS, INC. Á Entity Central Index Key 0001506492 Á Entity Incorporation, State or Country Code DE Á Entity Tax Identification Number 68-0533453 Á Entity Address, Address Line One 12988 Valley View Road Á Entity Address, City or Town Eden Prairie Á Entity Address, State or Province MN Á Entity Address, Postal Zip Code 55344 Á City Area Code 952 Á Local Phone Number 345-4200 Á Title of 12(b) Security Common Stock, par value \$0.0001 per share Á Trading Symbol NUWE Á Security Exchange Name NASDAQ Á Entity Current Reporting Status Yes Á Entity Interactive Data Current Yes Á Entity Filer Category Non-accelerated Filer Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Shell Company false Á Entity Common Stock, Shares Outstanding Á 4,373,968 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

Page 14 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1> <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 1>

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 15: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph \(SX 210.6-04\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99-Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20:

gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 5: http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap TemporaryEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef](https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Stockholders' equity (A) A Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 39,352,000 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized (in shares) 100,000,000 100,000,000 Common stock, shares issued (in shares) 1,866,890 162,356 Common stock, shares outstanding (in shares) 1,866,890 162,356 Series J Convertible Preferred Stock [Member] A Mezzanine Equity A A Mezzanine equity, par value (in dollars per share) $ 0.0001 $ 0.0001 Mezzanine equity, shares authorized (in shares) 600,000 600,000 Mezzanine equity, shares issued (in shares) 95 11,950 Mezzanine equity, shares outstanding (in shares) 95 11,950 Series A Junior Participating Preferred Stock [Member] A A Stockholders' equity A A Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 30,000 30,000 Preferred stock, shares outstanding (in shares) 0 0 Series F Convertible Preferred Stock [Member] A A Stockholders' equity A A Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 18,000 18,000 Preferred stock, shares issued (in shares) 127 127 Preferred stock, shares outstanding (in shares) 127 127 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI [https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares \(or preferred stock redeemable solely at the option of the issuer\) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares \(or preferred stock redeemable solely at the option of the issuer\) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI

conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na:Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_TemporaryEquitySharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na:Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na:Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=nuwe_SeriesPreferredStockMember Namespace Prefix: Data Type: na:Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesPPreferredStockMember Namespace Prefix: Data Type: na:Balance Type: Period Type: XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD (\$) (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] Á Á Á Net sales \$ 2,367 \$ 2,412 \$ 6,418 \$ 6,313 Cost of goods sold 711 1,031 2,097 2,718 Gross profit 1,656 1,381 4,321 3,595 Operating expenses: Á Á Á Selling, general and administrative 2,702 3,428 10,544 13,582 Research and development 486 1,117 2,378 4,050 Total operating expenses 3,188 4,545 12,922 17,632 Loss from operations (1,532) (3,164) (8,601) (14,037) Other income (expense), net 8 (204) (87) 98 Financing Expense 0 (5,607) 0 Change in fair value of warrant liability 3,882 0 4,602 (755) Income (loss) before income taxes 2,358 (3,368) (9,693) (14,694) Income tax expense 0 (2) (4) (6) Net income (loss) 2,358 (3,370) (9,697) (14,700) Deemed dividend attributable to Series J Convertible Preferred Stock 0 541 0 Net income (loss) attributable to common shareholders 2,358 (3,370) (9,156) (14,700) Basic net income (loss) per share (in dollars per share) \$ 1.74 (\$ (63.27) (\$ (14.99) (\$ (357.42) Diluted net income (loss) per share (in dollars per share) \$ 1.74 (\$ (63.27) (\$ (14.99) (\$ (357.42) Weighted average shares outstanding - basic (in shares) 1,351,939 53,265 647,079 41,128 Weighted average shares outstanding - diluted (in shares) 1,351,939 53,265 647,079 41,128 Other comprehensive loss: Á Á Á Foreign currency translation adjustments \$ (4) \$ 0 \$ (15) \$ (6) Total comprehensive income (loss) \$ 2,354 \$ (3,370) \$ (9,171) \$ (14,706) X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 4: <http://www.xbrl.org/2003/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-3> + Details Name: us-gaap_AmortizationOffinancingCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-94-26>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 7: <http://www.xbrl.org/2003/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-S99-1> + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na:Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na:Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_

Type: [xbrli:monetaryItemType](#) Balance Type: [debit](#) Period Type: [duration](#) X - Definition: [Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.](#) + [References](#) [Reference 1](#): <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32> [Reference 2](#): <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> [Reference 3](#): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) [Reference 5](#): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) [Reference 6](#): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) [Reference 7](#): [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) [Reference 8](#): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-32](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-32) [Reference 9](#): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-32](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-32) [Reference 10](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-32) [Reference 11](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-32) [Reference 12](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) [Reference 13](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 14](#): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 15](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 16](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 17](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 18](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32) [Reference 19](#): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/4](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-50-32)

https://asc.fasb.org/1943274/2147482740/230-145-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap OperatingExpenses Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OperatingExpensesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap OperatingIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943

885 Å Balance (in shares) at Mar. 31, 2024 194,327 Å Å Å Å Å Å Å Increase (Decrease) in Stockholders' Equity [Roll Forward] Å Å Å Å Å Å Å Net loss \$ 0 Å 0 Å 0 Å (7,725) Å (7,725) Å Unrealized foreign currency translation adjustment 0 Å 0 Å (2) Å 0 Å (2) Å Stock-based compensation, net \$ 0 Å 115 Å 0 Å 0 Å 115 Å Stock-based compensation, net (in shares) 0 Å Å Å Å Å Å Å Issuance of common stock, net \$ 0 Å (109) Å 0 Å 0 Å (109) Å Issuance of common stock, net (in shares) 321,417 Å Å Å Å Å Å Å Balance at Jun. 30, 2024 \$ 0 Å 292,887 Å (42) Å (299,681) Å (6,836) Å Balance (in shares) at Jun. 30, 2024 515,744 Å Å Å Å Å Å Å Increase (Decrease) in Stockholders' Equity [Roll Forward] Å Å Å Å Å Å Å Å Net loss \$ 0 Å 0 Å 2,358 Å 2,358 Å Unrealized foreign currency translation adjustment 0 Å 0 Å (4) Å 0 Å (4) Å Stock-based compensation, net (in shares) 0 Å 101 Å 0 Å 101 Å 101 Å Stock-based compensation, net (in shares) 0 Å Å Å Å Å Å Å Issuance of common stock, net \$ 0 Å 2,882 Å 0 Å 0 Å 2,882 Å Issuance of common stock, net (in shares) 952,658 Å Å Å Å Å Å Å Exercise of common stock warrants \$ 0 Å 1,182 Å 0 Å 0 Å 1,182 Å Exercise of common stock warrants (in shares) 398,488 Å Å Å Å Å Å Å Issuance costs \$ 0 Å (722) Å 0 Å 0 Å (722) Å Deemed dividend 0 Å (1) Å 0 Å 0 Å (1) Å Reclassification of warrants to equity 0 Å 4,217 Å 0 Å 0 Å 4,217 Å Balance at Sep. 30, 2024 \$ 0 Å 300,546 Å \$ (46) Å \$ (297,323) Å 0 Å 3,177 Å Balance (in shares) at Sep. 30, 2024 1,866,890 Å Å Å Å Å Å Å X - DefinitionAmount of decrease (increase) to additional paid in capital (APIC) resulting from deemed dividend. + ReferencesNo definition available. + Details Name: nuwe AdjustmentsToAdditionalPaidInCapitalDeemedDividend Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of warrants. + ReferencesNo definition available. + Details Name: nuwe StockIssuedDuringPeriodSharesConversionOfWarrants Namespace Prefix: nuwe_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: nuwe StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: nuwe_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of warrants. + ReferencesNo definition available. + Details Name: nuwe StockIssuedDuringPeriodValueConversionOfWarrants Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the exercise of warrants. + ReferencesNo definition available. + Details Name: nuwe StockIssuedDuringPeriodValueExerciseOfWarrants Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -SubParagraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference> 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference> 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference> 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-30-45-12> + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11> + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X -DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X -DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X -DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X -DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X -DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X -DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X -DefinitionAmount of increase (decrease) in equity for down round feature triggered for warrant classified as equity. +ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A + Details Name: us-gaap WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD (\$\$) in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating Activities: Á Á Á Á Á Á Net loss \$ 2,358 \$ (4,330) \$ (3,370) \$ (6,485) \$ (9,697) \$ (14,700) Á Adjustments to reconcile net loss to cash flows used in operating activities: Á Á Á Á Á Á Depreciation and amortization Á Á Á 227 253 Á Stock-based compensation expense Á Á Á 374 513 Á Change in fair value of warrant liability (3,882) Á 0 Á (4,602) 755 Á Warrant financing costs 0 Á 0 Á 5,607 0 Á Net realized gain on marketable securities Á Á Á 0 Á (65) Á Changes in operating assets and liabilities: Á Á Á Á Á Á Accounts receivable Á Á Á 658 (19) Á Inventory, net Á Á Á 120 325 Á Other current assets Á Á Á (275) (551) Á Other assets and liabilities Á Á Á Á (13) (16) Á Accounts payable and accrued expenses Á Á Á Á (486) (1,678) Á Net cash used in operating activities Á Á Á Á (8,087) (15,183) Á Investing Activities: Á Á Á Á Á Á Proceeds from sale of marketable securities Á Á Á Á 0 578 Á Additions to intangible assets Á Á Á Á 0 (99) Á Purchases of property and equipment Á Á Á (37) (185) Á Net cash provided by (used in) investing activities Á Á Á (37) 294 Á Financing Activities: Á Á Á Á Á Á Issuance of common stock from offering Á Á Á 2,403 Á Á Proceeds from the exercise of Series J Convertible Preferred Warrants Á Á Á Á 501 Á Proceeds from the exercise of April 2024 Warrants Á Á Á 1,182 Á Á Issuance of July and August 2024 Common Stock and Warrants Á Á Á Á 2,160 Á Proceeds from ATM stock offerings, net Á Á Á Á 0 2,108 Á Payments on finance lease liability Á Á Á Á 0 (20) Á Net cash provided by financing activities Á Á Á 6,246 2,088 Á Effect of exchange rate changes on cash Á Á Á (15) (6) Á Net decrease in cash and cash equivalents Á Á Á Á (1,893) (12,807) Á Cash and cash equivalents - beginning of period Á \$ 3,800 Á \$ 17,737 3,800 17,737 Á Cash and cash equivalents - end of period 1,907 Á 4,930 Á 1,907 4,930 Á Supplemental cash flow information Á Á Á Á Á Á Non-cash impact of conversion of warrants to common stock Á Á Á Á 0 6,868 Á Reclassification of April 2024 warrants to equity Á Á Á Á 4,217 Á Á Issuance of Series J Preferred Stock for exercise of warrants Á Á Á Á 1,857 Á Á Issuance of Common Stock for conversion of Series J Preferred Stock Á Á Á 1,535 Á Á Deemed dividend on Series J Preferred Stock \$ 0 Á \$ 0 Á \$ 541 \$ 0 Á X - DefinitionThe cash inflow from issuance of rights to purchase common stock and warrants. +ReferencesNo definition available. + Details Name: nuwe IssuanceOfCommonStockAndWarrants Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of issuance of common stock for conversion of preferred stock. +ReferencesNo definition available. + Details Name: nuwe IssuanceOfCommonStockForConversionOfPreferredStock Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of issuance of preferred stock for exercise of warrants. +ReferencesNo definition available. + Details Name: nuwe IssuanceOfPreferredStockForWarrantExercises Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of non-cash impact of conversion of warrants to common stock. +ReferencesNo definition available. + Details Name: nuwe NonCashImpactOfConversionOfWarrantsToCommonStock Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their warrants. +ReferencesNo definition available. + Details Name: nuwe ProceedsFromExerciseOfWarrants Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe reclassification of warrants to equity. +ReferencesNo definition available. + Details Name: nuwe ReclassificationOfWarrantsToEquity Namespace Prefix: nuwe Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. +ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap AmortizationOfFinancingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. +ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type:

xbrl:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleGainLoss](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleGainLoss) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities\) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(g\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\)Reference 4: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \\(g\\)\\(3\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2\)Reference 5: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\(SX 210.5-03\\(20\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2\)Reference 6: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.4-08\\(g\\)\\(1\\)\\(iii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1\)Reference 7: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3\)Reference 8: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28\)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 12: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1\)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\)Reference 15: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.7-04\\(18\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1\)Reference 20: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.6-07\\(9\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1\)Reference 21: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \\(SX 210.6-09\\(1\\)\\(d\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3\)Reference 22: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 23: \[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 24: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iii\\)\\(A\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 25: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 26: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(5\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 27: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 28: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iii\\)\\(B\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 29: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)Reference 30: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities)

Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-11> + Details Name: us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromWarrantExercises Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). + ReferencesNo definition available. + Details Name: us-gaap TemporaryEquityDividendsAdjustment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Nature of Business and Basis of Presentation [Abstract] Á Nature of Business and Basis of Presentation Note 1 â€” Nature of Business and Basis of Presentation Nature of Business:Á Nuwellis, Inc. (the “Company”) is a medical device company focused on developing, manufacturing, and commercializing the Aquadex FlexFlow® and Aquadex SmartFlow® systems (collectively, the “Aquadex System”) for ultrafiltration therapy. The Aquadex System is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg. or more whose fluid overload is unresponsive to medical management, including diuretics. Nuwellis, Inc. is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Ireland. The Company’s common stock began trading on the Nasdaq Capital Market in February 2012. In August 2016, the Company acquired the business associated with the Aquadex System (the “Aquadex Business”) from a subsidiary of Baxter International, Inc. (“Baxter”), and refocused its strategy to fully devote its resources to the Aquadex Business. On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to reflect the expansion of its customer base from treating fluid imbalance resulting from congestive heart failure to also include critical care and pediatric applications. Principles of Consolidation: The accompanying condensed consolidated balance sheet as of December 31, 2023, which has been derived from the consolidated audited financial statements, and the unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information and note disclosures normally included in the audited annual consolidated financial statements have been condensed or omitted pursuant to those rules and regulations. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive loss, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could differ materially from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Going Concern: The Company’s consolidated financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2023 and 2022 and through September 30, 2024, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. Since the Company’s inception and as of September 30, 2024, the Company had an accumulated deficit of \$297.3 million and it expects to incur losses for the immediate future. To date, the Company has been funded by equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through the next twelve months. The Company became a revenue-generating company after acquiring the Aquadex Business in August 2016.Á The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in its sales and marketing capabilities, product development, purchasing inventory, manufacturing components, generating additional clinical evidence supporting the efficacy of the Aquadex System, and complying with the requirements related to being a U.S. public company.Á To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and in outpatient care settings, and effectively and efficiently manufacturing, marketing, and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. On April 30, 2024, the Company closed on a best-efforts public offering of 240,571 shares of its common stock, 80,854 shares of its common stock for pre-funded warrants and warrants to purchase up to an aggregate of 3,214,288 shares of its common stock at a combined public offering price of \$8.40 per share.Á All pre-funded warrants were exercised on the date of the offering. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of \$2.10 per share, were exercisable immediately upon issuance, and expire five years following the date of issuance. Each whole common warrant entitles the holder thereof to purchase one share of common stock. The common warrants contain a reset of the exercise price, effective upon the Warrant Stockholder Approval, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the five trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the five trading days immediately following the date we obtain the Warrant Stockholder Approval.Á The Company secured the Warrant Stockholder Approval on June 6, 2024.Á In addition, the common warrants provided for, full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$2.10. The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million. On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company’s common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued to the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, were exercisable immediately following the date of issuance and have a term of five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement occurred on or about July 25, 2024. The gross proceeds to the Company from the registered direct offering and the concurrent private placement, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately \$2.0 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company’s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock.Á The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the offering, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, was approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services.Á The Board recently authorized the restoration of the Company 401k match effective October 1, 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.Á In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the “Series I Warrants”) and Series II common stock purchase warrants (the “Series II Warrants”) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. The Company believes that its existing capital resources will be sufficient to support its operating plan through May 31, 2025. However, the Company will seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof. There can be no assurance we will be successful in raising additional capital. Revenue Recognition: The Company recognizes revenue in accordance with Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 “Revenue Recognition below for additional disclosures. For the three months ended September 30, 2024, two customers represented 12% and 10% of net sales. For the nine months ended September 30, 2024, one customer represented 16% of net sales. For the three months ended September 30, 2023, two customers represented 21% and 11% of net sales. For the nine months ended September 30, 2023, two customers each represented 17% and 12% of net sales. Accounts Receivable: Accounts receivables are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management’s evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date, the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of September 30, 2024, or December 31, 2023. As of September 30, 2024, two customers represented 16% and 11% of the accounts receivable balance. As of December 31, 2023, two customers represented 14% and 15% of the total accounts receivable balance. Inventories: Inventories represent finished goods purchased from the Company’s suppliers and are recorded as the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred.Á Inventories consisted of the following: (in thousands) Á September 30, 2024 Á Á

December 31, 2023 Δ Finished Goods Δ \$ 538 Δ Δ \$ 393 Δ Work in Process Δ 220 Δ Δ 207 Δ Raw Materials Δ 1,150 Δ Δ 1,472 Δ Inventory Reserves Δ (44) Δ (75) Δ Total Δ \$ 1,864 Δ Δ 1,997 Δ Δ Loss per Share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. See Note 3 Δ Δ "Stockholders Δ " Δ Equity below for additional disclosures. Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: Δ September 30 Δ Δ 2024 Δ Δ 2023 Δ Δ Δ Δ Stock options Δ 3,890 Δ Δ 3,101 Δ Warrants to purchase common stock Δ 4,112,197 Δ Δ 37,401 Δ Series F convertible preferred stock Δ 68,961 Δ Δ 254 Δ Series J convertible preferred stock Δ 67 Δ Δ Δ Δ Total Δ 4,185,115 Δ Δ 40,756 Δ The following table reconciles reported net loss with reported net loss per share for each of the three and nine months ended September 30: Δ Three months ended September 30 Δ Nine months ended September 30 Δ Δ 2024 Δ Δ 2023 Δ Δ 2024 Δ Δ 2023 Δ (in thousands, except per share amounts) Δ Δ Δ Δ Δ Δ Δ Net income (loss) Δ \$ 2,358 Δ Δ (3,370) Δ Δ (9,697) Δ Δ (14,700) Δ Deemed dividend attributable to Series J Convertible Preferred Stock Δ Δ Δ Δ Δ Δ Δ Δ Net loss attributable to common shareholders Δ \$ 2,358 Δ Δ (3,370) Δ Δ (9,156) Δ Δ (14,700) Δ Weighted average shares outstanding Δ 1,352 Δ Δ 53 Δ Δ 53 Δ Δ 41 Δ Basic and diluted loss per share Δ \$ 1.74 Δ Δ (63.27) Δ Δ (14.99) Δ Δ (357.42) Δ Recently Issued Accounting Pronouncements: In November 2023, the Financial Accounting Standards Board (Δ Δ FASB Δ) issued Accounting Standards Update (Δ Δ ASU Δ) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance requires expanded interim and annual disclosures of segment information including the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within segment profit and loss. The guidance is effective for the Company's fiscal 2024 Form 10-K and interim periods thereafter. The Company is currently evaluating the ASU to determine its impact on the Company's disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The guidance requires expanded annual disclosures including the standardization and disaggregation of income tax rate reconciliation categories and the amount of income taxes paid by jurisdiction. The guidance is effective for the Company's fiscal 2025 Form 10-K. The Company is currently evaluating the ASU to determine its impact on the Company's disclosures. In March 2024, the SEC adopted rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires the disclosure of material Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements. For non-accelerated filers and smaller reporting companies, disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2027, subject to legal challenges and the SEC's voluntary stay of the disclosure requirements. The Company is currently evaluating the impact these rules will have on its consolidated financial statements and related disclosures. Subsequent Events: The Company evaluates events through the date the condensed consolidated financial statements are filed for events requiring adjustment to or disclosure in the condensed consolidated financial statements. Δ See note 9 Δ Δ Subsequent Events for additional disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContentReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/275/tableOfContentReference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/810/tableOfContentReference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/205/tableOfContent> + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition 9 Months Ended Sep. 30, 2024 Revenue Recognition [Abstract] Δ Revenue Recognition Note 2 Δ Δ Revenue Recognition Net Sales: The Company sells its products in the United States primarily through a direct salesforce. Customers who purchase the Company's products include hospitals and clinics throughout the United States. Δ In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, The Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, United Arab Emirates, and the United Kingdom. These distributors resell the Company's products to hospitals and clinics in their respective geographies. International revenue represents Δ 3% and Δ 5% of net sales for the three months ended September 30, 2024 and 2023, and 4% and 5% of net sales for the nine months ended September 30, 2024 and 2023, respectively. Revenue from product sales is recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company's standard shipping terms are FOB shipping point unless the customer requests that control and title to the inventory transfer upon delivery. Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company's contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers whose related revenue is recognized over time. This revenue represents less than 1% of net sales for the three and nine months ended September 30, 2024 and 2023. The unfulfilled performance obligations related to these extended service plans are included in deferred revenue, which is included in other current liabilities on the condensed consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: The Company offers customers a limited right of return for its products in case of non-conformity or performance issues. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Δ The Company currently estimates product return liabilities using available industry data and its own historical sales and returns information. Δ The Company has received minimal returns to date and believes that future returns of its products will be minimal. Therefore, revenue is recognized is not currently impacted by variable consideration related to product returns. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Topic 606-Publisher FASB-URI https://asc.fasb.org/606/tableOfContent> + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity [Abstract] Δ Stockholders' Equity Note 3 Δ Δ "Stockholders Δ " Δ Equity Δ Series F Convertible Preferred Stock: On November 27, 2017, the Company closed on an underwritten public offering of Series F convertible preferred stock and warrants to purchase shares of common stock. The Series F convertible preferred stock has full ratchet price-based anti-dilution protection, subject to customary carve-outs, in the event of a down-round financing at a price per share below the conversion price of the Series F convertible preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company's common stock exceeds 300% of the then-effective conversion price of the Series F convertible preferred stock and the daily dollar trading volume for each trading day during such period exceeds \$7,000,000). Effective for every stock offering or reverse stock split, the conversion price of the Series F convertible preferred stock has been recalculated based on the offering price. As of August 23, 2024 (the most recent stock offering), the conversion price of the Series F convertible preferred stock was recalculated Δ to \$542.01 Δ . As of September 30, 2024, and December 31, 2023, 127 shares of the Series F convertible preferred stock remained outstanding. Δ 2023 At-the-Market Program: In March 2023, the Company filed a Prospectus Supplement to its Registration Statement on Form S-3 with the SEC in connection with a proposed At-the-Market Securities offering (the Δ Δ At-the-Market Program Δ). During 2023, the Company issued 18,781 shares of common stock under the At-the-Market Program for gross proceeds of approximately \$2.3 million. Net proceeds totaled approximately \$2.1 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The Company terminated its At-the-Market Program in July of 2024. Supply Agreement Warrants: Δ On June 19, 2023, we entered into a Supply and Collaboration Agreement (the Δ Δ Supply Agreement Δ) with DaVita Inc., a Delaware corporation (Δ Δ DaVita Δ), pursuant to which DaVita would pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive heart failure and related conditions within select U.S. markets. The pilot program Δ launched by the end of fourth quarter 2023 and extended through May 31, 2024 (the Δ Δ Pilot Δ). On May 31, 2024, DaVita and Nuwellis amended the Supply and Collaboration Agreement extending the Pilot term through August 31, 2024. Through the Pilot, ultrafiltration therapy using Aquadex would be offered at a combination of DaVita's hospital customer and outpatient center locations, with both companies collaborating on the roll-out of the therapy, clinician training, and patient support. At the conclusion of the Pilot, DaVita had the option, in its sole discretion, to extend the Supply Agreement with the Company for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years (Δ Δ Ultrafiltration Services Approval Δ). The parties agreed to terminate the Supply Agreement effective August 21, 2024. In conjunction with the Supply Agreement, the Company issued DaVita a warrant to purchase up to an aggregate of 36,830 shares of common stock of the Company, par value \$0.0001 per share, at an exercise price of \$115.49 per share (the Δ Δ DaVita Warrant Δ), provided that at no time can the DaVita Warrant be exercised for an amount of shares that would represent greater than 19.9% ownership in the Company subject to certain vesting milestones. The DaVita Warrant was expected to vest in four tranches as follows: (i) 25% upon receipt of notice to extend the Supply Agreement past the initial pilot-term; (ii) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within twelve months of Ultrafiltration Services Approval; (iii) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within twenty-four months of Ultrafiltration Services Approval; and (iv) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within thirty-six months of Ultrafiltration Services Approval. This warrant terminated with the termination of the Supply Agreement on August 21, 2024. On August 21, 2024, the Company and DaVita Inc., a Delaware corporation (Δ Δ DaVita Δ) entered into a Termination Agreement and mutually agreed to terminate its Supply and Collaboration Agreement, dated as of June 19, 2023, as amended (the Δ Δ Supply Agreement Δ) and the related Common Stock Purchase Warrant (the Δ Δ Warrant Δ) and Registration Rights Agreement (the Δ Δ Registration Rights Agreement Δ), each dated as of June 19, 2023. The Supply Agreement, Warrant and Registration Rights Agreement are collectively referred to herein as the Δ Δ DaVita Agreements Δ . The termination of the Davita Agreements was effective immediately. The respective rights and obligations of each party under the Supply Agreement that survive termination pursuant to the terms and conditions set forth therein shall continue and all rented and unused Products (as defined in the Supply Agreement) shall be returned to the Company. The vesting milestones pursuant to the terms of the Supply Agreement were never attained and therefore the Warrant never vested. Additionally, because the Ultrafiltration Services Approval (as defined in the Supply Agreement) was never attained, the registration rights pursuant to the terms of the Registration Rights Agreement were never in effect. October 2023 Offering: Δ On October 12, 2023, Nuwellis, Inc. entered into a Placement Agency Agreement with Lake Street Capital Markets, LLC and Maxim Group LLC, pursuant to which the Company issued and sold, in a best efforts registered public offering by the Company, 150,000 units, with each Unit consisting of (A) one share of the Company's Series J Convertible Redeemable Preferred Stock, par value \$0.0001 per share, and (B) one warrant to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock, at a price to the public of \$15.00 per Unit, less placement agent fees and commissions. The public offering price of \$15.00 per Unit reflects the issuance of the Series J Convertible Preferred Stock with an original issue discount of 40%. The Company also registered under the Registration Statement (as defined below) an additional 362,933 shares of Series J Convertible Preferred Stock that will be issued, if and when the Company's Board of Directors declares such dividends, as paid in-kind dividends and the shares of Common Stock issuable upon conversion of the Series J Convertible Preferred Stock issued as PIK dividends. The Units, the shares of Series J Convertible Preferred Stock, the Warrants, the PIK Dividend Shares, the PIK Conversion Shares as well as the shares of Series J Convertible Preferred Stock issuable upon exercise of the Warrants and the shares of the Company's common stock, par value \$0.0001 per share, issuable upon conversion of the Series J Convertible Preferred Stock, were offered and sold by the Company pursuant to an effective registration statement on Form S-1. The closing of the Offering contemplated by the Placement Agency Agreement occurred on October 17, 2023. On October 17, 2023, the Company also entered into a warrant agency agreement with the Company's transfer agent, Equiniti Trust Company, LLC, who acts as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in this Offering. Each Warrant has an exercise price of \$262.50 per one-half of one (0.5) share of Series J Convertible Preferred Stock, is immediately exercisable and will expire three (3) years from the date of issuance. There is no established trading market for the Series J Convertible Preferred Stock or the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Series J Convertible Preferred Stock or the Warrants on The Nasdaq Capital Market or any other national securities exchange or any other nationally recognized trading system. The gross proceeds to the Company from the October 17, 2023, Offering were \$2.25 million. Δ Net proceeds were approximately \$1.5 million after deducting placement agent fees and commissions and Offering expenses payable by the Company. The Company used the net proceeds from the Offering for working capital and for general

corporate purposes. The SeriesA J Convertible Preferred Stock is classified as mezzanine equity and accreted to reflect its redemption value as of each reporting date. The accretion will be reflected as a deemed dividend adjustment to arrive at net loss attributed to common stockholders for earnings per share calculations. The Warrants are recorded as a liability and re-measured at fair value as of each reporting date with fair value changes being recorded as non-operating income or expense. The Warrants were valued on day 1 and exceeded the gross proceeds of the offering. This resulted in a day 1 financing expense of \$2.7 million. April 2024 Offering: On April 30, the Company closed on a best efforts public offering of 240,571 shares of its common stock, 80,854 shares of its common stock for pre-funded warrants and warrants to purchase up to an aggregate of 3,214,288 shares of its common stock at a combined public offering price of \$8.40 per share. All pre-funded warrants were exercised on the date of the offering. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of \$2.10 per share, were exercisable immediately upon issuance, and will expire five years following the date of issuance. Each whole common warrant entitles the holder thereof to purchase one share of common stock. The common warrants contain a reset of the exercise price, effective upon the Warrant Stockholder Approval, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the five trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the five trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024. Subsequent to June 30 2024, the number of shares underlying the common warrants were adjusted to 2,710,734 shares and the exercise price was adjusted to \$2.49 per share. In addition, the common warrants provided for full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$2.10. The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million. The warrants offered in this financing were originally classified as a liability on the balance sheet. An independent valuation of the warrants was performed and reviewed with management, and the valuation at issuance was \$7.8 million. The warrants had down-round protection and the price was reset from the July 2024 and the August 2024 offerings. At the August 2024 offering, the exercise price of these warrants were adjusted to \$2.10, which represented the floor price on these warrants. As the price floor was hit, there was no further down-round protection. The warrants were re-evaluated and classified as equity as of September 30, 2024. During the quarter, there were 398,488 of warrants exercised at a weighted average exercise price of \$2.97. The warrants are fair valued on the date of exercise and the adjustment to fair value is recorded to Additional Paid in Capital. There were 2,651,426 of warrants converted to equity resulting in \$4.2 million to Additional Paid in Capital. July 2024 Offering: On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, will be exercisable immediately following the date of issuance and have a term of five years from the date of issuance. The warrants issued in this offering were concluded to be equity classified. The closing of the registered direct offering and the concurrent private placement occurred on July 25, 2024. The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately \$2.0 million. After deducting placement agent fees and other offering expenses payable by the Company, net proceeds were approximately \$1.5 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. August 2024 Offering: On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company's common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the "SEC") on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The warrants issued in this offering were concluded to be equity classified. The gross proceeds of the Offering, before deducting the Placement Agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, will be approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. Underwriter and Placement Agent Fees: In connection with the offerings described above, the Company paid the underwriter or placement agent, as applicable, an aggregate cash fee of either 7% or 8% of the aggregate gross proceeds raised in each of the offerings, except with respect to the issuances made pursuant to the At-the-Market Program, for which the placement fee was equal to 3% of the aggregate gross proceeds. At the Company's annual meeting of stockholders on June 6, 2024, its stockholders approved a proposal to amend the Company's Fourth Amended and Restated Certificate of Incorporation to effect a reverse split of the Company's outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-70 to be determined at the discretion of our Board of Directors. On June 26, 2024, the Company's board of directors approved a one-for-thirty-five reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). On June 27, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the "Certificate of Amendment") to affect the Reverse Stock Split. The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on June 27, 2024, and the Company's common stock began trading on a split-adjusted basis when the market opened on June 28, 2024. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock splits for all periods presented. X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/214747848/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.4-08\)\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.4-08)(e)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep 30, 2024 Stock-Based Compensation [Abstract] A Stock-Based Compensation Note 4 - Stock-Based Compensation Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The following table presents the classification of stock-based compensation expense recognized for the periods below: A Three months ended September 30 A Nine months ended September 30 A (in thousands) A 2024 A 2023 A 2024 A 2023 A Selling, general and administrative expense A \$ 99 A \$ 133 A \$ 363 A \$ 484 A Research and development expense A 2 A 2 A 2 A 11 A 29 A Total stock-based compensation expense A 101 A \$ 135 A \$ 374 A \$ 513 A During the three months ended September 30, 2024, and 2023, under the 2017 Equity Incentive Plan, and the 2021 Inducement Plan, the Company granted zero and 532 stock options, respectively, to its directors, officers and employees. During the nine months ended September 30, 2024 and 2023, the Company granted 1,264 and 3,544 stock options, respectively, to its directors, officers and employees. Vesting generally occurs over an immediate to 48-month period based on a time-of-service condition. The weighted-average grant date fair value of the stock options issued during the three months ended September 30, 2024 and 2023 was zero and \$62.65 per share, respectively. The weighted-average grant date fair value of the stock options issued during the nine months ended September 30, 2024 and 2023 was \$24.14 and \$226.26 per share, respectively. The total number of stock options outstanding as of September 30, 2024 and September 30, 2023 was 3,890 and 3,101, respectively. A The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended September 30, 2024 and 2023: A Three months ended A Nine months ended A September 30 A September 30 A 2024 A 2023 A 2024 A 2023 A Expected volatility A 138.70 % A 131.06 % A 138.70 % A 152.59 % Expected Life of options (years) A 5.51 A 6.25 A 5.51 A 6.19 A Expected dividend yield A 0 % A 0 % A 0 % A 0 % Risk-free interest rate A 3.94 % A 4.29 % A 3.94 % A 4.16 % During the three months ended September 30, 2024 and 2023, 420 and 69 stock options vested, respectively, and 102 and 595 stock options were expired or forfeited during these periods, respectively. During the nine months ended September 30, 2024 and 2023, 1,767 and 129 stock options vested, respectively, and 465 and 680 stock options were expired or forfeited during these periods, respectively. During the three and nine months ended September 30, 2024 and 2023, no options were exercised. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/718/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value of Financial Instruments [Abstract] A Fair Value of Financial Instruments Note 5A Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents and warrants. Pursuant to the requirements of Accounting Standards Codification (ASC) 820 A Fair Value Measurement, the Company's financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: A Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges. A Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over-the-counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. A Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques. The fair value of the Company's common and preferred stock warrant liabilities related to the investor warrants issued in the October 2023, October 2022 and April 2024 public offerings was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. The following is a roll-forward of the fair value of the Level 3 warrants: (in thousands) A Balance at December 31, 2022 A \$ 6,868 A Change in fair value A 755 A Issuance of Common Stock for exercise of Series I warrants A (7,623) A October 17, 2023, issuance of Series J warrants A 4,965 A Exercise of Series J warrants A (536) A Change in fair value A (1,586) A Balance at December 31, 2023 A 2,843 A Exercise of Series J warrants A (1,357) A April 30, 2024, issuance of common warrants A 7,813 A Exercise of April 2024 warrants A (1,373) A Reclassification of April 2024 warrants to equity A (2,844) A Change in fair value A (4,602) A Balance at September 30, 2024 A \$ 480 A X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the

reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Taxes [Abstract] Â Income Taxes Note 6 â€” Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of its deferred tax assets. The Company has established a full valuation allowance for its U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements. As of September 30, 2024, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 14: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangement 3 Months Ended Sep. 30, 2024 Insider Trading Arrangements \[Line Items\] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1:](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events Note 9- Subsequent Events On October 20, 2024 (the â€œEffective Dateâ€), Nuwellis, Inc. (the â€œCompanyâ€) and SeaStar Medical Holding Corporation (â€œSeaStarâ€) entered into a Confidential Settlement Agreement and Release (the â€œSettlement Agreementâ€), which terminated the License and Distribution Agreement entered into by the Company and SeaStar, dated as of December 27, 2022 (the â€œDistribution Agreementâ€) and the Supplier and Distributor Quality Agreement dated as of March 5, 2024 (the â€œSupply Agreementâ€), and together with the Distribution Agreement, the â€œSeaStar Agreementsâ€) pursuant to which SeaStar appointed the Company as its exclusive distributor for the sale and distribution of SeaStarâ€™s product, QUELIMMUNE â„¢, with SeaStar agreeing to pay the Company $900,000 before December 31, 2024.Â The Company is accounting for the settlement as a gain contingency and will record the gain at the earlier of when the contingency is realized or realizable. The Company received payment of $500,000 on October 22, 2024 and was recognized in October 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the â€œExisting Warrantsâ€) to purchase up to an aggregate of 1,832,517 shares of the Companyâ€™s common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.Â A In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the â€œSeries I Warrantsâ€) and Series II common stock purchase warrants (the â€œSeries II Warrantsâ€) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the â€œSecurities Actâ€), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the â€œSECâ€) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. X - ReferencesNo definition available. + Details Name: us-gaap SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: <a href=)

respectively. Since the Company’s inception and as of September 30, 2024, the Company had an accumulated deficit of \$297.3 million and it expects to incur losses for the immediate future. To date, the Company has been funded by equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through the next twelve months. The Company became a revenue-generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in its sales and marketing capabilities, product development, purchasing inventory, manufacturing components, generating additional clinical evidence supporting the efficacy of the Aquadex System, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and in outpatient care settings, and effectively and efficiently manufacturing, marketing, and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. On April 30, 2024, the Company closed on a best-efforts public offering of 240,571 shares of its common stock, 80,854 shares of its common stock for pre-funded warrants and warrants to purchase up to an aggregate of 3,214,288 shares of its common stock at a combined public offering price \$8.40 per share. All pre-funded warrants were exercised on the date of the offering. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of \$2.10 per share, were exercisable immediately upon issuance, and expire five years following the date of issuance. Each whole common warrant entitles the holder thereof to purchase one share of common stock. The common warrants contain a reset of the exercise price, effective upon the Warrant Stockholder Approval, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the five trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the five trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024. In addition, the common warrants provided for, full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$2.10. The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million. On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company’s common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued to the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, were exercisable immediately following the date of issuance and have a term of five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement occurred on or about July 25, 2024. The gross proceeds to the Company from the registered direct offering and the concurrent private placement, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately \$2.0 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company’s common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant. The Shares were sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering. Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The gross proceeds of the offering, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, was approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029. Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services. The Board recently authorized the restoration of the Company 401k match effective October 1, 2024. On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the “Series I Warrants”) and Series II common stock purchase warrants (the “Series II Warrants”) to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants. The Company believes that its existing capital resources will be sufficient to support its operating plan through May 31, 2025. However, the Company will seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof. There can be no assurance we will be successful in raising additional capital. Revenue Recognition Revenue Recognition: The Company recognizes revenue in accordance with Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 “Revenue Recognition below for additional disclosures. For the three months ended September 30, 2024, two customers represented 12% and 10% of net sales. For the nine months ended September 30, 2024, one customer represented 16% of net sales. For the three months ended September 30, 2023, two customers represented 21% and 11% of net sales. For the nine months ended September 30, 2023, two customers each represented 17% and 12% of net sales. Accounts Receivable Accounts Receivable: Accounts receivables are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management’s evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date, the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of September 30, 2024, or December 31, 2023. As of September 30, 2024, two customers represented 16% and 11% of the accounts receivable balance. As of December 31, 2023, two customers represented 14% and 15% of the total accounts receivable balance. Inventories Inventories: Inventories represent finished goods purchased from the Company’s suppliers and are recorded as the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. Inventories consisted of the following: (in thousands) Á September 30, 2024 Á December 31, 2023 Á Finished Goods Á \$38 Á \$393 Á Work in Process Á \$220 Á \$207 Á Raw Materials Á \$1,150 Á \$1,472 Á Inventory Reserves Á (44) Á (75) Total Á \$1,864 Á \$1,997 Á Loss per Share Loss per Share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. See Note 3 “Stockholders’ Equity below for additional disclosures. Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: Á September 30 Á 2024 Á 2023 Á (in thousands, except per share amounts) Á 3,890 Á 3,101 Á Warrants to purchase common stock Á 4,112,197 Á 37,401 Á Series F convertible preferred stock Á 68,961 Á 254 Á Series J convertible preferred stock Á 67 Á 67 Á Total Á 4,185,115 Á 40,756 Á The following table reconciles reported net loss with reported net loss per share for each of the three and nine months ended September 30: Á Three months ended September 30 Á Nine months ended September 30 Á 2024 Á 2023 Á 2024 Á 2023 Á (in thousands, except per share amounts) Á Á Á Á Á Net income (loss) Á \$2,358 Á \$(3,370) Á \$(9,697) Á \$(14,700) Deemed dividend attributable to Series J Convertible Preferred Stock Á Á Á Á Á Á Á Á Á Net loss attributable to common shareholders Á \$2,358 Á \$(3,370) Á \$(9,156) Á \$(14,700) Weighted average shares outstanding Á 1,352 Á 53 Á Á Á 647 Á 41 Á Basic and diluted loss per share Á \$1.74 Á \$(63.27) Á \$(14.99) Á \$(357.42) Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements: In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (the “ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance requires expanded interim and annual disclosures of segment information including the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within segment profit and loss. The guidance is effective for the Company’s fiscal 2024 Form 10-K and interim periods thereafter. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The guidance requires expanded annual disclosures including the standardization and disaggregation of income tax rate reconciliation categories and the amount of income taxes paid by jurisdiction. The guidance is effective for the Company’s fiscal 2025 Form 10-K. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures. In March 2024, the SEC adopted rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires the disclosure of material Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements. For non-accelerated filers and smaller reporting companies, disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2027, subject to legal challenges and the SEC’s voluntary stay of the disclosure requirements. The Company is currently evaluating the impact these rules will have on its consolidated financial statements and related disclosures. Subsequent Events Subsequent Events: The Company evaluates events through the date the condensed consolidated financial statements are filed for events requiring adjustment to or disclosure in the condensed consolidated financial statements. See Note 9 “Subsequent Events for additional disclosures. X - DefinitionDisclosure of accounting policy for the going concern when substantial doubt is raised about the ability to continue as a going concern. + ReferencesNo definition available. + Details Name: nuwe GoingConcernPolicyTextBlock Namespace Prefix: nuwe Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://www.xbrl.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: https://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-5-02/6(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reporting subsequent events. + ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business and Basis of Presentation (Tables) 9 Months Ended Sep. 30, 2024 Nature of Business and Basis of Presentation [Abstract] Á Inventories Inventories consisted of the following: (in thousands) Á September 30, 2024 Á Á December 31, 2023 Á Finished Goods Á \$ 538 Á Á \$ 393 Á Work in Process Á 220 Á Á 207 Á Raw Materials Á 1,150 Á Á 1,472 Á Inventory Reserves Á (44) Á Á (75) Á Total Á \$ 1,864 Á Á \$ 1,997 Á Potential Shares of Common Stock not Included in Diluted Net Loss Per Share The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: Á September 30 Á Á 2024 Á Á 2023 Á Á Á Á Stock options Á 3,890 Á Á 3,101 Á Warrants to purchase common stock Á 4,112,197 Á Á 37,401 Á Series F convertible preferred stock Á 68,961 Á Á 254 Á Series J convertible preferred stock Á 67 Á Á Á Total Á 4,185,115 Á Á 40,756 Á Reconciliation of Reported Net Loss with Reported Net Loss Per Share The following table reconciles reported net loss with reported net loss per share for each of the three and nine months ended September 30: Á Á Three months ended September 30 Á Á Nine months ended September 30 Á Á 2024 Á Á 2023 Á Á 2024 Á Á 2023 Á (in thousands, except per share amounts) Á Á Á Á Á Net income (loss) Á 2,358 Á Á (3,370) Á Á (9,697) Á Á (\$14,700) Deemed dividend attributable to Series J Convertible Preferred Stock Á á Á Á Á Net loss attributable to common shareholders Á \$ 2,358 Á Á (3,370) Á Á (\$9,156) Á Á (\$14,700) Weighted average shares outstanding Á 1,352 Á Á 53 Á Á 647 Á Á 41 Á Basic and diluted loss per share Á \$ 1.74 Á Á (\$6.27) Á Á (\$14.99) Á Á (\$357.42) X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02)(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02)(b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-Based Compensation [Abstract] Á Classification of Stock-Based Compensation Expense The following table presents the classification of stock-based compensation expense recognized for the periods below: Á Three months ended September 30 Á Á Nine months ended September 30 Á (in thousands) Á 2024 Á Á 2023 Á Á 2024 Á Á 2023 Á Selling, general and administrative expense Á \$ 99 Á Á \$ 133 Á Á \$ 363 Á Á \$ 484 Á Research and development expense Á 2 Á Á 2 Á Á 11 Á Á 29 Á Total stock-based compensation expense Á \$ 101 Á Á \$ 135 Á Á \$ 374 Á Á \$ 513 Á Weighted Average Assumptions used in Black-Scholes Option Pricing Model The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended September 30, 2024 and 2023: Á Three months ended Á Á Nine months ended Á Á September 30 Á Á September 30 Á Á 2024 Á Á 2023 Á Á 2024 Á Á 2023 Á Expected volatility Á 138.70 % Á 131.06 % Á 138.70 % Á 152.59 % Expected Life of options (years) Á 5.51 Á Á 6.25 Á Á 5.51 Á Á 6.19 Á Expected dividend yield Á 0 % Á Á 0 % Á Á 0 % Á 0 % Risk-free interest rate Á 3.94 % Á Á 4.29 % Á Á 3.94 % Á Á 4.16 % X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value of Financial Instruments [Abstract] Á Roll-Forward of Fair Value of Level 3 Warrants The following is a roll-forward of the fair value of the Level 3 warrants: (in thousands) Á Á Balance at December 31, 2022 Á \$ 6,868 Á Change in fair value Á 755 Á Issuance of Common Stock for exercise of Series I warrants Á (7,623) Á October 17, 2023, issuance of Series J warrants Á 4,965 Á Exercise of Series J warrants Á (536) Á Change in fair value Á (1,586) Á Balance at December 31, 2023 Á 2,843 Á Exercise of Series J warrants Á (1,357) Á April 30, 2024, issuance of common warrants Á 7,813 Á Exercise of April 2024 warrants Á (1,373) Á Reclassification of April 2024 warrants to equity Á (2,844) Á Change in fair value Á (4,602) Á Balance at September 30, 2024 Á \$ 480 Á X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details) \$ / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Nov. 05, 2024 USD (\$) \$ / shares shares Aug. 23, 2024 USD (\$) \$ / shares shares Jul. 24, 2024 USD (\$) \$ / shares shares Apr. 30, 2024 USD (\$) Warrant \$ / shares shares Sep. 30, 2024 USD (\$) Customer \$ / shares shares Sep. 30, 2023 Customer Sep. 30, 2024 USD (\$) Customer \$ / shares shares Sep. 30, 2023 USD (\$) Customer Dec. 31, 2023 USD (\$) Customer \$ / shares Aug. 30, 2024 \$ / shares Aug. 13, 2024 \$ / shares shares Going Concern [Abstract] Á Á Á Á Á Á Á Á Accumulated deficit Á Á Á \$ (297,323) Á Á \$ (297,323) Á Á Common stock, par value (in dollars per share) | \$ / shares Á Á Á \$ 0.0001 Á Á \$ 0.0001 Á Á Reduce our monthly cash burn rate Á Á Á Á 40.00% Á Á Á Merit increases to base salaries of named executive officer or employee Á Á Á Á \$ 0 Á Á Cash bonuses to named executive officer or employee Á Á Á Á 0 Á Á Gross proceeds received through exercise of warrants Á Á Á Á \$ 501 Á Á \$ 0 Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Accounts receivables maximum credit period from invoice date Á Á Á Á 30 days Á Á Allowance for doubtful accounts Á Á Á \$ 0 Á \$ 0 Á Inventories [Abstract] Á Á Á Á Á Á Finished Goods Á Á Á 538 Á 538 Á 393 Á Á Work in Process Á Á Á 220 Á 220 Á 207 Á Á Raw Materials Á Á Á 1,150 Á 1,150 Á 1,472 Á Á Inventory Reserves Á Á Á (44) Á (44) Á (75) Á Á Total Á Á Á \$ 1,864 Á \$ 1,864 Á \$ 1,997 Á Á Subsequent Event [Member] Á Á Á Á Á Á Going Concern [Abstract] Á Á Á Á Á Á Warrants to purchase shares of common stock (in shares) | shares 1,832,517 Á Á Á Á Á Á Exercise price of warrants (in dollars per share) | \$ / shares \$ 2.1 Á Á Á Á Á Gross proceeds prior to deducting inducement agent fees and estimated offering expenses \$ 3,800 Á Á Á Á Á Gross proceeds received through exercise of warrants \$ 1,300 Á Á Á Á Á Net Sales [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Number of major customers | Customer Á Á Á 2 Á 2 Á Accounts Receivable [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Number of major customers | Customer Á Á Á 2 Á 2 Á Customer One [Member] | Net Sales [Member] | Customer Concentration Risk [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Concentration risk percentage Á Á Á 12.00% 21.00% 16.00% 17.00% Á Á Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Concentration risk percentage Á Á Á 16.00% Á 14.00% Á Customer Two [Member] | Net Sales [Member] | Customer Concentration Risk [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Concentration risk percentage Á Á Á 10.00% 11.00% 12.00% Á Á Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] Á Á Á Á Á Á Revenue Recognition [Abstract] Á Á Á Á Á Á Concentration risk percentage Á Á Á Á 11.00% Á 15.00% Á Securities Purchase Agreement [Member] Á Á Á Á Á Á Going Concern [Abstract] Á Á Á Á Á Á Issuance of common stock, net (in shares) | shares Á Á 469,340 Á Á Á Á Warrants to purchase shares of common stock (in shares) | shares Á 938,680 Á Á Á Á Common stock offering price per share (in dollars per share) | \$ / shares Á \$ 4.24 Á Á Á Á Exercise price of warrants (in dollars per share) | \$ / shares Á \$ 3.99 Á Á Á Á Warrant expiry period Á 5 years Á Á Á Gross proceeds before deducting placement agent fees and commissions and offering expenses Á \$ 2,000 Á Á Á Á Series I Warrants and Series II Warrants [Member] | Subsequent Event [Member] Á Á Á Á

[illegible]

`us-gaap` StockIssuedDuringPeriodSharesNewIssue Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap SubsequentEventTypeAxis=us-gaap SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByBenchmarkAxis=us-gaap SalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByBenchmarkAxis=us-gaap AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt MajorCustomersAxis=nuwe CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByTypeAxis=us-gaap CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt MajorCustomersAxis=nuwe CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=nuwe SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=nuwe SeriesIWarrantsAndSeriesI IWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=nuwe SeriesIWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=nuwe April2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=nuwe August2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$ 3.22.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business and Basis of Presentation, Loss Per Share (Details) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2023 Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Á Á Á Á Á 4,185,115 40,756 Reported net loss with reported net loss per share [Abstract] Á Á Á Á Á Net income (loss) \$ 2,358 \$ (7,725) \$ (4,330) \$ (3,370) \$ (4,845) \$ (6,485) \$ (9,697) \$ (14,700) Deemed dividend attributable to Series J Convertible Preferred Stock 0 Á 0 Á 541 0 Net income (loss) attributable to common shareholders \$ 2,358 Á \$ (3,370) Á \$ (9,156) Á \$ (14,700) Weighted average shares outstanding - basic (in shares) 1,351,939 Á 53,265 Á 647,079 Á 1,28 Weighted average shares outstanding - diluted (in shares) 1,351,939 Á 53,265 Á 647,079 Á 1,28 Basic loss per share (in dollars per share) \$ 1.74 Á Á \$ (63.27) Á \$ (14.99) \$ (357.42) Diluted loss per share (in dollars per share) \$ 1.74 Á Á \$ (63.27) Á \$ (14.99) \$ (357.42) Stock Options [Member] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Á Á Á Á Á 3,890 3,101 Warrants to Purchase Common Stock [Member] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Á Á Á Á Á 4,112,197 37,401 Series F Convertible Preferred Stock [Member] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Á Á Á Á Á 68,961 254 Series J Convertible Preferred Stock [Member] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract] Á Á Á Á Á Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) Á Á Á Á Á 67 0 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence) 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence) 25:
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence) 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Supparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1ARefrence) 27:
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph (SX 210.13-02(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 29:
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 31:
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference) 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 34:
<http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Supparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1ARefrence](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Supparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1ARefrence) 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Supparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Supparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference) 37:
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Supparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income \(loss\) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Supparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference) 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference)

of warrants expected to vest 25.00% of the Period of warrants expected to vest 24 months Supply Agreement [Member] | DaVita Warrant [Member] | Tranche Four [Member] | Class of Stock Disclosures [Abstract] | Percentage of warrants expected to vest 25.00% of the Period of warrants expected to vest 36 months Supply Agreement [Member] | DaVita Warrant [Member] | Maximum [Member] | Class of Stock Disclosures [Abstract] | Warrants to be exercised for amount of shares ownership percentage in entity 19.90% of the Securities Purchase Agreement [Member] | Class of Stock Disclosures [Abstract] | Issuance of common stock, net (in shares) 469,340 Warrants to purchase shares of common stock (in shares) 938,680 Exercise price of warrants (in dollars per share) | \$ / shares \$ 3.99 Gross proceeds before deducting placement agent fees and commissions and offering expenses | \$ \$ 2,000 Common stock offering price per share (in dollars per share) | \$ / shares \$ 4.24 Warrant expiry period 5 years Class of Stock Disclosures [Abstract] | Securities Purchase Agreement [Member] | July 2024 Offering [Member] | Issuance of common stock, net (in shares) 469,340 Warrants to purchase shares of common stock (in shares) 938,680 Exercise price of warrants (in dollars per share) | \$ / shares \$ 3.99 Gross proceeds before deducting placement agent fees and commissions and offering expenses | \$ \$ 2,000 Net proceeds after deducting placement agent fees and commissions and offering expenses | \$ \$ 1,500 Common stock offering price per share (in dollars per share) | \$ / shares \$ 4.24 Warrant expiry period 5 years Securities Purchase Agreement [Member] | August 2024 Offering [Member] | Class of Stock Disclosures [Abstract] | Issuance of common stock, net (in shares) 483,351 Warrants to purchase shares of common stock, par value (in dollars per share) | \$ / shares \$ 0.0001 Exercise price of warrants (in dollars per share) | \$ / shares 1.72 Common stock offering price per share (in dollars per share) | \$ / shares 1.845 Series F Convertible Preferred Stock [Member] | Class of Stock Disclosures [Abstract] | Number of consecutive trading days considered for expiration 20 days Number of consecutive trading days 30 days Percentage of volume weighted average price of common stock 300.00% Trading volume for each trading day | \$ \$ 7,000 Conversion price (in dollars per share) | \$ / shares \$ 542.01 Preferred stock, shares outstanding (in shares) 127 A 127 A Preferred stock, par value (in dollars per share) | \$ / shares \$ 0.0001 Series F Convertible Preferred Stock [Member] | Minimum [Member] | Class of Stock Disclosures [Abstract] | Aggregate cash fee paid to underwriter or placement agent 7.00% Series F Convertible Preferred Stock [Member] | Maximum [Member] | Class of Stock Disclosures [Abstract] | Aggregate cash fee paid to underwriter or placement agent 8.00% Series J Convertible Preferred Stock [Member] | October 2023 Offering [Member] | Class of Stock Disclosures [Abstract] | Issuance of common stock, net (in shares) 150,000 Warrants to purchase shares of common stock (in shares) 0.5 A Number of shares in one unit (in shares) 1 A 1 A Original issue discount percentage 40.00% Additional shares issuable upon declaration of dividends (in shares) 362,933 Common stock offering price per share (in dollars per share) | \$ / shares \$ 15 A Preferred stock, par value (in dollars per share) | \$ / shares \$ 0.0001 Number of warrants included in each unit 1 A 1 A Common Stock [Member] | Class of Stock Disclosures [Abstract] | Issuance of common stock, net (in shares) 952,658 321,417 18,781 A No of warrants converted to equity (in shares) 300 A Converted warrant | \$ A \$ 0 A \$ 0 A Common Stock [Member] | Series J Convertible Preferred Stock [Member] | October 2023 Offering [Member] | Class of Stock Disclosures [Abstract] | Common stock, par value (in dollars per share) | \$ / shares \$ 0.0001 A Warrants [Member] | Class of Stock Disclosures [Abstract] | Common stock warrant liability | \$ A \$ 7,800 A Warrants [Member] | October 2023 Offering [Member] | Class of Stock Disclosures [Abstract] | Gross proceeds before deducting placement agent fees and commissions and offering expenses | \$ A \$ 2,250 A Net proceeds after deducting placement agent fees and commissions and offering expenses | \$ A \$ 1,500 A Financing expense | \$ A \$ 2.7 A Warrants [Member] | Series J Convertible Preferred Stock [Member] | October 2023 Offering [Member] | Class of Stock Disclosures [Abstract] | Warrants to purchase shares of common stock (in shares) 0.5 A Exercise price of warrants (in dollars per share) | \$ / shares \$ 262.5 A Warrants term A 3 years A 3 years A X - DefinitionNumber of securities into which the class of warrant or right may be converted. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsToPurchaseSharesOfCommonStock Namespace Prefix: nuwe_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of tranches in which the warrants/rights will vest. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightNumberOfTranches Namespace Prefix: nuwe_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPeriod warrants expiry , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightWarrantExpiryPeriod Namespace Prefix: nuwe_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWarrants to be exercised for amount of shares ownership percentage in entity subject to certain vesting milestones. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightWarrantsToBeExercisedForAmountOfSharesOwnershipPercentageInEntitySubjectToCertainVestingMilestones Namespace Prefix: nuwe_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of common stock warrant liability, due after one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: nuwe_CommonStockWarrantLiabilityNoncurrent Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRefers to price per share of the preferred stock at conversion into common stock. + ReferencesNo definition available. + Details Name: nuwe_ConversionOfStockSharesConversionPrice Namespace Prefix: nuwe_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionConvertible preferred stock shares issuable upon declaration of dividends. + ReferencesNo definition available. + Details Name: nuwe_ConvertiblePreferredStockIssuableUponDeclarationOfDividendsPaidInKind Namespace Prefix: nuwe_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of original issue discount on convertible preferred stock issued. + ReferencesNo definition available. + Details Name: nuwe_ConvertiblePreferredStockOriginalIssueDiscountPercentagePerUnit Namespace Prefix: nuwe_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of financing expense incurred for liability in excess of gross proceeds of offering on day 1. + ReferencesNo definition available. + Details Name: nuwe_FinancingExpenseForLiabilityInExcessOfGrossProceedsOfOffering Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe floor price per share represents the lowest price (lowest level) at which an IPO may be bid on. + ReferencesNo definition available. + Details Name: nuwe_FloorPricePerShare Namespace Prefix: nuwe_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe amount of gross proceeds before deducting placement agent fees and commissions and offering expenses. + ReferencesNo definition available. + Details Name: nuwe_GrossProceedsBeforeDeductingPlacementAgentFeesAndCommissionsAndOfferingExpenses Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of gross proceeds before deducting the placement agent fees and other offering expenses. + ReferencesNo definition available. + Details Name: nuwe_GrossProceedsFromOfferingBeforeDeductingThePlacementAgentFeesAndOtherOfferingExpenses Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net proceeds after deducting placement agent fees and commissions and offering expenses. + ReferencesNo definition available. + Details Name: nuwe_NetProceedsAfterDeductingPlacementAgentFeesAndCommissionsAndOfferingExpenses Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of consecutive trading days in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_NumberOfConsecutiveTradingDays Namespace Prefix: nuwe_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of consecutive trading days considered for expiration in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_NumberOfConsecutiveTradingDaysConsideredForExpiration Namespace Prefix: nuwe_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares included in one unit. + ReferencesNo definition available. + Details Name: nuwe_NumberOfSharesInOneUnit Namespace Prefix: nuwe_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of trading days immediately following the date the company effects a reverse stock split in the future, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_NumberOfTradingDays Namespace Prefix: nuwe_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants included in each unit in a public offering. + ReferencesNo definition available. + Details Name: nuwe_NumberOfWarrantsInEachUnit Namespace Prefix: nuwe_Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRefers to percentage of placement fee paid to underwriter or placement agent, based on aggregate gross proceeds raised in the offering and issued warrants. + ReferencesNo definition available. + Details Name: nuwe_PercentageOfFeesPaidToUnderwriterOrPlacementAgentInCash Namespace Prefix: nuwe_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of volume weighted average price of the common stock. + ReferencesNo definition available. + Details Name: nuwe_PercentageOfVolumeWeightedAveragePriceOfCommonStock Namespace Prefix: nuwe_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionTerm of continued provision of both inpatient and outpatient ultrafiltration services, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_PeriodForUltrafiltrationServices Namespace Prefix: nuwe_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe net cash inflow from the additional capital contribution to the entity. + ReferencesNo definition available. + Details Name: nuwe_ProceedsFromIssuanceOfCommonStockNet Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTrading volume for each trading day during the period. + ReferencesNo definition available. + Details Name: nuwe_TradingVolumeForEachTradingDay Namespace Prefix: nuwe_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ClassOfStockDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1:

contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-3> + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-4> + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in equity for down round feature triggered for warrant classified as equity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-3A> + Details Name: us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMndTnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=nuwe_AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=nuwe_April2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=nuwe_August2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nuwe_SupplyAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nuwe_DaVitaWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=nuwe_ShareBasedCompensationAwardTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nuwe_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=nuwe_July2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesPPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=nuwe_SeriesJConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=nuwe_October2023OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=nuwe_AdditionalPaidInCapitalAttributableToConvertibleOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock-Based Compensation Expense Items [Abstract] Á Á Á Stock-based compensation expense \$ 101 \$ 135 \$ 374 \$ 513 Additional Disclosures [Abstract] Á Á Á Vesting period Á Á 48 months Á Outstanding stock options (in shares) 3,890 3,101 3,890 3,101 Selling, General and Administrative Expense [Member] Á Á Á Stock-Based Compensation Expense Items [Abstract] Á Á Á Stock-based compensation expense \$ 99 \$ 133 \$ 363 \$ 484 Research and Development Expense [Member] Á Á Á Stock-Based Compensation Expense Items [Abstract] Á Á Á Stock-based compensation expense \$ 2 \$ 2 \$ 11 \$ 29 Stock Options [Member] Á Á Á Additional Disclosures [Abstract] Á Á Á Stock options granted (in shares) 0 532 1,264 3,544 Weighted average grant date fair value of stock options issued (in dollars per share) \$ 0 \$ 62.65 \$ 24.14 \$ 226.26 Weighted Average Assumptions used in Black-Scholes Option Pricing Model [Abstract] Á Á Á Expected volatility 138.70% 131.06% 138.70% 152.59% Expected life of options (years) 5 years 6 months 3 days 6 years 3 months 5 years 6 months 3 days 6 years 2 months 8 days Expected dividend yield 0.00% 0.00% 0.00% 0.00% Risk-free interest rate 3.94% 4.29% 3.94% 4.16% Stock options vested (in shares) 420 69 1,767 129 Stock options expired or forfeited (in shares) 102 595 465 680 Exercise of stock options (in shares) 0 0 0 0 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LaborAndRelatedExpenseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) (iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMndTnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/reit/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/reit/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_ StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_ IncomeStatementLocationAxis=us-gaap_ SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ IncomeStatementLocationAxis=us-gaap_ ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ AwardTypeAxis=us-gaap_ EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Details) - Warrants [Member] - USD (\$) \$ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward] A A Beginning balance \$ 2,843 \$ 6,686 Exercise of warrants (1,357) A Change in fair value (4,602) A Ending balance 480 2,843 October 18, 2022 Series I Warrants Issuance [Member] A A Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward] A A Issuance of Common Stock for exercise of warrants A (7,623) Change in fair value A 755 October 17, 2023 Series J Warrants Issuance [Member] A A Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward] A A Issuance A 4,965 Exercise of warrants A (536) Change in fair value A \$ (1,586) April 30, 2024 Warrants Issuance [Member] A A Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward] A A Issuance 7,813 A Exercise of warrants (1,373) A Reclassification to Equity \$ (2,844) A X - DefinitionAmount of exercise value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesNo definition available. + Details Name: nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuesExerciseOfWarrants Namespace Prefix: nuwe_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of reclassification to equity measured at fair value on recurring basis using unobservable input (level 3). + ReferencesNo definition available. + Details Name: nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity Namespace Prefix: nuwe_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of issuance of common stock in equity for warrants measured at fair value on recurring basis using unobservable input (level 3). + ReferencesNo definition available. + Details Name: nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityStockIssuedForConversionOfWarrants Namespace Prefix: nuwe_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - DefinitionArea of leased property under operating lease. + ReferencesNo definition available. + Details Name: nuwe_OperatingLeaseAreaForLease Namespace Prefix: nuwe_ Data Type: xbrli:decimalItem Type Balance Type: na Period Type: duration X - DefinitionAmount of monthly rent and common area maintenance charges, including estimated property tax for headquarters. + ReferencesNo definition available. + Details Name: nuwe_OperatingLeaseMonthlyRentAndCommonAreaMaintenanceCharges Namespace Prefix: nuwe_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) - USD (\$) 9 Months Ended Nov. 05, 2024 Oct. 22, 2024 Sep. 30, 2024 Sep. 30, 2023 Oct. 20, 2024 Stockholders' equity [Abstract] A A A A Gross proceeds received through exercise of warrants A \$ 501,000 \$ 0 A Subsequent Event [Member] A A A A Stockholders' equity [Abstract] A A A A Aggregate purchase of warrants (in shares) 1,832,517 A A A Warrant exercise price per share (in dollars per share) \$ 2.1 A A A A Gross proceeds prior to deducting inducement agent fees and estimated offering expenses \$ 3,800,000 A A A Gross proceeds received through exercise of warrants \$ 1,300,000 A A A Subsequent Event [Member] | Series I Warrants and Series II Warrants [Member] A A A A Stockholders' equity [Abstract] A A A A Aggregate purchase of warrants (in shares) 3,665,034 A A A Subsequent Event [Member] | Series I Warrants [Member] A A A A Stockholders' equity [Abstract] A A A A Warrant exercise price per share (in dollars per share) \$ 1.94 A A A Warrant expiry period 5 years A A A Warrants exercisable period 6 months A A A Subsequent Event [Member] | Series II Warrants [Member] A A A A Stockholders' equity [Abstract] A A A A Warrant exercise price per share (in dollars per share) \$ 1.94 A A A Warrant expiry period 2 years A A A Warrants exercisable period 6 months A A A Subsequent Event [Member] | SeaStar Medical Holding Corporation [Member] A A A A Subsequent Event [Line Items] A A A A Agreement settlement amount receivable A A A \$ 900,000 Agreement settlement amount received A \$ 500,000 A A X - DefinitionPeriod of time when Warrants becomes exercisable, in PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightExercisableWarrantsOrRightsPeriod Namespace Prefix: nuwe_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPeriod warrants expiry , in PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nuwe_ClassOfWarrantOrRightWarrantExpiryPeriod Namespace Prefix: nuwe_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of gross proceeds prior deducting inducement agent fees and estimated offering expenses. + ReferencesNo definition available. + Details Name: nuwe_GrossProceedsFromOfferingPriorDeductingInducementAgentFeesAndEstimatedOfferingExpenses Namespace Prefix: nuwe_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 + Details Name: us-gaap_LossContingencyReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow from the collection of receivables related to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_LossContingencyReceivableProceeds Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference

[illegible]

[illegible]

[illegible]

[illegible]

http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 040000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 060100 - Disclosure - Nature of Business and Basis of Presentation Sheet http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 7 false false R8.htm 060200 - Disclosure - Revenue Recognition Sheet http://sunshineheart.com/role/RevenueRecognition Revenue Recognition Notes 8 false false R9.htm 060300 - Disclosure - Stockholders' Equity Sheet http://sunshineheart.com/role/StockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 060400 - Disclosure - Stock-Based Compensation Sheet http://sunshineheart.com/role/StockbasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 060500 - Disclosure - Fair Value of Financial Instruments Sheet http://sunshineheart.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 11 false false R12.htm 060600 - Disclosure - Income Taxes Sheet http://sunshineheart.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 060700 - Disclosure - Operating Leases Sheet http://sunshineheart.com/role/OperatingLeases Operating Leases Notes 13 false false R14.htm 060800 - Disclosure - Commitments and Contingencies Sheet http://sunshineheart.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 060900 - Disclosure - Subsequent Events Sheet http://sunshineheart.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 061000 - Disclosure - Insider Trading Arrangement Sheet http://sunshineheart.com/role/InsiderTradingArrangement Insider Trading Arrangement Notes 16 false false R17.htm 070100 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies Nature of Business and Basis of Presentation (Policies) Policies 17 false false R18.htm 080100 - Disclosure - Nature of Business and Basis of Presentation (Tables) Sheet http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationTables Nature of Business and Basis of Presentation (Tables) Tables http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentation 18 false false R19.htm 080400 - Disclosure - Stock-Based Compensation (Tables) Sheet http://sunshineheart.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://sunshineheart.com/role/StockbasedCompensation 19 false false R20.htm 080500 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://sunshineheart.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://sunshineheart.com/role/FairValueOfFinancialInstruments 20 false false R21.htm 090100 - Disclosure - Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details) Sheet http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details) Details 21 false false R22.htm 090102 - Disclosure - Nature of Business and Basis of Presentation, Loss Per Share (Details) Sheet http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails Nature of Business and Basis of Presentation, Loss Per Share (Details) Details 22 false false R23.htm 090200 - Disclosure - Revenue Recognition (Details) Sheet http://sunshineheart.com/role/RevenueRecognitionDetails Revenue Recognition (Details) Details http://sunshineheart.com/role/RevenueRecognition 23 false false R24.htm 090300 - Disclosure - Stockholders' Equity (Details) Sheet http://sunshineheart.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://sunshineheart.com/role/StockholdersEquity 24 false false R25.htm 090400 - Disclosure - Stock-Based Compensation (Details) Sheet http://sunshineheart.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) Details http://sunshineheart.com/role/StockbasedCompensationTables 25 false false R26.htm 090500 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://sunshineheart.com/role/FairValueOfFinancialInstrumentsTables 26 false false R27.htm 090700 - Disclosure - Operating Leases (Details) Sheet http://sunshineheart.com/role/OperatingLeasesDetails Operating Leases (Details) Details http://sunshineheart.com/role/OperatingLeases 27 false false R28.htm 090900 - Disclosure - Subsequent Events (Details) Sheet http://sunshineheart.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://sunshineheart.com/role/SubsequentEvents 28 false false All Reports Book All Reports ef20034581 10q.htm nuwe-20240930.xsd nuwe-20240930 cal.xml nuwe-20240930 def.xml nuwe-20240930 lab.xml nuwe-20240930 pre.xml http://fasb.org/stpr/2024/ef20034581 10q.htm. {"version": "2.2", "instance": { "ef20034581 10q.htm": { "nsprefix": "nuwe", "nsuri": "http://sunshineheart.com/20240930", "dts": { "inline": { "ef20034581 10q.htm" } }, "schema": { "local": { "nuwe-20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/12-31.xsd", "http://www.xbrl.org/2003/xbrl-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-2003-12-31.xsd", "http://www.xbrl.org/2004/ef2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "nuwe-20240930 cal.xml" }, "definitionLink": { "local": { "nuwe-20240930 def.xml" } }, "labelLink": { "local": { "nuwe-20240930 lab.xml" } } }, "presentationLink": { "local": { "nuwe-20240930 pre.xml" } } }, "keyStandard": 179, "keyCustom": 49, "axisStandard": 18, "axisCustom": 0, "memberStandard": 24, "memberCustom": 21, "hidden": { "total": 16, "http://sunshineheart.com/20240930": 6, "http://fasb.org/us-gaap/2024": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 196, "entityCount": 1, "segmentCount": 48, "elementCount": 372, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 660, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://sunshineheart.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "div", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "div", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "div", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "R2": { "role": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "longName": "010000 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c20240930", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "div": "td", "tr": "table", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240930", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "div": "td", "tr": "table", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "R3": { "role": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c20240930", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U003", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "us-gaap:PreferredStockParOrStatedValuePerShare", "span": "div", "td": "tr", "table", "div": "div", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240930", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "us-gaap:PreferredStockSharesAuthorized", "span": "div", "td": "tr", "table", "div": "div", "div": "div", "body": "body", "html": "reportCount": 1, "baseRef": "ef20034581 10q.htm", "first": true, "unique": true }, "R4": { "role": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c20240701to20240930", "name": "us-gaap:RevenueFromContractWithCustomerEx

"baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://sunshineheart.com/role/SubsequentEvents", "longName": "060900 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://sunshineheart.com/role/InsiderTradingArrangement", "longName": "061000 - Disclosure - Insider Trading Arrangement", "shortName": "Insider Trading Arrangement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c20240701to20240930", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmtdFlag", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240701to20240930", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmtdFlag", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies", "longName": "070100 - Disclosure - Nature of Business and Basis of Presentation (Policies)", "shortName": "Nature of Business and Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationTables", "longName": "080100 - Disclosure - Nature of Business and Basis of Presentation (Tables)", "shortName": "Nature of Business and Basis of Presentation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://sunshineheart.com/role/StockbasedCompensationTables", "longName": "080400 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsTables", "longName": "080500 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "longName": "090100 - Disclosure - Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details)", "shortName": "Nature of Business and Basis of Presentation, Going Concern, Revenue Recognition, Accounts Receivable and Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "c20240930", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "nuwe:PercentageOfReduceInMonthlyCashBurnRate", "unitRef": "U005", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "unique": true } }, "R22": { "role": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails", "longName": "090200 - Disclosure - Nature of Business and Basis of Presentation, Loss Per Share (Details)", "shortName": "Nature of Business and Basis of Presentation, Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U001", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U001", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://sunshineheart.com/role/RevenueRecognitionDetails", "longName": "090200 - Disclosure - Revenue Recognition (Details)", "shortName": "Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c20240930", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240701to20240930", "name": "us-gaap:ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_RangeAxis_MaximumMember_Timin", "unitRef": "U005", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "unique": true } }, "R24": { "role": "http://sunshineheart.com/role/StockholdersEquityDetails", "longName": "090300 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c20240930", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "U001", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230101to20231231", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U001", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "unique": true } }, "R25": { "role": "http://sunshineheart.com/role/StockbasedCompensationDetails", "longName": "090400 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c20240701to20240930", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240701to20240930", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails", "longName": "090500 - Disclosure - Fair Value of Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c20231231", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20221231", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "unique": true } }, "R27": { "role": "http://sunshineheart.com/role/OperatingLeasesDetails", "longName": "090700 - Disclosure - Operating Leases (Details)", "shortName": "Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "nuwe:OperatingLeaseAreaForLease", "unitRef": "U009", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240930", "name": "nuwe:OperatingLeaseAreaForLease", "unitRef": "U009", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://sunshineheart.com/role/SubsequentEventsDetails", "longName": "090900 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c20240101to20240930", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20241020", "name": "us-gaap:LossContingencyReceivable", "unitRef": "U002", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20034581_10q.htm", "unique": true } }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-US", "role": { "label": "Nature of Business and Basis of Presentation (Abstract)" } }, "auth ref": [] }, "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities" } } }, "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. } } }, "auth ref": ["r37", "r38"] }, "us-gaap:AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold. } } }, "auth ref": ["r603"] }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. } } }, "auth ref": ["r70"] }, "nuwe:AccountsReceivablesMaximumCreditPeriodFromInvoiceDate": { "xbrltype": "durationItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AccountsReceivablesMaximumCreditPeriodFromInvoiceDate", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Represents the typical credit period from the invoice date, after which unpaid accounts are individually analyzed for collectability in PnYnMdnTHnMns format, for example, P1Y5M13D, represents the reported fact of one year, five months, and thirteen days." } } }, "auth ref": [] }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Accumulated other comprehensive income (loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. } } }, "auth ref": ["r120", "r123", "r124", "r125", "r388"] }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. } } }, "auth ref": ["r120", "r123", "r124", "r125", "r388"] }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent. } } }, "auth ref": ["r2", "r8",

"r14", "r55", "r56", "r131", "r132", "r395", "r396", "r397", "r398", "r399", "r700" }, {"us-gaap AdditionalPaidInCapital": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"role": {"terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, {"auth ref": ["r47", "r651", "r812"]}, {"nuwe AdditionalPaidInCapitalAttributableToConvertibleOptionMember": {"xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AdditionalPaidInCapitalAttributableToConvertibleOptionMember", "presentation": "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" }, {"lang": {"en-us": {"role": {"documentation": "Additional paid-in capital attributable to conversion (for example, stock purchase warrants, detachable call options) or other instrument features (for example, embedded conversion option) that satisfy the conditions for equity classification.", "label": "Additional Paid-in Capital, Attributable to Convertible Option [Member]", "terseLabel": "Warrants [Member]" } } } }, {"auth ref": [] }, {"us-gaap AdditionalPaidInCapitalMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" }, {"en-us": {"role": {"terseLabel": "Additional Paid in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } }, {"auth ref": ["r518", "r709", "r710", "r711", "r712", "r764", "r813"]}, {"us-gaap AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" }, {"lang": {"en-us": {"role": {"label": "Adjustments to reconcile net loss to cash flows used in operating activities." } } } }, {"auth ref": [] }, {"nuwe AdjustmentsToAdditionalPaidInCapitalDeemedDividend": {"xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividend", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" }, {"en-us": {"role": {"documentation": "Amount of decrease (increase) to additional paid in capital (APIC) resulting from deemed dividend.", "label": "Adjustments to Additional Paid In Capital, Deemed Dividend", "terseLabel": "Series I convertible preferred stock deemed dividend" } } } }, {"auth ref": [] }, {"us-gaap AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" }, {"en-us": {"role": {"negatedLabel": "Deemed dividend", "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } } }, {"auth ref": ["r9", "r81"]}, {"us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" }, {"en-us": {"role": {"negatedLabel": "Issuance costs", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } } }, {"auth ref": ["r9", "r81"]}, {"us-gaap AllocatedShareBasedCompensationExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": "http://sunshineheart.com/role/StockbasedCompensationDetails" }, {"en-us": {"role": {"terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, {"auth ref": ["r325", "r330"]}, {"us-gaap AllowanceForDoubtfulAccountsReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" }, {"lang": {"en-us": {"role": {"label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } } }, {"auth ref": ["r115", "r185", "r221"]}, {"dei AmendmentFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": "http://sunshineheart.com/role/DocumentAndEntityInformation" }, {"lang": {"en-us": {"role": {"label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } }, {"auth ref": [] }, {"us-gaap AmortizationOfFinancingCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" }, {"en-us": {"role": {"label": "Warrant financing costs", "negatedTerseLabel": "Financing Expense", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } } }, {"auth ref": ["r65", "r253", "r706", "r772"]}, {"nuwe AnnualBaseRentIncreasePerSquareFoot": {"xbrltype": "decimalItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AnnualBaseRentIncreasePerSquareFoot", "presentation": "http://sunshineheart.com/role/OperatingLeasesDetails" }, {"lang": {"en-us": {"role": {"documentation": "Annual increase in the amount of rent expense per square foot for leased assets.", "label": "Annual base rent increase per square foot", "verboseLabel": "Annual increase per square foot (in dollars per square foot)" } } } }, {"auth ref": [] }, {"nuwe AnnualBaseRentPerSquareFoot": {"xbrltype": "decimalItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AnnualBaseRentPerSquareFoot", "presentation": "http://sunshineheart.com/role/OperatingLeasesDetails" }, {"lang": {"en-us": {"role": {"documentation": "Amount of base rent expense per square foot for leased assets.", "label": "Annual Base Rent per Square Foot", "verboseLabel": "Annual base rent (per square foot)" } } } }, {"auth ref": [] }, {"us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails" }, {"lang": {"en-us": {"role": {"verboseLabel": "Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, {"auth ref": ["r166"]}, {"us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails" }, {"lang": {"en-us": {"role": {"label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } }, {"auth ref": ["r18"]}, {"us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails" }, {"lang": {"en-us": {"role": {"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, {"auth ref": [] }, {"us-gaap AntidilutiveSecuritiesNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails" }, {"lang": {"en-us": {"role": {"label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, {"auth ref": ["r18"]}, {"nuwe April2024OfferingMember": {"xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "April2024OfferingMember", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" }, {"lang": {"en-us": {"role": {"documentation": "The April 2024 stock offering to the public.", "label": "April 2024 Offering [Member]", "terseLabel": "April 2024 Offering [Member]" } } } }, {"auth ref": [] }, {"nuwe April302024WarrantsIssuanceMember": {"xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "April302024WarrantsIssuanceMember", "presentation": "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails" }, {"lang": {"en-us": {"role": {"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "April 30, 2024 Warrants Issuance [Member]", "terseLabel": "April 30, 2024 Warrants Issuance [Member]" } } } }, {"auth ref": [] }, {"us-gaap ArrangementsAndNonarrangementTransactionsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" }, {"lang": {"en-us": {"role": {"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } }, {"auth ref": ["r355"]}, {"us-gaap Assets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"lang": {"en-us": {"role": {"totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } }, {"auth ref": ["r86", "r94", "r111", "r140", "r169", "r173", "r178", "r179", "r218", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r356", "r358", "r389", "r484", "r555", "r626", "r627", "r651", "r675", "r733", "r734", "r773"]}, {"us-gaap AssetsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"lang": {"en-us": {"role": {"terseLabel": "ASSETS", "label": "Assets [Abstract]" } } } }, {"auth ref": [] }, {"us-gaap AssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"lang": {"en-us": {"role": {"totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } }, {"auth ref": ["r106", "r119", "r140", "r218", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r356", "r358", "r389", "r651", "r733", "r734", "r773"]}, {"us-gaap AssetsCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"lang": {"en-us": {"role": {"terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } } }, {"auth ref": [] }, {"nuwe AtTheMarketOfferingMember": {"xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": "http://sunshineheart.com/role/StockholdersEquityDetails" }, {"lang": {"en-us": {"role": {"documentation": "An [at-the-market] offering is an offering of securities into an existing trading market for outstanding shares of the same class at other than a fixed price on, or through the facilities of, a national securities exchange, or to or through a market maker otherwise than on an exchange.", "label": "At The Market Offering [Member]", "verboseLabel": "At-The Market Program [Member]" } } } }, {"auth ref": [] }, {"nuwe August2024OfferingMember": {"xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "August2024OfferingMember", "presentation": "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" }, {"lang": {"en-us": {"role": {"documentation": "The August 2024 stock offering to the public.", "label": "August 2024 Offering [Member]", "terseLabel": "August 2024 Offering [Member]" } } } }, {"auth ref": [] }, {"us-gaap AwardTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": "http://sunshineheart.com/role/StockbasedCompensationDetails" }, {"lang": {"en-us": {"role": {"label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } } }, {"auth ref": ["r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324"]}, {"us-gaap CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" }, {"lang": {"en-us": {"role": {"terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } }, {"auth ref": ["r17", "r109", "r619"]}, {"us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" }, {"lang": {"en-us": {"role": {"periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth ref": ["r17", "r68", "r138"]}, {"us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" }, {"lang": {"en-us": {"role": {"totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth ref": ["r1", "r68"]}, {"dei CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": "http://sunshineheart.com/role/DocumentAndEntityInformation" }, {"lang": {"en-us": {"role": {"label": "City Area Code", "documentation": "Area code of city" } } } }, {"auth ref": [] }, {"us-gaap ClassOfStockDisclosuresAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDisclosuresAbstract", "presentation": "http://sunshineheart.com/role/DocumentAndEntityInformation" }, {"lang": {"en-us": {"role": {"label": "City Area Code", "documentation": "Area code of city" } } } }, {"auth ref": [] }, {"us-gaap

"http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": []
"http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r103", "r112", "r113", "r114", "r140", "r159", "r160", "r163", "r165", "r171", "r172", "r18", "r243", "r245", "r246", "r247", "r250", "r251", "r256", "r257", "r260", "r263", "r270", "r389", "r512", "r513", "r514", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r543", "r564", "r582", "r596", "r597", "r598", "r599", "r600", "r684", "r707", "r713"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r112", "r113", "r114", "r171", "r256", "r257", "r258", "r260", "r263", "r268", "r270", "r512", "r513", "r514", "r515", "r630", "r684", "r707"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r30"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] },
"nuwe_ClassOfWarrantOrRightExercisableWarrantsOrRightsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ClassOfWarrantOrRightExercisableWarrantsOrRightsPeriod", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Period of time when Warrants becomes exercisable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Exercisable Warrants or Rights Period", "terseLabel": "Warrants exercisable period" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Exercise price of warrants (in dollars per share)", "terseLabel": "Warrant exercise price per share (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r271"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of common stock (in shares)", "verboselabel": "Aggregate purchase of warrants (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r271"] },
"nuwe_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsToPurchaseSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsToPurchaseSharesOfCommonStock", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights to Purchase Shares of Common Stock", "terseLabel": "Warrants to purchase common shares (in shares)" } } }, "auth_ref": [] }, "nuwe_ClassOfWarrantOrRightNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ClassOfWarrantOrRightNumberOfTranches", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of tranches in which the warrants/rights will vest.", "label": "Class of Warrant or Right, Number of Tranches", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightUnissued", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for pre-funded warrants (in shares)", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref": [] },
"nuwe_ClassOfWarrantOrRightWarrantExpiryPeriod": { "xbrltype": "durationItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ClassOfWarrantOrRightWarrantExpiryPeriod", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Period warrants expiry, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Warrant Expiry Period", "terseLabel": "Warrant expiry period" } } }, "auth_ref": [] },
"nuwe_ClassOfWarrantOrRightWarrantsToBeExercisedForAmountOfSharesOwnershipPercentageInEntitySubjectToCertainVestingMilestones": { "xbrltype": "percentItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsToBeExercisedForAmountOfSharesOwnershipPercentageInEntitySubjectToCertainVestingMilestones", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants to be exercised for amount of shares ownership percentage in entity subject to certain vesting milestones.", "label": "Class of Warrant or Right, Warrants to be Exercised for Amount of Shares Ownership Percentage in Entity Subject to Certain Vesting Milestones", "terseLabel": "Warrants to be exercised for amount of shares ownership percentage in entity" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r42", "r87", "r485", "r542"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesTextBlock", "presentation": ["http://sunshineheart.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r76", "r237", "r238", "r604", "r729", "r731"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r665", "r666", "r667", "r669", "r670", "r671", "r672", "r709", "r710", "r712", "r764", "r811", "r813"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": []
"http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r46"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": []
"http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r46", "r543"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": []
"http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r46"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r46", "r543", "r561", "r813", "r814"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": []
"http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock as of September 30, 2024 and December 31, 2023, par value \$0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,866,890 and 162,356, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r46", "r487", "r651"] },
"nuwe_CommonStockWarrantLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "CommonStockWarrantLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of common stock warrant liability, due after one year or the normal operating cycle, if longer.", "label": "Common Stock Warrant Liability, Noncurrent", "terseLabel": "Common stock warrant liability" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r15", "r127", "r129", "r133", "r480", "r496", "r497"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r20", "r21", "r34", "r35", "r183", "r603"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r20", "r21", "r34", "r35", "r183", "r510", "r603"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": []
"http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails",
"http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Percentage of net sales", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the denominator in the equation, this concept represents the

concentration percentage derived from the division." } } } , "auth_ref": ["r20", "r21", "r34", "r35", "r183"] } } , "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [] } , "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails"] , "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } } , "auth_ref": ["r20", "r21", "r34", "r35", "r183", "r603"] } } , "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies"] , "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } } , "auth_ref": ["r33", "r621"] } } , "nuwe_ConversionOfStockSharesConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "ConversionOfStockSharesConversionPrice", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "documentation": "Refers to price per share of the preferred stock at conversion into common stock.", "label": "Conversion of Stock, Shares Conversion Price", "verboseLabel": "Conversion price (in dollars per share)" } } } , "auth_ref": [] } } , "nuwe_ConvertiblePreferredStockIssuableUponDeclarationOfDividendsPaidInKind": { "xbrltype": "sharesItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "ConvertiblePreferredStockIssuableUponDeclarationOfDividendsPaidInKind", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock shares issuable upon declaration of dividends.", "label": "Convertible Preferred Stock Issuable Upon Declaration of Dividends Paid In Kind", "terseLabel": "Additional shares issuable upon declaration of dividends (in shares)" } } } , "auth_ref": [] } } , "nuwe_ConvertiblePreferredStockOriginalIssueDiscountPercentagePerUnit": { "xbrltype": "percentItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "ConvertiblePreferredStockOriginalIssueDiscountPercentagePerUnit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "documentation": "Percentage of original issue discount on convertible preferred stock issued.", "label": "Convertible Preferred Stock Original Issue Discount Percentage Per Unit", "terseLabel": "Original issue discount percentage" } } } , "auth_ref": [] } } , "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"] , "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } } , "auth_ref": ["r60", "r61", "r448"] , "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } } , "auth_ref": [] } } , "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } } , "auth_ref": [] } } , "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails"] , "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } } , "auth_ref": ["r73", "r183"] } } , "nuwe_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "CustomerOneMember", "presentation": [] } } , "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"] , "lang": { "en-us": { "role": { "documentation": "A major single external customer or group of external customers representing concentration risk.", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } } , "auth_ref": [] } } , "nuwe_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "CustomerTwoMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"] , "lang": { "en-us": { "role": { "documentation": "A major single external customer or group of external customers representing concentration risk.", "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } } , "auth_ref": [] } } , "nuwe_DaVitaWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "DaVitaWarrantMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] , "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "DaVita Warrant [Member]", "terseLabel": "DaVita Warrant [Member]" } } } , "auth_ref": [] } } , "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleGainLoss", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "en-us": { "role": { "negatedLabel": "Net realized gain on marketable securities", "label": "Debt Securities, Available for Sale, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } , "auth_ref": ["r701", "r702"] } } , "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } } , "auth_ref": ["r6", "r22"] } } , "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails"] , "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r291", "r631", "r632", "r633", "r634", "r635", "r636", "r637"] } } , "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails"] , "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } } , "auth_ref": ["r291", "r631", "r632", "r633", "r634", "r635", "r636", "r637"] } } , "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [] } } , "http://sunshineheart.com/role/StockbasedCompensation"] , "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } } , "auth_ref": ["r295", "r298", "r326", "r327", "r328", "r639"] } } , "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Abstract]" } } } , "auth_ref": [] } } , "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-OT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } , "auth_ref": [] } } , "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } } , "auth_ref": [] } } , "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } } , "auth_ref": [] } } , "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } } , "auth_ref": ["r679"] } } , "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } } , "auth_ref": ["r680"] } } , "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } } , "auth_ref": [] } } , "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails"] , "lang": { "en-us": { "role": { "label": "Basic loss per share (in dollars per share)", "terseLabel": "Basic net income (loss) per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } , "auth_ref": ["r134", "r147", "r148", "r149", "r150", "r151", "r152", "r156", "r159", "r163", "r164", "r165", "r168", "r351", "r354", "r369", "r370", "r481", "r498", "r623"] } } , "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails"] , "lang": { "en-us": { "role": { "label": "Diluted loss per share (in dollars per share)", "terseLabel": "Diluted net income (loss) per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": ["r134", "r147", "r148", "r149", "r150", "r151", "r152", "r159", "r163", "r164", "r165", "r168", "r351", "r354", "r369", "r370", "r481", "r498", "r623"] } } , "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]", "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } } , "auth_ref": [] } } , "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies"] , "lang": { "en-us": { "role": { "terseLabel": "Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } } , "auth_ref": ["r18", "r19", "r167"] } } , "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Reported net loss with reported net loss per share [Abstract]", "label": "Earnings Per Share Reconciliation [Abstract]" } } } , "auth_ref": [] } } , "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth_ref": ["r392"] } } , "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } , "auth_ref": ["r38"] } } , "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [] } } , "http://sunshineheart.com/role/StockbasedCompensationDetails"] , "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Stock Options [Member]" }, "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One" }, "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r677"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r677"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r677"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r683"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r677"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r677"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r677"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r677"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r104", "r130", "r131", "r132", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r170", "r219", "r220", "r233", "r273", "r341", "r342", "r348", "r349", "r350", "r352", "r353", "r354", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r403", "r411", "r494", "r504", "r505", "r506", "r518", "r582"] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r6"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstruments"] }, "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r376", "r378", "r379", "r380", "r382", "r383", "r384", "r385", "r386", "r479", "r641", "r645"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r372", "r373", "r374", "r375", "r376", "r377"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r372", "r373", "r374", "r375", "r376", "r377", "r381"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsTables"] }, "lang": { "en-us": { "role": { "label": "Roll-Forward of Fair Value of Level 3 Warrants", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r372", "r377", "r381"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r373", "r381"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Issuance", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r375", "r381"] }, "nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuesExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuesExerciseOfWarrants", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "Amount of exercise value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [] }, "nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Reclassification to Equity", "documentation": "Amount of reclassification to equity measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [] }, "nuwe_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityStockIssuedForConversionOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityStockIssuedForConversionOfWarrants", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"] }, "lang": { "en-us": { "role": { "label": "Issuance of Common Stock for exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [

"http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails" l, "lang": { "en-us": { "role": { "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r372", "r381"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "negatedLabel": "Payments on finance lease liability", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r406", "r408"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails" l, "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r254", "r268", "r366", "r387", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r495", "r629", "r631", "r642", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r724", "r725", "r726", "r727", "r765", "r766", "r767", "r768", "r769", "r770"] }, "nuwe_FinancingExpenseForLiabilityInExcessOfGrossProceedsOfOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "FinancingExpenseForLiabilityInExcessOfGrossProceedsOfOffering", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails" l, "lang": { "en-us": { "role": { "documentation": "Amount of financing expense incurred for liability in excess of gross proceeds of offering on day 1.", "label": "Financing Expense for Liability in Excess of Gross Proceeds of Offering", "verboselabel": "Financing expense" } } }, "auth_ref": [] }, "nuwe_FloorPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "FloorPricePerShare", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" l, "lang": { "en-us": { "role": { "documentation": "The floor price per share represents the lowest price (lowest level) at which an IPO may be bid on.", "label": "Floor Price Per Share", "terseLabel": "Floor price per share (in dollars per share)" } } }, "auth_ref": [] }, "nuwe_GoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "GoingConcernAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]", "terseLabel": "Going Concern [Abstract]" } } }, "auth_ref": [] }, "nuwe_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "GoingConcernPolicyTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" l, "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the going concern when substantial doubt is raised about the ability to continue as a going concern.", "label": "Going Concern [Policy Text Block]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "nuwe_GrossProceedsBeforeDeductingPlacementAgentFeesAndCommissionsAndOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "GrossProceedsBeforeDeductingPlacementAgentFeesAndCommissionsAndOfferingExpenses", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" l, "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds before deducting placement agent fees and commissions and offering expenses.", "label": "Gross Proceeds Before Deducting Placement Agent Fees and Commissions and Offering Expenses", "terseLabel": "Gross proceeds before deducting placement agent fees and commissions and offering expenses" } } }, "auth_ref": [] }, "nuwe_GrossProceedsFromOfferingBeforeDeductingThePlacementAgentFeesAndOtherOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "GrossProceedsFromOfferingBeforeDeductingThePlacementAgentFeesAndOtherOfferingExpenses", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails" l, "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds before deducting placement agent fees and commissions and offering expenses.", "label": "Gross Proceeds Before Deducting Placement Agent Fees and Other Offering Expenses", "terseLabel": "Gross proceeds before deducting the placement agent fees and other offering expenses" } } }, "auth_ref": [] }, "nuwe_GrossProceedsFromOfferingBeforeDeductingThePlacementAgentFeesAndOtherOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "GrossProceedsFromOfferingBeforeDeductingThePlacementAgentFeesAndOtherOfferingExpenses", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" l, "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds prior to deducting inducement agent fees and estimated offering expenses.", "label": "Gross Proceeds from Offering Prior Deducting Inducement Agent Fees and Estimated Offering Expenses", "verboselabel": "Gross proceeds prior to deducting inducement agent fees and estimated offering expenses" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" l, "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r58", "r62", "r93", "r140", "r218", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r389", "r625", "r626", "r715", "r716", "r717", "r718", "r719", "r733"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" l, "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r59", "r89", "r93", "r482", "r492", "r625", "r626", "r715", "r716", "r717", "r718", "r719"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r234", "r235", "r236", "r373", "r377", "r381", "r501", "r503", "r567", "r616", "r643", "r783"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails" l, "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r235", "r236", "r373", "r377", "r381", "r501", "r503", "r567", "r616", "r643", "r783"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://sunshineheart.com/role/IncomeTaxes" l, "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r141", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r345", "r346", "r347", "r517", "r640"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" l, "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r98", "r101", "r154", "r155", "r169", "r176", "r179", "r334", "r335", "r344", "r499", "r640"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "negatedLabel": "Inventory, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r705"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "negatedLabel": "Other assets and liabilities", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" l, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "label": "Finished Goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r696"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r117", "r620", "r651"] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" l, "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r99", "r108", "r116", "r230", "r231", "r232", "r447", "r622"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "label": "Raw Materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r698"] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "negatedLabel": "Inventory Reserves", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r75", "r699"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l, "lang": { "en-us": { "role": { "label": "Work in Process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r697"] }, "nuwe_IssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "IssuanceOfCommonStockAndWarrants", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common stock and warrants.", "label": "Issuance of Common Stock and Warrants", "terseLabel": "Issuance of July and August 2024 Common Stock and Warrants" } } }, "auth_ref": [] }, "nuwe_IssuanceOfCommonStockForConversionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "IssuanceOfCommonStockForConversionOfPreferredStock", "crdr": "debit", "presentation": [

http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l."lang": { "en-us": { "role": { "documentation": "The amount of issuance of common stock for conversion of preferred stock." , "label": "Issuance of Common Stock for Conversion of Preferred Stock" , "terselabel": "Issuance of Common Stock for conversion of Series J Preferred Stock" } } } , "auth_ref": [] , "nuwe_IssuanceOfPreferredStockForWarrantExercises": { "xbrltype": "monetaryItemType" , "nsuri": "http://sunshineheart.com/20240930" , "localname": "IssuanceOfPreferredStockForWarrantExercises" , "crdr": "debit" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" l."lang": { "en-us": { "role": { "documentation": "The amount of issuance of preferred stock for exercise of warrants." , "label": "Issuance of Preferred Stock for Warrant Exercises" , "terselabel": "Issuance of Series J Preferred Stock for exercise of warrants" } } } , "auth_ref": [] } , "nuwe_July2024OfferingMember": { "xbrltype": "domainItemType" , "nsuri": "http://sunshineheart.com/20240930" , "localname": "July2024OfferingMember" , "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails" l."lang": { "en-us": { "role": { "documentation": "The July 2024 stock offering to the public." , "label": "July 2024 Offering [Member]" , "terselabel": "July 2024 Offering [Member]" } } } , "auth_ref": [] } , "us-gaap_LaborAndRelatedExpenseAbstract": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LaborAndRelatedExpenseAbstract" , "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails" l."lang": { "en-us": { "role": { "role": { "terselabel": "Stock-Based Compensation Expense Items [Abstract]" , "label": "Income Statement Compensation Expense Items [Abstract]" } } } } , "auth_ref": [] } , "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LeasesAbstract" , "lang": { "en-us": { "role": { "label": "Operating Leases [Abstract]" } } } , "auth_ref": [] } , "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LesseeLeaseDescriptionLineItems" , "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails" l."lang": { "en-us": { "role": { "label": "Lessee Lease Description [Line Items]" , "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r407" , "r410"] } , "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LesseeLeaseDescriptionTable" , "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails" l."lang": { "en-us": { "role": { "label": "Lessee Lease Description [Table]" , "documentation": "Disclosure of information about lessee's leases." } } } , "auth_ref": ["r407" , "r410"] } , "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LesseeOperatingLeasesTextBlock" , "presentation": ["http://sunshineheart.com/role/OperatingLeases" l."lang": { "en-us": { "role": { "label": "Operating Leases" , "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } } , "auth_ref": ["r402"] } , "us-gaap_Liabilities": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "Liabilities" , "crdr": "credit" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" l."lang": { "en-us": { "role": { "totalLabel": "Total liabilities" , "label": "Liabilities" , "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } } , "auth_ref": ["r11" , "r37" , "r38" , "r39" , "r40" , "r41" , "r42" , "r43" , "r140" , "r218" , "r243" , "r244" , "r245" , "r246" , "r247" , "r248" , "r249" , "r250" , "r251" , "r357" , "r358" , "r359" , "r389" , "r541" , "r624" , "r675" , "r733" , "r773" , "r774"] } , "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LiabilitiesAndStockholdersEquity" , "crdr": "credit" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" l."lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY" , "label": "Liabilities and Equity" , "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } , "auth_ref": ["r51" , "r88" , "r490" , "r651" , "r708" , "r728" , "r771"] } , "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LiabilitiesAndStockholdersEquityAbstract" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" l."lang": { "en-us": { "role": { "label": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" } } } , "auth_ref": [] } , "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LiabilitiesCurrent" , "crdr": "credit" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" l."lang": { "en-us": { "role": { "totalLabel": "Total current liabilities" , "label": "Liabilities, Current" , "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } , "auth_ref": ["r39" , "r107" , "r140" , "r218" , "r243" , "r244" , "r245" , "r246" , "r247" , "r248" , "r249" , "r250" , "r251" , "r357" , "r358" , "r359" , "r389" , "r651" , "r733" , "r773" , "r774"] } , "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LiabilitiesCurrentAbstract" , "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets" l."lang": { "en-us": { "role": { "terselabel": "Current liabilities" , "label": "Liabilities, Current [Abstract]" } } } , "auth_ref": [] } , "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType" , "nsuri": "http://xbrl.sec.gov/dei/2024" , "localname": "LocalPhoneNumber" , "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation" l."lang": { "en-us": { "role": { "label": "Local Phone Number" , "documentation": "Local phone number for entity." } } } , "auth_ref": [] } , "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LossContingencyReceivable" , "crdr": "debit" , "presentation": ["http://sunshineheart.com/role/SubsequentEventsDetails" l."lang": { "en-us": { "role": { "terselabel": "Agreement settlement amount receivable" , "label": "Loss Contingency Receivable" , "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } } , "auth_ref": ["r732"] } , "us-gaap_LossContingencyReceivableProceeds": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "LossContingencyReceivableProceeds" , "crdr": "debit" , "presentation": ["http://sunshineheart.com/role/SubsequentEventsDetails" l."lang": { "en-us": { "role": { "terselabel": "Agreement settlement amount received" , "label": "Loss Contingency Receivable, Proceeds" , "documentation": "Amount of cash inflow from the collection of receivables related to a loss contingency." } } } , "auth_ref": ["r704" , "r732"] } , "srt_MajorCustomersAxis": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "MajorCustomersAxis" , "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l."lang": { "en-us": { "role": { "label": "Customer [Axis]" } } } , "auth_ref": ["r183" , "r633" , "r661" , "r664" , "r737" , "r782" , "r784" , "r785" , "r786" , "r787" , "r788" , "r789" , "r790" , "r791" , "r792" , "r793" , "r794" , "r795" , "r796" , "r797" , "r798" , "r799" , "r800" , "r801" , "r802" , "r803" , "r804" , "r805" , "r806" , "r807" , "r808" , "r809" , "r810"] } , "srt_MaximumMember": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "MaximumMember" , "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails" l."lang": { "en-us": { "role": { "label": "Maximum [Member]" } } } , "auth_ref": ["r239" , "r240" , "r241" , "r242" , "r294" , "r331" , "r371" , "r446" , "r500" , "r502" , "r509" , "r533" , "r534" , "r587" , "r589" , "r591" , "r592" , "r594" , "r614" , "r615" , "r628" , "r630" , "r638" , "r644" , "r645" , "r649" , "r650" , "r662" , "r735" , "r775" , "r776" , "r777" , "r778" , "r779" , "r780"] } , "nuwe_MeritIncreasesToBaseSalariesOfNamedExecutiveOfficerOrEmployee": { "xbrltype": "monetaryItemType" , "nsuri": "http://sunshineheart.com/20240930" , "localname": "MeritIncreasesToBaseSalariesOfNamedExecutiveOfficerOrEmployee" , "crdr": "debit" , "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l."lang": { "en-us": { "role": { "documentation": "Amount of merit increases to base salaries of named executive officer or employee during the period." , "label": "Merit Increases to Base Salaries of Named Executive Officer or Employee" , "terselabel": "Merit increases to base salaries of named executive officer or employee" } } } , "auth_ref": [] } , "srt_MinimumMember": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "MinimumMember" , "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails" l."lang": { "en-us": { "role": { "label": "Minimum [Member]" } } } , "auth_ref": ["r239" , "r240" , "r241" , "r242" , "r294" , "r331" , "r371" , "r446" , "r500" , "r502" , "r509" , "r533" , "r534" , "r587" , "r589" , "r591" , "r592" , "r594" , "r614" , "r615" , "r628" , "r630" , "r638" , "r644" , "r645" , "r649" , "r650" , "r662" , "r735" , "r775" , "r776" , "r777" , "r778" , "r779" , "r780"] } , "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "NameOfMajorCustomerDomain" , "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails" l."lang": { "en-us": { "role": {

"Number of consecutive trading days considered for expiration in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Number of Consecutive Trading Days Considered for Expiration", "terseLabel": "Number of consecutive trading days considered for expiration" } } }, "auth_ref": [] }, "nuwe_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "NumberOfMajorCustomers", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of major customers of the entity.", "label": "Number of Major Customers", "terseLabel": "Number of major customers" } } }, "auth_ref": [] }, "nuwe_NumberOfShareInOneUnit": { "xbrltype": "sharesItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "NumberOfShareInOneUnit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of shares included in one unit.", "label": "Number of Share in One Unit", "terseLabel": "Number of shares in one unit (in shares)" } } }, "auth_ref": [] }, "nuwe_NumberOfTradingDays": { "xbrltype": "durationItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "NumberOfTradingDays", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of trading days immediately following the date the Company effects a reverse stock split in the future, in PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Number of Trading Days", "terseLabel": "Number of trading days" } } }, "auth_ref": [] }, "nuwe_NumberOfWarrantsInEachUnit": { "xbrltype": "integerItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "NumberOfWarrantsInEachUnit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants included in each unit in a public offering.", "label": "Number of Warrants in Each Unit", "terseLabel": "Number of warrants included in each unit" } } }, "auth_ref": [] }, "nuwe_October172023WarrantsIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "October172023WarrantsIssuanceMember", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "October 17, 2023 Warrants Issuance [Member]", "terseLabel": "October 17, 2023 Series I Warrants Issuance [Member]" } } }, "auth_ref": [] }, "nuwe_October182022WarrantsIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "October182022WarrantsIssuanceMember", "presentation": ["http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "October 18, 2022 Warrants Issuance [Member]", "terseLabel": "October 18, 2022 Series I Warrants Issuance [Member]" } } }, "auth_ref": [] }, "nuwe_October2023OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "October2023OfferingMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The October 2023 stock offering to the public.", "label": "October 2023 Offering [Member]", "terseLabel": "October 2023 Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating expenses." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r93", "r625", "r715", "r716", "r717", "r718", "r719"] }, "nuwe_OperatingLeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "OperatingLeaseAbstract", "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease [Abstract]", "terseLabel": "Operating Leases [Abstract]" } } }, "auth_ref": [] }, "nuwe_OperatingLeaseAreaForLease": { "xbrltype": "decimalItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "OperatingLeaseAreaForLease", "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Area of leased property under operating lease.", "label": "Operating Lease, Area for Lease", "terseLabel": "Area of property leased under operating lease" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r405"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r405"] }, "nuwe_OperatingLeaseMonthlyRentAndCommonAreaMaintenanceCharges": { "xbrltype": "monetaryItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "OperatingLeaseMonthlyRentAndCommonAreaMaintenanceCharges", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of monthly rent and common area maintenance charges, including estimated property tax for headquarters.", "label": "Operating Lease, Monthly Rent and Common Area Maintenance Charges", "terseLabel": "Monthly rent and common area maintenance charges" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r404"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Nature of Business and Basis of Presentation", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r36", "r71", "r72", "r84"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r118", "r651"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r110"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r4", "r8", "r85"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Unrealized foreign currency translation adjustment", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r55", "r56", "r57", "r390", "r391", "r393"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r121", "r122", "r123", "r494"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r38", "r651"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r66"] }, "nuwe_PaymentForCashBonus": { "xbrltype": "monetaryItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "PaymentForCashBonus", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash bonuses paid to any named executive officer or employee during the period.", "label": "Payment for Cash Bonus", "terseLabel": "Cash bonuses to named executive officer or employee" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Additions to intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r67"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r67"] }, "nuwe_PercentageOfFeesPaidToUnderwriterOrPlacementAgentInCash": { "xbrltype": "percentItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "PercentageOfFeesPaidToUnderwriterOrPlacementAgentInCash", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Refers to percentage of placement fee paid to underwriter or placement agent, based on aggregate gross proceeds raised in the offering and issued warrants.", "label": "Percentage of Fees Paid to Underwriter or Placement Agent in Cash", "terseLabel": "Aggregate cash fee paid to underwriter or placement agent" } } }, "auth_ref": [] }, "nuwe_PercentageOfReduceInMonthlyCashBurnRate": { "xbrltype": "percentItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "PercentageOfReduceInMonthlyCashBurnRate", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Refers to percentage of reduction in monthly burn rate balanced against strategic growth initiatives.", "label": "Percentage of Reduce in Monthly Cash Burn Rate", "terseLabel": "Reduce our monthly cash burn rate" } } }, "auth_ref": [] }, "nuwe_PercentageOfVolumeWeightedAveragePriceOfCommonStock": { "xbrltype": "percentItemtype", "nsuri": "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of volume weighted average price of the common stock.", "label": "Percentage of Volume Weighted Average Price of Common Stock", "terseLabel": "Percentage of volume weighted average price of common stock" } } }, "auth_ref": [] }, "nuwe_PeriodForUltrafiltrationServices": { "xbrltype": "durationItemtype", "nsuri": "http://sunshineheart.com/20240930", "localname": "PeriodForUltrafiltrationServices", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Term of continued provision of both inpatient and outpatient ultrafiltration services, in PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Period for Ultrafiltration Services", "terseLabel": "Period for ultrafiltration services" } } }, "auth_ref": [] }, "us-gaap_PreferedStockParOrStatedValuePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParentetical", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r45", "r256"] }, "us-gaap PreferredStockSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r45", "r543"] }, "us-gaap PreferredStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r45", "r256"] }, "us-gaap PreferredStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r45", "r543", "r561", "r813", "r814"] }, "us-gaap PreferredStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r45", "r486", "r651"] }, "nuwe ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their warrants.", "label": "Proceeds From Exercise of Warrants", "terseLabel": "Proceeds from the exercise of April 2024 Warrants" } } }, "auth_ref": [] }, "us-gaap ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from ATM stock offerings, net", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r31"] }, "us-gaap ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Issuance of common stock from offering", "terseLabel": "Gross proceeds from public stock offering", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r31"] }, "nuwe ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The net cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock, Net", "terseLabel": "Net proceeds from public stock offering" } } }, "auth_ref": [] }, "us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r16", "r136", "r186", "r217"] }, "us-gaap ProceedsFromWarrantExercises": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Gross proceeds received through exercise of warrants", "terseLabel": "Proceeds from the exercise of Series J Convertible Preferred Warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r703"] }, "us-gaap PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r409", "r483", "r491", "r651"] }, "nuwe PurchaseAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "PurchaseAgreementMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the securities purchase agreement with an institutional investor.", "label": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "srt RangeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r293", "r294", "r321", "r322", "r323", "r331", "r371", "r421", "r430", "r446", "r500", "r502", "r509", "r533", "r534", "r587", "r589", "r591", "r592", "r594", "r614", "r615", "r628", "r630", "r638", "r644", "r645", "r649", "r650", "r662", "r667", "r730", "r735", "r767", "r776", "r777", "r778", "r779", "r780"] }, "srt RangeMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://sunshineheart.com/role/OperatingLeasesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r293", "r294", "r321", "r322", "r323", "r331", "r371", "r421", "r430", "r446", "r500", "r502", "r509", "r533", "r534", "r587", "r589", "r591", "r592", "r594", "r614", "r615", "r628", "r630", "r638", "r644", "r645", "r649", "r650", "r662", "r667", "r730", "r735", "r767", "r776", "r777", "r778", "r779", "r780"] }, "nuwe ReclassificationOfWarrantsToEquity": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "ReclassificationOfWarrantsToEquity", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The reclassification of warrants to equity.", "label": "Reclassification of Warrants to Equity", "terseLabel": "Reclassification of April 2024 warrants to equity" } } }, "auth_ref": [] }, "us-gaap ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r332", "r616", "r626", "r781"] }, "us-gaap ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r48", "r81", "r489", "r507", "r508", "r516", "r544", "r651"] }, "us-gaap RetainedEarningsMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r104", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r219", "r220", "r233", "r341", "r342", "r348", "r349", "r350", "r352", "r353", "r354", "r360", "r362", "r363", "r365", "r368", "r401", "r403", "r504", "r506", "r518", "r813"] }, "us-gaap RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "us-gaap RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r91", "r92", "r169", "r174", "r175", "r177", "r179", "r180", "r181", "r183", "r290", "r291", "r448"] }, "us-gaap RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r102", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r617"] }, "us-gaap RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://sunshineheart.com/role/RevenueRecognition"], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r102", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r292"] }, "us-gaap RevenuePerformanceObligationAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuePerformanceObligationAbstract", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation [Abstract]", "label": "Revenue, Performance Obligation [Abstract]" } } }, "auth_ref": [] }, "nuwe RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionAbstract": { "xbrltype": "stringItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionAbstract", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]" } } }, "auth_ref": [] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Expected timing of satisfaction, period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r100"] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r100"] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "ecd Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://sunshineheart.com/role/InsiderTradingArrangement"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r682"] }, "ecd Rule10b51ArrTrmmtFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmmtFlag", "presentation": ["http://sunshineheart.com/role/InsiderTradingArrangement"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r682"] }, "nuwe SaleOfStockAggregateOfferingPrice": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "SaleOfStockAggregateOfferingPrice", "crdr": "debit", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate offering price of shares offer or sold in the stock transaction.", "label": "Sale of Stock Aggregate Offering Price" } } }, "auth_ref": [] }, "us-gaap SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap SaleOfStockPricePerShare": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "SaleOfStockPricePerShare", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Common stock offering price per share (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Net Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } }, "auth_ref": ["r10"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Sales Revenue [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } }, "auth_ref": ["r183", "r685"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationTables"], "lang": { "en-us": { "role": { "label": "Potential Shares of Common Stock not Included in Diluted Net Loss Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationTables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Reported Net Loss with Reported Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } }, "auth_ref": ["r714"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Classification of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationTables"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } }, "auth_ref": ["r13", "r52", "r53", "r54"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } }, "auth_ref": ["r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Assumptions used in Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } }, "auth_ref": ["r83"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } }, "auth_ref": ["r24", "r25", "r26", "r27", "r28", "r29", "r77", "r79", "r80", "r81", "r112", "r113", "r114", "r171", "r256", "r257", "r258", "r260", "r263", "r268", "r270", "r512", "r513", "r514", "r515", "r630", "r684", "r707"] }, "nuwe_SeaStarMedicalHoldingCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SeaStarMedicalHoldingCorporationMember", "presentation": ["http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune responses including hyperinflammation on vital organs (V'SeaStar®)." }, "label": "SeaStar Medical Holding Corporation [Member]", "terseLabel": "SeaStar Medical Holding Corporation [Member]" } }, "auth_ref": [] }, "nuwe_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The agreement entered by the company with certain institutional investors for the purchase and sale of shares." }, "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement [Member]" } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }, "auth_ref": ["r676"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://sunshineheart.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } }, "auth_ref": ["r678"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } }, "auth_ref": ["r181", "r182", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } }, "auth_ref": ["r64"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expense [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Series A Junior Participating Preferred Stock [Member]", "documentation": "Series A preferred stock." } }, "auth_ref": ["r694", "r695", "r736"] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesFPreferredStockMember", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Series F Convertible Preferred Stock [Member]", "documentation": "Series F preferred stock." } }, "auth_ref": ["r694", "r695", "r736"] }, "nuwe_SeriesIIWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SeriesIIWarrantsMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrant security classified as series II, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." }, "label": "Series II Warrants [Member]", "terseLabel": "Series II Warrants [Member]" } }, "auth_ref": [] }, "nuwe_SeriesIWarrantsAndSeriesIIWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SeriesIWarrantsAndSeriesIIWarrantsMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrant security classified as series I and series II, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." }, "label": "Series I Warrants and Series II Warrants [Member]", "terseLabel": "Series I Warrants and Series II Warrants [Member]" } }, "auth_ref": [] }, "nuwe_SeriesIWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SeriesIWarrantsMember", "presentation": ["http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrant security classified as series I, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." }, "label": "Series I Warrants [Member]", "terseLabel": "Series I Warrants [Member]" } }, "auth_ref": [] }, "nuwe_SeriesJConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshineheart.com/20240930", "localname": "SeriesJConvertiblePreferredStockMember", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Series J preferred stock." }, "label": "Series J Preferred Stock [Member]", "terseLabel": "Series J Convertible Preferred Stock [Member]", "verboseLabel": "Series J Convertible Preferred Stock [Member]" } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Period of warrants expected to vest", "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } }, "auth_ref": ["r639"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Assumptions used in Black-Scholes Option Pricing Model [Abstract]", "documentation": "Weighted average assumptions used in Black-Scholes option pricing model." } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by

Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth ref": ["r322"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth ref": ["r321"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth ref": ["r323"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Additional Disclosures [Abstract]" } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Stock options expired or forfeited (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth ref": ["r744"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Stock options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth ref": ["r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value of stock options issued (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Outstanding stock options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth ref": ["r302", "r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth ref": ["r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324"] }, "nuve_ShareBasedCompensationAwardTrancheFourMember": { "xbrltype": "domainItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "ShareBasedCompensationAwardTrancheFourMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "documentation": "Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "label": "Share Based Compensation Award Tranche Four [Member]", "terseLabel": "Tranche Four [Member]" } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth ref": ["r738"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Expected Life of options (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth ref": ["r320"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://sunshineheart.com/role/StockbasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Stock options vested (in shares)", "documentation": "Number of options vested." } } }, "auth ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth ref": ["r103", "r112", "r113", "r114", "r140", "r159", "r160", "r163", "r165", "r171", "r172", "r218", "r243", "r245", "r246", "r247", "r250", "r251", "r256", "r257", "r260", "r263", "r270", "r389", "r512", "r513", "r514", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r534", "r564", "r582", "r596", "r597", "r598", "r599", "r600", "r684", "r707", "r713"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth ref": ["r9", "r46", "r49", "r50", "r104", "r130", "r131", "r132", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r170", "r199", "r220", "r233", "r273", "r341", "r342", "r348", "r349", "r350", "r352", "r353", "r354", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r403", "r411", "r494", "r504", "r505", "r506", "r518", "r582"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://sunshineheart.com/role/RevenueRecognitionDetails"] }, "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth ref": ["r181", "r182", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r530", "r531", "r532", "r588", "r590", "r593", "r595", "r602", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r618", "r632", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r667", "r737", "r782", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r142", "r143", "r144", "r170", "r403", "r448", "r511", "r529", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r562", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r668"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlowsAbstract"] }, "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth ref": ["r142", "r143", "r144", "r170", "r184", "r403", "r448", "r511", "r529", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r562", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r668"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "No of warrants converted to equity (in shares)", "terseLabel": "Conversion of preferred stock into common stock (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth ref": ["r9", "r26", "r46", "r49", "r81", "r252"] }, "nuve_StockIssuedDuringPeriodSharesConversionOfWarrants": { "xbrltype": "sharesItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "StockIssuedDuringPeriodSharesConversionOfWarrants", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of warrants." } } }, "label": "Stock Issued During Period, Shares, Conversion of Warrants", "terseLabel": "Conversion of warrants into common stock (in shares)" } } }, "auth ref": [] }, "nuve_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the exercise of warrants." } } }, "label": "Stock Issued During Period, Shares, Exercise of Warrants", "terseLabel": "Exercise of common stock warrants (in shares)" } } }, "auth ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Issuance of common stock, net (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth ref": ["r9", "r45", "r46", "r81", "r512", "r582", "r597"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"] }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation, net (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement." } } }, "auth ref": [] }

```


Issued shares or units issued under employee stock ownership plan (ESOP). } } } . "auth_ref": "r9", "r45", "r46", "r81" } } . "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://sunshineheart.com/role/StockbasedCompensationDetails" ] . "lang": { "en-us": { "role": { "label": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } } . "auth_ref": [ "r9", "r45", "r46", "r81" ] . "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "label": "Conversion of preferred stock into common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } } . "auth_ref": [ "r9", "r46", "r49", "r50", "r81" ] . "nuwe_StockIssuedDuringPeriodValueConversionOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "StockIssuedDuringPeriodValueConversionOfWarrants", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of warrants." } } } . "label": "Stock Issued During Period, Value, Conversion of Warrants", "terseLabel": "Conversion of warrants into common stock" } } } . "auth_ref": [ ] . "nuwe_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the exercise of warrants." } } } . "label": "Stock Issued During Period, Value, Exercise of Warrants", "terseLabel": "Exercise of common stock warrants" } } } . "auth_ref": [ ] . "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "label": "Issuance of common stock, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } } . "auth_ref": [ "r9", "r45", "r46", "r81", "r518", "r582", "r597", "r674" ] . "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation, net", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "auth_ref": [ "r31", "r45", "r46", "r81" ] . "us-gaap_StockOptionMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails" ] . "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "auth_ref": [ "r667" ] . "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "negatedLabel": "Issuance of common stock, net", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } } . "auth_ref": [ "r9", "r45", "r46", "r81", "r518", "r582", "r599", "r674" ] . "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ] . "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } } . "auth_ref": [ "r46", "r49", "r50", "r74", "r545", "r561", "r583", "r584", "r651", "r675", "r708", "r728", "r771", "r813" ] . "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheets", "http://sunshineheart.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Stockholders' equity", "terseLabel": "Stockholders' equity [Abstract]" } } } . "auth_ref": [ ] . "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://sunshineheart.com/role/StockholdersEquity" ] . "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } } . "auth_ref": [ "r78", "r139", "r255", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r273", "r367", "r585", "r586", "r601" ] . "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://sunshineheart.com/role/StockholdersEquityDetails" ] . "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } } . "auth_ref": [ "r82" ] . "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } } . "auth_ref": [ "r400", "r413" ] . "us-gaap_SubsequentEventMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } . "auth_ref": [ "r400", "r413" ] . "us-gaap_SubsequentEventTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } } . "auth_ref": [ "r400", "r413" ] . "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } . "auth_ref": [ "r400", "r413" ] . "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/SubsequentEventsDetails" ] . "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } . "auth_ref": [ "r400", "r413" ] . "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } } . "auth_ref": [ ] . "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" ] . "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } } . "auth_ref": [ ] . "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://sunshineheart.com/role/SubsequentEvents" ] . "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } } . "auth_ref": [ "r412", "r414" ] . "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails", "http://sunshineheart.com/role/StockholdersEquityDetails" ] . "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } } . "auth_ref": [ ] . "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfCashFlows" ] . "lang": { "en-us": { "role": { "label": "Supplemental cash flow information", "auth_ref": [ ] . "nuwe_SupplyAndCollaborationAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "SupplyAndCollaborationAgreementMember", "presentation": [ "http://sunshineheart.com/role/StockholdersEquityDetails"


```

or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }.

"auth_ref": ["r44"] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": { "http://sunshineheart.com/role/RevenueRecognitionDetails": { "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": ["r636", "r737"] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": { "http://sunshineheart.com/role/RevenueRecognitionDetails": { "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": ["r636", "r737"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationPolicies": { "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r95", "r96", "r97", "r721", "r722", "r723"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://sunshineheart.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "nuwe_TradingVolumeForEachTradingDay": { "xbrltype": "monetaryItem", "nsuri": "http://sunshineheart.com/20240930", "localname": "TradingVolumeForEachTradingDay", "crdr": "credit", "presentation": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "documentation": "Trading volume for each trading day during the period.", "label": "Trading Volume for Each Trading Day", "terseLabel": "Trading volume for each trading day" } } }, "auth_ref": [] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": { "http://sunshineheart.com/role/RevenueRecognitionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognized over Time [Member]", "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": ["r636"] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": { "http://sunshineheart.com/role/FairValueOfFinancialInstrumentsDetails": { "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r254", "r268", "r366", "r387", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r495", "r641", "r642", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r724", "r725", "r726", "r727", "r765", "r766", "r767", "r768", "r769", "r770"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "http://sunshineheart.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r355"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763"] }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount", "crdr": "credit", "presentation": { "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Converted warrant", "terseLabel": "Reclassification of warrants to equity", "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount", "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity." } } }, "auth_ref": ["r270", "r272"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationGoingConcernRevenueRecognitionAccountsReceivableAndInventoriesDetails": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Warrants to Purchase Common Stock [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r665", "r666", "r669", "r670", "r671", "r672"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": { "http://sunshineheart.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Warrants term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r766", "r767", "r768"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": { "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails": { "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r158", "r165"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { "http://sunshineheart.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "http://sunshineheart.com/role/NatureOfBusinessAndBasisOfPresentationLossPerShareDetails": { "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units or other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r156", "r165"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-4

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
"Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4", "r653": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147477215/932-235-50-17", "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards  
Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21", "r655": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147477215/932-235-50-29", "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards  
Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3", "r657": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147477916/932-235-55-2", "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards  
Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4", "r659": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147477916/932-235-55-5", "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards  
Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6", "r661": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)",  
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H", "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40",  
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F", "r663": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)",  
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":  
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r665":  
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)  
(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1", "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",  
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6",  
"r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":  
"FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1", "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name":  
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1", "r669": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX  
210.12-12(Column A)Footnote 2(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1", "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef",  
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)Footnote 2)", "Publisher":  
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2", "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":  
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)Footnote 1(a))", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3", "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards  
Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)Footnote 2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-  
6", "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10",  
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10", "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830",  
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11", "r675": { "role":  
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147479168/946-830-55-12", "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240",  
"Section": "12", "Subsection": "b", "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",  
"Subsection": "b-2", "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1",  
"r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a", "r680": { "role":  
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K 10-Q 20-F", "Number": "240", "Section": "13", "Subsection": "a-1", "r681": { "role":  
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "r682": { "role":  
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1", "r683": { "role":  
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405", "r684": { "role":  
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher":  
"FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3", "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification",  
"Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18", "r686": { "role":  
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB",  
"URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B", "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",  
"Section": "140
```

[illegible]

"role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".944". "SubTopic": ".80". "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": ".2", "Subparagraph": "(b)", "Publisher": "FASB". "URL": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r810": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".944", "SubTopic": ".80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": ".2", "Subparagraph": "(c)", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r811": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r812": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147479130/946-210-S99-1", "r813": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r814": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1", "r816": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12(Column A)Footnote 2(i))", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1", "r817": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12(Column A)Footnote 2(j))", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3", "r818": { "role": "http://www.xrbl.org/2009/role/commonPracticeRef", "Topic": ".946", "SubTopic": ".320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)Footnote 2)", "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6", } ZIP 50 0001140361-24-046166-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-046166-xbrl.zip M4\$!#I@ { %&'()*+,-./:;<=>?[]^_`{|}~\"'\" \"> <-P> .C= #NYYNN< :MK.WWU?ZGJ9N-EVIZ?>?M MVIT? 7XVM=?&.C&EIJ&Y->A&Y-VF-AQ-?-?&Y-Z.A.-?.. M2GS?CSH?#=5+8 MUTEO9 =>?>, P.- ?I -80XPXRJK=>Y+- M-Y+NAS(?T... #X? ZV->S?>fj MW,SFX.?08Z? /ROSSO'A==ZI6YZVSOX</R/I TIT6ZOI?<=>NY,Z3-8?W'L MFQA4?TIL?SVZ,WZ.<=>.27WSWG4HXIX<^\\JI9EHK/B?<6WN:N).CI.XI-J+Q.I.MEXX9Z>.+?>?7IAWO?TGSH+6SO&>=>9/U.O.S.(f69z+IG+C^OL3=N<^BW,M.N>NWLOI/? C95IIJZW,NW.#@ PARAZYWLP.@? JLMTE,P.PW9O=M,O7.ON/@(I8-.O.KFEKG.ZI#@OC39IR+8SD,IUT-X&LIONICIULNIJC(O,M.)>+&N+US2LSBKSK5KHBBAB?EMRYNT?SMRYNT+S+2?=RS<^.l@=-16,XKP.JKY.YMM29TA34=? W.DJL< IUUVWEV.HX-K3WIYD>+? V^6o:|WW^IK?,%JO)^&GLX MISKF/JIZRT/ORU?UI2SO.FA'?=>.G2IMI?'> DY&GX^9^-?/9S>F>+1KE'^< M?>CY=>JHS-O^K8HKOM[PV?9H+LKBTOWT:M3MOZ?IO+OK-LISLV-U-C O HIYO M86GCMKR-O54)?/<^//I @. IJ2VI9RIJ?GTW=PZ4AAFO)BDDB-I-9.OIB04(% MO9)PE,RSY? *\$MOD7[9AU+LKAN^KW@.9.MOA8R8?ZIJIF9C2 MI-ID=YWA^AYIDBg,.?OGNIE&?<?/R358IORGCNNB>JDHOOHJ?ZT#+6 +FP.CPI.O4AM9>KYKDGRBV*F DHU.EODE#F008BI.UQ.:XYOV MVL JEKZ7CO=:1#?<^? F/13.^J8LB.L6/(I2)&.@SI.%6C@ET?.'^??TM=ISTCCL.GMOS-V4CMD2.QOI 7_L 3CU6UE.NUYIPOHD FLZ+8V%-%(KO Q> 2 ML \\ RE@I* YLSI -90(C2FMSTIQL.LLNW#IMBEKT4DJ5Z&62# YYVRZMB LGMZ+2KJSREYEIV? .. OIN&PN+ONZJE?LE=LIS=6TI(SIV_F L-M RG3&TL-NLI+6<EF4YHI.VI:CWSWXBS14WR-R:1% 7.22 UJUGSTJUC=C+7KV>=?>70L.S4T 9KRDR.M@F<(COK YJ.48DP(HI#^KKIW?F2 M384A&U?)E?<RA.UDEI?43-(8.OI)%Y6Io=5A2?(2CSIOTINI5? UI#@)=1;%.=>.NF.9L.13ITA4(BRLICLL^ KJR3J(L&XGY?QO,K?K%^+1I26I).9B2TR(G,@BAHUI6A.#@I2.R2WFINN=KLVO7MVVDIJZZP:>.I64PI^XI(+A0IFAJJ34\$&KI^IH7'M/L..MP&K4'=B@ T.X3 IPBG:TVR^H-H^2+c+=NRT2OWI<#-'S DIUR&PKIASCBW.#?<=#(G32%EEN%94AILAM:C6ZVV2/Ell47BL&L R2I6B2?2<c6P(<ZL16\$&#:#&O 9(DJ5# 8&JT2L86K0YSU82M.D&?2TI:IHM@7CGOR:PWT '55VO MUAT0%'>9F2 S2CIIIODZ'D3^<RSSY@KN^?>?>#R+W&K:SEC=8TIUMDH92OIAGCWVZSPW?! OV MRWU<=>EI1FEZ?+AP7I=C \$P.OOF7I_W.P&RRER6W=XWIZX?>?.E-F EYS M>=IRSJG:PPTN3 M3I +-?GAMZSG:?%=@&7&P0& N_P-P W1M.T8T?H8/O^K?&7X?ON3-!!SF M@>5ZG:T&P.MI?OIHA\$?CVYT.# TI:J7IA:KO?<#.S3.997%*>P>S?> MOI^ ONIJA?<S0..#?/L-5ZYK-3C EXB\\)UKSU#@6JAX6C!%6I>IU/XHASI/_9-%Sv2'L+?:SRVG(I MJ.II)IHGN(AOMOIQJ)&X'.&+^ MB-RJOTAKROKS'SVG&O!%XCPCOB@?> M:LZA(AYAI^<\$2YIINSQS<X^?LX+I?95DKNM?ZPD!UU,>FG&+SLMI3HT'I 2ML?U79?>=[SKMW++4.WI: 28(#2K8^R<2M \$EU:15(O MEV+E8R/LBC>+PGFCB@?> B*B*=IU.OMMD+6S'+5(OEV6-YOJ26-[IWOGLM.M+?<:= 9E^<DIJNS2=N:S.YFFVD 7:'=>06+BHR+>#'I?LA(KLYL'U)'9FI9ZNI MN&GOIJOIVOTS2HB\$<40TKRV2D+=LYI4BR2DG4+.E]>RCWBBSB_K'OEWGE?ER<7_M.O.B C69=BOJ66=\$tI9RW(V _I+D=F.I.K:X&MSFDXO'(LU14I3OP&BMACXX CM IHG/C5U,G;&X:- N=#6 '^'1HEMPY?d8DI FI/QIO=U?!'6IY98B4IPRM0=U.M.K3FKXH2JKA:1.6=&+I&C&T_X.ZQB139.X%IVP(U8B5_'L=D''U%>D36 MKV8_-9C>9P-C69YNNG7,QVF^K.X3MY>;.VSLSi3CN'THVHCLO59ICJ>V*MK?RT&OHNB3NUI=8+!O+:U+&W(WOIO^NO& ^N^V%; 3 MMACZ-3ZOK>Z-WP?P'\$ IVENC83Z?@UMCH12I_Z.VYM98&+v8I)& <5A=-X52 M6VK6(T%YR66CN:C@J54T;Z(JI^U7OVX050=-NDG@7Y.O+A::JGD MID<*9's<<-OO6EB[J42 WK^<70_U'8V:1VGIVF536I !?VYY''O+S4RE^E]I MUEE95? HF&I.1.S.PR6:(OI<I&UBUO.Z AN5K1MRU BUQ&37%N!)L/MZZT7QH8 UV@F3V.GJ{HRSO'FH3GG4%4X^<@.LV3IO3MMM,H+I JRU>LD< MX# _JM5366ZF=?> R98++TXZXGWJPL#+YSSIVA ESof7? 2*8%IO?SEOOV MG,UHU&WANL=E SI3UI4WC.GUJK='T\$!@<@%OPCPXS,VTFANI.2H(!< IL DMNGN?<I_{.YCUC/'U}(U52k) @/'T328.::~^*_P 2 =B OR^?TS9.OO MIGVIN)=(M?Z&@&+> XEFI(NOLI44AEVOARENC&G KIIMOZ+> M&@>E9V /E6V +2+UDU?I1FVCVI(M+VRF>? T.WI.14M(^<!OE5.FRHHOTT'E' MYPIE/>[HGICZ3\$? GJDB3@FFPI<@%I2_JF-=H+'RJWJZJF> zep1:2U:KU-l.6 MRX M<MQ(.5LRU)QTP<=>I-K3SK-TYVND/R_I ?O5O?W.ITT+4IT+_V7 MK68.OP^>K3:J8L- 'R2RY2%M.SVOFUU?=.9.O4K7LKIJVWLJIO(QO5TK3.F5M^K^KM-SUM(Y4_*&HDNJ&PF^<:.G8+9H.BX M_O:V9N?6EG-C/GK J3Y?IQT.RB9^I=VWL _>F5.4UUNIZI>2.M9I5.PI@NsZ?> <=667OUVNVNDNJW_I MP'-?>?>4WKI.LWAF2TIZ.Z3C.N57 8<SWY,LJ6<8Y&6&A3MICV54_.M'IJ7U?26WKHUC&DL@L<SNIN9WQIZ?O--7&8&MBELIHW/V_C-/CID2?9 MOF2\$SV* D09L2&W_V_KI6&4I2@&@K*K'TOOEV4(SIAD1ZW>2K26@&=<=< NMW&

[illegible]

[illegible]

[illegible]

[illegible]

MN+OX8#12GGY47WGPZKNWY[*]<= JPP?X6H800E<<1 CV-Z:0W=71; .M.#68\$/'1/O.IH. AK%/Z)B# M 8X8>N(25#P@T.#1ZR=69=>XT\$XCFA MD'.OFLJN*~8*RZCJ]J0>|A>=> &H/A =>?KJ[REI5K>0962+MF+?>=>=O MU70MINX8BSKSOU\$C1'+HN+YCF+H1FBX7V+5H1TJHISV9B\$YR<=> MN9#E7.2 #02.UA+@.61N7VTJ /@+WXRW804030GCM6;P=0^H7+1.R9 M@=>DNY+51M0I28N>?>O5O <=2QJISN145.S62M6^VZ1B>DOZT6L>=> M6C8EK+RU#F NR4Y5Y5N. &3%]>=> KC/ + QS -10EG.GB<@AJHD=14>0QIGTEQO0VYZ.UC' M1G3K#(=> XZ3.A068ZGZ6-NYA.W5.T1J]P>?8B1+XE.PA#A! <5\$2=O MUUY4^YO1>=&(O.S.P Y?>ZDU9V.U]M1+^AIU0UA@#^AIF.X#B22.UM ?.* MX# (?8.R07WK120^TC9*18?> *1^XIM.EFHUIJ.OQOCQW.6G*HGGOV.8UUU.M4.XF3^<Q1R5+>NVAGI9PFRVTD.12A>B01M0Q1P.W/D+H2E.ZP2R^&CO' M*7JA\$\$.GVO;H\$3.6\$&67J1A\$> <@BZXZK3THINIK@&+E7FY2?E.EJYYV#BSYIC91^> MA0!1.2\$%FE.H1H3?>3- &1JW+1B1M4>1^1A1H4Z6.4ET1A7.MRHHXU/1^>B3K3+>1+H6MTC6.\$S\$&UC#> XKG.W357DV.YY=3X!<= M/TF*K\$&SRT.5CY1@.TL1..M3X\$>_DIBC \$>J4DU.Y2.AS.ZQUUBH+6>V@.1!@.M#>=D1%\$.0D4O@D/4S\$&\$.B;3YIKO)7+!Q4>=O!0E_UVOKJAKJ0B)^!AT.M&96G3NM2E?7*63P24*26R2M^TU1? JHCHEUM?>#6P.K+V+.AHUT+V1@>+V1^>OE7?>2C\$5F^W0#1JFR2MJB0=>3^YB?57>ZD1!@.DVE^>C.T.5_ULG^?M2^AT.EG>@&MS&UOGJ+K1EJKTZ\$H\$.DP5<= M@WA#11BX#^16+>1@1TFDD<QJ8+>+6+!B+IKO!E3<1^>?%88ETCD9293X1!..T+M!>#&4%I/V..1BD@E3+>BM0+!JGLYQS7A.C#KF.L^1^3Z?#61!GS@GK.4.FBA_ZO>+M^V!>M^VU.SU.MW!X.#>D1..DL2..2Q\$.H^6!EJEK>J#B#V1V!66 39!>9X<=>@B3PEM?P=JZU.M!>UNNU>Z<3L_IYV+1^>?K92?2U4)9GRL^&ONS\$!&H.M9.N.#>#&\$.N%3.QY+V^**1^!AVH7WTF.@5\$S.YB^!<=<9!^!M6I2N.C9M5SEK&984#&6\$FWK!>^!^2.K.#&@<DAVE.6Y^!Y<1^!>L\$AM5X=29WZE.M14XZ\$5M6<.<1.6=>=ZG.EH.L\$.S.Q002%KDFH+>V@D&FY9)7.MBR.FE#M=U8%G.#&@15;L\$EM\$&R^EUK2>R^R^Y2JHTE\$?>?B\$OQC!6P?M13QIP.VM32455H.L\$P.GZPQK9^A4A0Q^X#D1.968PB1B.B95AH\$4.9)2B/M4WM/W.M14L0?> 6_<CE83EUKV7MNT.O8M8J(7%5Y^>UT@IG@I6P2R^AP.D.GG\$&S0?M5X!>H?>LJKL2L@&F67.29518+&8H1W4L^&T3CAP@&T6W(8KM.XL6C+!97.M.GJTUM1D>V>vXG&\$&^W>C^AZK<=<5MVU.Y>=>JE\$!9?U2V20E.U!>=V^R0'.M&O)2..5E48+4RG\$53MH5!G1C3P#K.FDK(\$0+!+>#>N^Y>=>=>8!SFRP^<K1G=>IO.ML.R^KMV1\$+!+H.L.1Z!%K\$H=\$\$;~?V2X.W8.RJ&XJC0=3/NOK<=<IMU19X.MK0J1#981.S1OA.T5\$>~BTEVD647M2U93.S!@#(LDOIW!>+L.PXG.EH.M9^>P2F?O>V=>C.V4P.^!H^!W1%0!>=W\$#0.._P_@0GGXU000%68_V%NHL.A7N=>=>M^HYMH2O>|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p>
</div>
<div data-bbox=

[illegible]

~~1?0?X\KQ~~

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

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

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f>+TIC^>4CV^52^H2Z_X>0IGZ13^>3^<4I#^+>A^MO^>30X3_VV2B768FH3.DS.H0^J5(L1^59_1J2^HGBI^MH0I^ZMSH3^+N2IG.D2U^>@PHT^?S105I08.&F^?7Y/A67JCMS2WH_4 M^X1+544_K%52^0^JDI^?2N^S^PS&H\$00Q^WTK8IK00M^>B6(5_PSK=>^7Y^ZIE MYENY0S_8(16^TZ25SZR8.3<1=Z8V^_M^0Y3_VZCUEVFMH>@(&F^B10 M^4JH^KJ XNH4M\$2%5L77M>+V/&f5_277SLA&+1\$1_4S^?FM;JPNSBP M,D%R40/YJ@^UG8L1PAJ&(+IY8YEL/3FE=<1<>H^".P04^_XH0N01B7R(PT(AE MLC+733I/\$+H4I 76JGY6NS;J44@WDBHJ>U_P7.914YR@C^F^J+>A^*NKM2CYLV^>4BP;O0E0\$1 MVS;J73U=^?>JRSJ^F7>Z07^_1Q8N0YM9_R_Y>V^F14^4TWP_90 M0Y^?JDS>?>D(f\$8G? QC&A1^2_1@1@UAYVHYW+16GRMLR61BPD/HW1^M^<40^_OR_63E^=CHH^UJK_1E^F^PNHJH^2%+F&AOHR^>=^1^#Q^4APZ M7^<8;10^>OXYLU? 1.D.38F4HPW^BN09T^<M^<M^<4U1^>H/8^>1S M&P131S+AKK(1+G^&EGS69^_TGV;FS&R^E=5E.WMZEHE@Z6.U^*G<+T M.WV^G^A^2^B5#^?FPC6Y021D0ZF+Z6 1X(58Z4U^Y6C&X_ZEM41DF65N=1 MGFU>1%1FEEZ3.N)^>7^<10="G^1^U9=81^82YV127SGEZ@H M9=^H1H^>9^<G1<7^M^G^6E216G;BMZS;UE^Y2B;440U1=;8;9I M+U>JRZ^H8_CJ4K0PRB^0PY7Q&FH82R^3&(&E4C14B^47(8=U/X)^40I+5 M71307@VTE=W^F^>WDV@4 FF^>NXDK-G_6XL13K3>H6XT2D>NM(f2M&SK1_M#L<f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fTE:56.@AL45^>T1^A^>P@=?&.\$f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s&1^>J^>T1K^>?01^>AYX^>J^>P^>RM^K^>BYVO<2^>MBW1^>@O&X^>9 PK^>A98<6>=^>FTYQI04EM^>51LW7^>2ANX^>MX8>0&@>O\$>2>377^>MZK^&C.AQ96KK0? 1&A1^&@R&WAIW19X.%@O^>Z20H@>^>C^>PBJ\$X^>fFE^>6 M7^>_A52^>?U72P.SXY+>U^>W1S^>U8TQFZ0^>H^>4JD@M5T^>LZQNK&1^>H2QNK&16 M&X0VA1^>VYSG1BM^>@=> >2008A PG.RH@ZP9ARV8DE4I@&V372+>R^>S1U4T MWF@81&S^>=A37G4\$^>7JIT^>H<9+H1F1342^>Y^>B.W>=X^>Z+ZRU06^>RJL^> MD6f6S6S5U90E1H^>1^>V8;S1^>YDDB&^>BL^>fC^>P^>35G^>F^>SWR&X^>U^>(KT0B0^>M10SOHPSB^>Z49C^>21^>X0Q^>Z1A37&S^>G10 M^>X>N2H1Z41WC.R#M4>=>N1F1<1%G9XG ^>fZB-HB;MK.#S.ODW+R@.0-EJ2DKI/P?^>#Y01U=IVS^>W&ZFED;8MW,S>L1&4.RB;^&^>MAT2N0R0^>M1)M@Y0PIE^>^>G1^>T^>M2RPT1^>1^>QUOI^>*>V=1^>V7+^>@+>6K M^>N^>? &EGS;3WI+>@BT4+>01.IXA01^>PPB^>AT^>^>N^>G^>N^>?>U^>EU(f12^>41^>4^>8BE>=MP2+1^>M^>X^>Y^>f3T3>=>M1^>T^>HA6BKT<@.SSdM066z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f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f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f9^>F^>M^>J^>U^>4#1^>^>CX>2+>SEN^>S00&4T7+>A^>W19I L^>O\$>7^>H1^>8I^>SC_>1^>#K^>W1^>MR^>60M5>37^>C^>O^>D^>C^>B^>f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

0E5^>#0H^>E3^>D1L^>#^>XA3C.05;_ M5AH+3R&@OJK^>9D^>CE^>E3+Q^>E16M3^>#10E57%>D&CUP_H1A^>#5%>%(1)0^>M^>_US^>fE&NYSU^>V^>H^>1^>1&1^>Q10^>YHT&I <00@fTG1^>4%\$^>BEK^>ZV7X^>5^>M3S0O^>QT2^>16LMK^>0^>G1XP121>=5^>1^>E^>ZW^>SP^>CC2^>V^>+A012^>7Y^>WJDP21^>MOV(\$1^>DKF^>OY^>0^> 4=YHHHOT4NRK;G1&S^>Y4RYU^>S1S^>YQ&1S16H1^>I^>M^>X^>X^>1^>H^>S^>H16+^>Y^>N^>Q^>K1=1^>4R5Z^>N^>1^>)O15^>5NE8^>=530M^>1^>63 ML@S^>?>F7#@>XSG1A^>5HJ&R^>Y^>WGBX^>#^>1Q6_84^K1>+DOM^>#S1HYA^>OR12>9FIY^>MWO^>A^>10S^>Z>7>QK5EOHG^>MBJHNBH^>PIR^>A^>??>)G.ISD61^>H4&KS0BOAK1^> <V^>9U^>C^>1^>A^>1^>#^>MBPD1^>fU8H1^>G^>H1EE+1^>4L^>6C^>6&^>IP6<G^>9^K1V_N1^>L^>G^>+f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f^>H^>9L8^>7^>MYIDS2.F^>#1^>U9.^>f36^>5^>OPFLZIS^>J^>0C2^>EHMB/6.UFCW(\$/SR\$)^>5^>F64^>MT8S4^>/_@E67G6WIE X+L^>M^>V8 E.SSB^>#2H+1^>(V^KY^>U^>A^>6^>65E^>f57^>H0^>U^>M80FOXE1^>f5E79W^>L2^>2&S1^>1^>R^K^>?^>2^>S1^>V^>N^>O^>W^>F&S^>9^>P^>9^>83^>H0^>+>M^>Z^>MDY^>R&G^>W^>X7^>1.55^>O1T1N^>1^>HGR1^>L^> M^K1B;C^>4074^>A1^>5TK3Z^>KEE5^>S^>^>R^>D1^>L^>U^>=>S^>H^>4H&GL^>VE^>T^>2Y1^>F^>M^>L^>2^>S1^>@^>W^>H1^>A6W1PU^>#^>N^>1^>D91^>H1^>TQPIR^>P^KB^>1^>SOO^>H&K^>A8A^>AMT14^>(<4> M9W>=>@>78YK5^>170^>91NN4B2^>9@>1^>H^>WDBY^>1^>UTBPR.N^>U2^>VELH^>H7Z^>BA MD^>7030101^>CBH^>54^>4^>R^>Y^>T^>U^>K^>U^>K^>M^>H^>M^>1^>C4IT^>TW^>X^>K^>L^>#^>N^>O^>V^>W^>OZ^>I^>R^>Y^>NCD? AGCY92M^>YU^>f^>M^>X^>M^>Y^>K^>J^>@^>C^>M^>H^>A1^>H4^>X^>R^>O5RAN\$0KMB1B(f6C70H1^>Y00E1^>=10E923+3^>M^>4^>1^>5^>T9121^>Y2W^>9^>N2^>L^>4^>Y^>Y^&

+I2%P:3GUFNMCY2LPTUG+JCC%>I371#0YRA6 M7 -I^~750X%~KVAL^S-RFP-VV:31Z^C,I8#IDCF)-OS6W7T9~5FASE4-MARTA5?
%RILBI%+MJ#PLCJNKITDGF%F^SALXGWH:4T^+<ITFNKNP/#HLD M=1&OK:~"~F%NUNK&PYC%0IAKU0CV^B6.#P=18ZRZYX#LHERNPT(EYI;H+3
MYB3:IGX~*%(EE%>3N^I+I+(-E=XS:U+G,B1>=UVR^A9E<K=3QU M2IO:K+A~%#4W416MDGA^Q=5V1=)XKS)JH36?>K0^L,D6,B9,3#M0VRIH MD+IAT^RIMBG 6@>7DI:
~0XZ~I=WE5UW^MN4I+HPI@RPG6^*MR(0@>D4^LXN+ M^3JF I30H^L:X7I7VH^U^5J+52G3XW5^K55#F5<1^UCV-MIO^5XJBBHR^BTO%?
L^Q1DID\$993%+H.29%YNAHF.W.<5TOJ~W#\$8 M+HIT%QU# HE^UY9//Y2:,4*KT35>*+T^GOZ,&\$DD<~"~G^D\$^YC.%~I207.%94KN; M/(DIF^V8Q^I@0(2RD.%S2:
\$4&MJ9C^4U77YIM%#%:/U G+4Y~WM193^X MEI2308I+>M2IT^6?~#IN%7LDSU>><^<#;L^6ET^DC01IXT^YR7H545 M4P2M.B~.0YKB
M77BI\$=YVW/BS+9TMIH^K~I%67%~QFVWK~HJK\$ I1# M=ZHR#NIHTS 7IPI@377ZLS\$S 05^H2TIF4Y>>XU9I3WURM@BYIN=32IS M2B=C2>.B/P*=V.I CRECXCG
K.C&EL2V:MSI@>TTHREHS?76E> M415MUA0=4^C.O1P93+D^1EOHX^I(SU238^D9:9H;K Q/OZB OW^P=0 M2PS^% 4~I~<609I^S^KRX 0^:410 \$@>~\$ M968R.# S-
4X.5I%~N:IM4\$LI A0#% @ 7%L68L^E-8W9 7<^I M4 I+I+<I^k5E.C.P.SOU2%#297@5+3\$S+FAI:51^I04 M-Q0 (%R:L%GYOCQ=20&KPA 5~58~>IE9G(P.M.#T-
3@Q7V5X.RTO~YH=&U02P\$^% 4~I~<60QK8.FLK4) #B.0 M%0 @ \$%)@ (968R.# S=4X.5I^E>#Q+3\$N:IM4\$LI A0# M% @ 7%L6/LP/TV^0 23\$ I4 I+IBI^&5E.C P.M.SOU.#%?
97@S.2TR+FAI:51+ 04 Q0 (%R:L%F5IHBP0 *0/ 5 M~5HY^IE9C(P.#T+3@Q7V5X.C.M.2YH=&U02P\$^% 4 M~I~<609CJYV.N(\$ I\$E@ %0 @ \$8@ (968R.# S M-
#4X.5I^E~R+3(N:IM4\$LI A0#% @ 7%L6>\$OIS^A#% @ B0 I\$ M I(#4~&YU=V4M.C.R M^Y.S N>~D4\$LI A0#% @ M7(%L60I^PS@0^0 X^ I4 I+G5\$~&YU=V4M.C.R M^Y.M.SI?
8V%I+GAM%> 04 Q0 (%R:L%DSG.&I#<~I P5 M~>=>@ I^N=7+S(C.P.VOP.3.P7VI9BYX:6002PS^% 4~I~<60Q9 PTBNCB2^I P@ %0 @ \$E@ (G5W92TR.#(T.#DS
M%L68L%>+UL4\$LI A0#% @ 7%L614IKOY4=2@ HL\$ I4 M I^YD#&YU=V4M.C.R M^Y.SI?<^E+GAM;I+I08 ~.IT# I^YXML 51^I200434581 I0q-htm.xml IDEA: XBRL
DOCUMENT 0001506492 2024-01-012024-09-30 0001506492 2024-11-08 0001506492 2023-12-31 0001506492 2024-09-30 0001506492 us-
gaap:SeriesPreferredStockMember 2023-12-31 0001506492 us-gaap:SeriesPreferredStockMember 2024-09-30 0001506492 us-gaap:SeriesPreferredStockMember 2024-09-30 0001506492 us-gaap:SeriesPreferredStockMember 2023-12-31 0001506492
nuwe:SeriesPreferredStockMember 2023-12-31 0001506492 nuwe:SeriesPreferredStockMember 2023-12-31 0001506492
nuwe:SeriesPreferredStockMember 2024-09-30 0001506492 2023-07-012023-09-30 0001506492 2023-01-012023-09-30 0001506492 2024-07-012024-09-30 0001506492 us-
gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506492 us-gaap:CommonStockMember 2022-12-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember
2023-12-31 0001506492 us-gaap:RetainedEarningsMember 2022-12-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001506492 us-
gaap:CommonStockMember 2023-12-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506492 2022-12-31 0001506492 us-
gaap:RetainedEarningsMember 2023-12-31 0001506492 us-gaap:CommonStockMember 2023-07-012023-09-30 0001506492 us-gaap:CommonStockMember 2023-04-012023-
06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-012023-06-30 0001506492 us-gaap:RetainedEarningsMember 2023-07-012023-09-30
0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001506492 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001506492 2023-01-
012023-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-
012023-03-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-012024-06-30 0001506492 us-gaap:RetainedEarningsMember 2024-04-012024-06-30
0001506492 2024-01-012024-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001506492 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-07-012024-09-30 0001506492 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001506492 us-
gaap:RetainedEarningsMember 2023-01-012023-03-31 0001506492 us-gaap:CommonStockMember 2024-01-012024-03-31 0001506492 us-gaap:RetainedEarningsMember
2023-04-012023-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-012023-09-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-
01-012024-03-31 0001506492 2024-04-012024-06-30 0001506492 2023-04-012023-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31
0001506492 us-gaap:CommonStockMember 2024-04-012024-06-30 0001506492 us-gaap:CommonStockMember 2024-07-012024-09-30 0001506492 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001506492 us-
gaap:CommonStockMember 2023-01-012023-03-31 0001506492 nuwe:SeriesPreferredStockMember us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-03-
31 0001506492 nuwe:SeriesPreferredStockMember us-gaap:CommonStockMember 2024-01-012024-03-31 0001506492 nuwe:SeriesPreferredStockMember us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001506492 nuwe:SeriesPreferredStockMember 2024-01-012024-03-31 0001506492
nuwe:SeriesPreferredStockMember us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001506492 us-gaap:CommonStockMember 2023-09-30 0001506492 2023-03-
31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506492 2024-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30
0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001506492 us-
gaap:RetainedEarningsMember 2023-09-30 0001506492 us-gaap:CommonStockMember 2023-03-31 0001506492 us-gaap:CommonStockMember 2024-06-30 0001506492 us-
gaap:RetainedEarningsMember 2023-06-30 0001506492 us-gaap:RetainedEarningsMember 2024-03-31 0001506492 us-gaap:CommonStockMember 2024-03-31 0001506492
us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001506492 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001506492 2023-06-30 0001506492 2024-03-31 0001506492 2023-09-30 0001506492 us-gaap:RetainedEarningsMember
2024-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001506492 us-gaap:RetainedEarningsMember 2023-03-31 0001506492 us-
gaap:CommonStockMember 2023-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-06-30
0001506492 us-gaap:RetainedEarningsMember 2024-09-30 0001506492 us-gaap:CommonStockMember 2024-09-30 0001506492 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001506492
nuwe:August2024OfferingMember nuwe:SecuritiesPurchaseAgreementMember 2024-08-232024-08-23 0001506492 nuwe:SecuritiesPurchaseAgreementMember 2024-07-
242024-07-24 0001506492 nuwe:April2024OfferingMember 2024-04-302024-04-30 0001506492 nuwe:April2024OfferingMember 2024-04-30 0001506492
nuwe:SecuritiesPurchaseAgreementMember 2024-07-24 0001506492 nuwe:August2024OfferingMember 2024-08-23 0001506492
nuwe:August2024OfferingMember nuwe:SecuritiesPurchaseAgreementMember 2024-08-23 0001506492 us-gaap:SubsequentEventMember 2024-11-05 0001506492
nuwe:SeriesWarrantsAndSeriesHWarrantsMember us-gaap:SubsequentEventMember 2024-11-05 0001506492 us-gaap:WarrantMember nuwe:April2024OfferingMember 2024-
04-30 0001506492 nuwe:SeriesHWarrantsMember us-gaap:SubsequentEventMember 2024-11-05 0001506492 nuwe:SeriesWarrantsMember us-gaap:SubsequentEventMember 2024-
2024-11-05 0001506492 nuwe:SeriesHWarrantsMember us-gaap:SubsequentEventMember 2024-11-052024-11-05 0001506492 nuwe:SeriesWarrantsMember us-
gaap:SubsequentEventMember 2024-11-052024-11-05 0001506492 us-gaap:WarrantMember nuwe:April2024OfferingMember 2024-04-302024-04-30 0001506492
nuwe:August2024OfferingMember 2024-08-232024-08-23 0001506492 us-gaap:SubsequentEventMember 2024-11-052024-11-05 0001506492 us-gaap:SalesMember 2024-07-
012024-09-30 0001506492 us-gaap:AccountsReceivableMember 2024-01-012024-09-30 0001506492 us-gaap:AccountsReceivableMember 2023-01-012023-12-31 0001506492
us-gaap:SalesMember 2023-01-012023-09-30 0001506492 us-gaap:SalesMember 2024-01-012024-09-30 0001506492 us-gaap:SalesMember 2023-07-012023-09-30
0001506492 nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001506492
nuwe:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001506492
nuwe:CustomerTwoMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0001506492 nuwe:CustomerOneMember us-
gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001506492 nuwe:CustomerOneMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001506492 nuwe:CustomerOneMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001506492 nuwe:CustomerTwoMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001506492 nuwe:CustomerTwoMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember
2024-07-012024-09-30 0001506492 nuwe:CustomerTwoMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001506492
nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001506492 nuwe:CustomerOneMember us-
gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001506492 us-gaap:WarrantMember 2023-01-012023-09-30 0001506492
nuwe:SeriesConvertiblePreferredStockMember 2024-01-012024-09-30 0001506492 us-gaap:WarrantMember 2024-01-012024-09-30 0001506492 us-
gaap:SeriesPreferredStockMember 2023-01-012023-09-30 0001506492 us-gaap:SeriesPreferredStockMember 2024-01-012024-09-30 0001506492 us-
gaap:StockOptionMember 2024-01-012024-09-30 0001506492 nuwe:SeriesConvertiblePreferredStockMember 2023-01-012023-09-30 0001506492 us-
gaap:StockOptionMember 2023-01-012023-09-30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-
gaap:TransferredOverTimeMember 2024-07-012024-09-30 0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2023-07-012023-09-30 0001506492 srt:MaximumMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2023-01-012023-09-30 0001506492 us-
gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-07-012024-09-30 0001506492
srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2023-07-012023-09-30 0001506492
us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2023-01-012023-09-30
0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-01-012024-09-
30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-01-012024-
09-30 0001506492 2024-10-01 2024-09-30 0001506492 us-gaap:SeriesPreferredStockMember 2024-01-012024-09-30 0001506492 us-gaap:SeriesPreferredStockMember
2017-11-27 0001506492 us-gaap:SeriesPreferredStockMember 2017-11-272017-11-27 0001506492 us-gaap:SeriesPreferredStockMember 2024-08-23 0001506492
nuwe:july2024OfferingMember nuwe:SecuritiesPurchaseAgreementMember 2024-07-242024-07-24 0001506492 nuwe:AtTheMarketOfferingMember 2023-01-012023-12-31
0001506492 nuwe:SeriesConvertiblePreferredStockMember nuwe:October2023OfferingMember 2023-10-122023-10-12 0001506492
srt:MaximumMember nuwe:SupplyAndCollaborationAgreementMember 2024-01-012024-09-30 0001506492 nuwe:April2024OfferingMember 2024-08-13 0001506492
nuwe:SeriesConvertiblePreferredStockMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember nuwe:October2023OfferingMember 2023-10-17
0001506492 nuwe:july2024OfferingMember nuwe:SecuritiesPurchaseAgreementMember 2024-07-24 0001506492
nuwe:SeriesConvertiblePreferredStockMember nuwe:October2023OfferingMember 2023-10-12 0001506492
nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember 2023-06-19 0001506492 nuwe:SeriesConvertiblePreferredStockMember us-
gaap:CommonStockMember nuwe:October2023OfferingMember 2023-10-12 0001506492 nuwe:April2024OfferingMember 2024-09-30 0001506492
nuwe:August2024OfferingMember 2024-08-30 0001506492 nuwe:April2024OfferingMember 2024-07-012024-09-30 0001506492
srt:MaximumMember nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember 2023-06-192023-06-19 0001506492
nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember 2023-06-192023-06-19 0001506492
nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember nuwe:ShareBasedCompensationAwardTrancheFourMember 2023-06-192023-06-19 0001506492
nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-06-192023-06-19
0001506492 nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-06-192023-
06-19 0001506492 nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-06-
192023-06-19 0001506492 nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember nuwe:ShareBasedCompensationAwardTrancheFourMember 2024-01-
012024-09-30 0001506492 nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-
01-012024-09-30 0001506492 nuwe:DaVitaWarrantMember nuwe:SupplyAndCollaborationAgreementMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember
2024-01-012024-09-30 0001506492
nuwe:SeriesConvertiblePreferredStockMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember nuwe:October2023OfferingMember 2024-09-30
0001506492 nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember nuwe:October2023OfferingMember 2023-10-172023-10-17 0001506492
srt:MinimumMember us-gaap:SeriesPreferredStockMember 2019-03-122019-03-12 0001506492 srt:MaximumMember us-gaap:SeriesPreferredStockMember 2019-03-
122019-03-12 0001506492 nuwe:AtTheMarketOfferingMember 2024-01-012024-09-30 0001506492 nuwe:April2024OfferingMember 2024-01-012024-09-30 0001506492 us-
gaap:WarrantMember nuwe:April2024OfferingMember 2024-01-012024-09-30 0001506492 us-gaap:WarrantMember nuwe:April2024OfferingMember 2024-09-30 0001506492
nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2023-10-17 0001506492 srt:MinimumMember 2024-06-062024-06-06 0001506492
srt:MaximumMember 2024-06-062024-06-06 0001506492 2024-06-262024-06-26 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30
0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-
012024-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2023-
07-012023-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0001506492 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-
30 0001506492 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001506492 us-
gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001506492

[illegible]

New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"></br></div><div style="font-weight: normal; font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"></div><div style="font-weight: normal; font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at the market under Nasdaq rules.</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In addition, in a concurrent private placement, the Company issued to the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, were exercisable immediately following the date of issuance and have a term of five years from the date of issuance.</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The closing of the registered direct offering and the concurrent private placement occurred on or about July 25, 2024.</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The gross proceeds to the Company from the registered direct offering and the concurrent private placement, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately \$2.0 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes.</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On August 23, 2024, the Company entered into a placement agency agreement with Eadenburg Thalmann Kamp; Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company's common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant.
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Shares were sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the "SEC") on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering.
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers, warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares.
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: Times New Roman"; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The gross proceeds of the offering, before deducting the Placement Agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, was approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029.
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left;">Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services. The Board recently authorized the restoration of the Company 401k match effective October 1, 2024.</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left;">On November 5, 2024, the Company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of \$2.10 per share for total gross proceeds of approximately \$3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional \$1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the "Series I Warrants") and Series II common stock purchase warrants (the "Series II Warrants") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of \$1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants.
</div><div>
</div><div>
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: Times New Roman"; font-size: 10pt; font-style: normal; font-variant: normal; text-align: left;">
</div><div style="background-color: rgb(255, 255, 255);">
</div><div style="background-color: rgb(255, 255, 255);">
</div><div style="text-align: center;">
</div><div style="text-align: center;">
</div><div style="text-align: center;">
</div><div style="text-align: center;">
</div><div style="text-align: center;"><span style="font-family

[illegible]

[illegible]

[illegible]

[illegible]

Room, text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On August 23, 2024, the Company entered into a placement agency agreement with Eadenburg Thalmann & Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company's common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant.
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Shares were sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the "SEC") on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering.
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares.
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The gross proceeds of the offering, before deducting the Placement Agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, was approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029.
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Understanding the near-term need to raise capital, the Company has recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions include, but are not limited to the following: selected job eliminations, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of Company 401k match, travel reductions, and reductions to select professional services. The Board recently authorized the restoration of the Company 401k match effective October 1, 2024.</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;">
</div><div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Revenue from product sales is recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company's standard shipping terms are FOB shipping point unless the customer requests that control and title to the inventory transfer upon delivery.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company's contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers whose related revenue is recognized over time. This revenue represents less than 1% of net sales for the three and nine months ended September 30, 2024 and 2023. The unfulfilled performance obligations related to these extended service plans are included in deferred revenue, which is included in other current liabilities on the condensed consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Sales taxes and value added taxes in foreign jurisdictions are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Product Returns

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company offers customers a limited right of return for its products in case of non-conformity or performance issues. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own historical sales and returns information. The Company has received minimal returns to date and believes that future returns of its product will be minimal. Therefore, revenue recognized is not currently impacted by variable consideration related to product returns.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 – Stockholders' Equity

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Series F Convertible Preferred Stock

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On November 27, 2017, the Company closed an underwritten public offering of Series F convertible preferred stock and warrants to purchase shares of common stock. The Series F convertible preferred stock has full ratchet price-based anti-dilution protection, subject to customary carve-outs, in the event of a down-round financing at a price per share below the conversion price of the Series F convertible preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company's common stock exceeds 300% of the then-effective conversion price of the Series F convertible preferred stock and the daily dollar trading volume for each trading day during such period exceeds \$7,000,000). Effective for every stock offering or reverse stock split, the conversion price of the Series F convertible preferred stock has been recalculated based on the offering price.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of September 30, 2024, and December 31, 2023, 127 shares of the Series F convertible preferred stock remained outstanding.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">At the Market Program

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In March 2023, the Company filed a Prospectus Supplement to its Registration Statement on Form S-3 with the SEC in connection with a proposed At-the-Market Securities offering (the "At-the-Market Program"). During 2023, the Company issued 18,781 shares of common stock under the At-the-Market Program for gross proceeds of approximately \$2.3 million. Net proceeds totaled approximately \$2.1 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The Company terminated its At-the-Market Program in July of 2024.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Supply Agreement

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On June 19, 2023, we entered into a Supply and Collaboration Agreement (the "Supply Agreement") with DaVita Inc., a Delaware corporation, pursuant to which DaVita would pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive heart failure and related conditions within select U.S. markets. The pilot program, launched by the end of fourth quarter 2023 and extended through May 31, 2024 (the "Pilot Program"). On May 31, 2024, DaVita and Nuwellis amended the Supply and Collaboration Agreement extending the Pilot term through August 31, 2024. Through the Pilot, ultrafiltration therapy using Aquadex would be offered at a combination of DaVita's hospital customer and outpatient center locations, with both companies collaborating on the roll-out of the therapy, clinician training, and patient support. At the conclusion of the Pilot, DaVita had the option, in its sole discretion, to extend the Supply Agreement with the Company for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Ultrafiltration Services Approval

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The parties agreed to terminate the Supply Agreement effective August 21, 2024.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">DaVita Warrant

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The warrant was expected to vest in four tranches as follows: (i) 25% upon receipt of notice to extend the Supply Agreement past the initial pilot term; (ii) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within twelve months of Ultrafiltration Services Approval; (iii) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within twenty-four months of Ultrafiltration Services Approval; and (iv) 25% upon the attainment by the Company of a net revenue achievement from DaVita's efforts pursuant to the Supply Agreement within thirty-six months of Ultrafiltration Services Approval. This warrant terminated with the termination of the Supply Agreement on August 21, 2024.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">October 2023 Offering

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On October 12, 2023, Nuwellis, Inc. entered into a Placement Agency Agreement with Lake Street Capital Markets, LLC and Maxim Group LLC, pursuant to which the Company issued and sold, in a best efforts registered public offering by the Company, 150,000 units, with each Unit consisting of (A) one share of the Company's Series J Convertible Redeemable Preferred Stock, par value \$0.0001 per share, and (B) one warrant to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock, at a price to the public of \$15.00 per Unit, less placement agent fees and commissions. The public offering price of \$15.00 per Unit reflects the issuance of the Series J Convertible Preferred Stock with an original issue discount of 40%. The Company also registered under the Registration Statement (as defined below) an additional 362,933 shares of Series J Convertible Preferred Stock that will be issued, if and when the Company's Board of Directors declares such dividends, as paid in-kind dividends and the shares of Common Stock issuable upon conversion of the Series J Convertible Preferred Stock issued as PIK dividends.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Units, the shares of Series J Convertible Preferred Stock, the Warrants, the PIK Dividend Shares, the PIK Conversion Shares as well as the shares of Series J Convertible Preferred Stock issuable upon exercise of the Warrants and the shares of the Company's common stock, par value \$0.0001 per share, issuable upon conversion of the Series J Convertible Preferred Stock, were offered and sold by the Company pursuant to an effective registration statement on Form S-1. The closing of the offering contemplated by the Placement Agency Agreement occurred on October 17, 2023.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On October 17, 2023, the Company also entered into a warrant agency agreement with the Company's transfer agent, Equinix Trust Company, LLC, who acts as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in this offering.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each Warrant has an exercise price of \$262.50 per one-half of one (0.5) share of Series J Convertible Preferred Stock, is immediately exercisable and will expire three (3) years from the date of issuance.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There is no established trading market for the Series J Convertible Preferred Stock or the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Series J Convertible Preferred Stock or the Warrants on The Nasdaq Capital Market or any other national securities exchange or any other nationally recognized trading system.

Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The gross proceeds to the Company from the October 17,

2023. Offering were \$2.25 million. Net proceeds were approximately \$1.5 million after deducting placement agent fees and commissions and Offering expenses payable by the Company. The Company used the net proceeds from the Offering for working capital and for general corporate purposes.

The Series J Convertible Preferred Stock is classified as mezzanine equity and accreted to reflect its redemption value as of each reporting date. The accretion will be reflected as a deemed dividend adjustment to arrive at net loss attributable to common stockholders for earnings per share calculations.

The Warrants are recorded as a liability and re-measured at fair value as of each reporting date with fair value changes being recorded as non-operating income or expense. The Warrants were valued on day 1 and exceeded the gross proceeds of the offering. This resulted in a day 1 financing expense of \$2.7 million.

The common warrants contain a reset of the exercise price, effective upon the Warrant Stockholder Approval, to a price equal to the lesser of (i) the then exercise price, (ii) the lowest volume weighted average price for the trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024. Subsequent to June 30, 2024, the number of shares underlying the common warrants were adjusted to 2,710,734 shares and the exercise price was adjusted to \$2.49 per share. In addition, the common warrants provided for full ratchet anti-dilution adjustment to the exercise price and number of shares underlying the common warrants upon our issuance of our common stock or common stock equivalents at a price per share that is less than the exercise price of the common warrants, subject to certain exemptions. In no event will the exercise price of the common warrants with respect to either adjustment be reduced below a floor price of \$2.10.

The gross proceeds to the Company from the offering, before deducting the placement agent fees and other offering expenses were approximately \$2.7 million.

The warrants had down round protection and the price was reset from the July 2024 and the August 2024 offerings. At the August 2024 offering, the exercise price of these warrants were adjusted to \$2.10, which represented the floor price on these warrants. As the price floor was hit, there was no further down-round protection. The warrants were re-evaluated and classified as equity as of September 30, 2024. During the quarter, there were 398,488 of warrants exercised at a weighted average exercise price of \$2.97. The warrants are fair valued on the date of exercise and the adjustment to fair value is recorded to Additional Paid in Capital. There were 2,651,426 of warrants converted to equity resulting in \$4.2 million to Additional Paid in Capital.

July 2024 Offering:

On July 24, 2024, the Company announced that it had entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of \$4.24 per share of common stock in a registered direct offering priced at the market under Nasdaq rules.

In addition, in a concurrent private placement, the Company issued the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of \$3.99 per share, they will be exercisable immediately following the date of issuance and have a term of five years from the date of issuance. The warrants issued in this offering were concluded to be equity classified.

The closing of the registered direct offering and the concurrent private placement occurred on July 25, 2024.

The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately \$2.0 million. After deducting placement agent fees and other offering expenses payable by the Company, net proceeds were approximately \$1.5 million. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes.

August 2024 Offering:

On August 23, 2024, the Company entered into a placement agency agreement with Ladenburg Thalmann Kamp, Co. Inc. and a securities purchase agreement with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 483,351 shares of the Company's common stock, \$0.0001 par value per share, at a purchase price of \$1.8450 per Share and accompanying Common Warrant.

The Shares were sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-280647), including a base prospectus contained therein, which was originally filed with the Securities and Exchange Commission (the "SEC") on July 1, 2024, and was declared effective by the SEC on July 9, 2024, and a related prospectus supplement, dated August 23, 2024, related to the Registered Offering.

Pursuant to the Purchase Agreement, in a concurrent private placement the Company also agreed to sell and issue to the Purchasers warrants to purchase up to 483,351 shares of Common Stock. The Common Warrants have an exercise price of \$1.72 per share, are immediately exercisable and expire on the fifth anniversary on the effective date of the registration statement to be filed for the purpose of registering the Common Warrant Shares. The warrants issued in this offering were concluded to be equity classified.

The gross proceeds of the Offering, before deducting the Placement Agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants or Placement Agent Warrants, will be approximately \$892,000. The Offering closed on August 26, 2024. The Company also issued to the Placement Agent, or its designees, warrants to purchase up to 14,501 shares of our Common Stock as part of the compensation payable to the Placement Agent in connection with this offering. The Placement Agent Warrants are not registered pursuant to the prospectus supplement and the accompanying prospectus. The Placement Agent Warrants have substantially the same terms as the Common Warrants described above, except that the Placement Agent Warrants will have an exercise price of \$3.04425 per share and will expire August 23, 2029.

Underwriter and Placement Agent Fees

In connection with the offerings described above, the Company paid the underwriter or placement agent, as applicable, an aggregate cash fee of either 7% or 8% of the aggregate gross proceeds raised in each of the offerings.

At the Company's annual meeting of stockholders on June 6, 2024, its stockholders approved a proposal to amend the Company's Fourth Amended and Restated Certificate of Incorporation to effect a reverse split of the Company's outstanding Common Stock at a ratio in the range of 1-for-3 to 1-for-5.

On June 26, 2024, the Company's board of directors approved a 1-for-3 Reverse Stock Split. The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on June 27, 2024, and the Company's common stock began trading on a split-adjusted basis when the market opened on June 28, 2024. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock splits for all periods presented.

Note 4 - Stock-Based Compensation

Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.

The following table presents the classification of stock-based compensation expense recognized for the periods below:

	Three months ended	Year ended
Stock-based compensation expense	\$1,115,490	\$1,115,490
Reverse stock split	(1,115,490)	(1,115,490)
Total	\$0	\$0

Times New Roman'; font-size: 10pt; font-weight: bold; ">Nine months ended September 30, 2024

	2024	2023
Total stock-based compensation expense	\$484	\$101
Research and development expense	\$133	\$135
Other	\$351	\$374

During the three months ended September 30, 2024 and 2023, under the 2017 Equity Incentive Plan, and the 2021 Inducement Plan, the Company granted zero and 532 stock options, respectively, to its directors, officers and employees. During the nine months ended September 30, 2024 and 2023, the Company granted 1,264 and 3,544 stock options, respectively, to its directors, officers and employees. Vesting generally occurs over an immediate to 48-month period based on a time-of-service condition. The weighted-average grant date fair value of the stock options issued during the three months ended September 30, 2024 and 2023 was zero and \$62.65 per share, respectively. The weighted-average grant date fair value of the stock options issued during the nine months ended September 30, 2024 and 2023 was \$24.14 and \$226.26 per share, respectively.

The total number of stock options outstanding as of September 30, 2024 and September 30, 2023 was 3,890 and 3,101, respectively.

During the three months ended September 30, 2024 and 2023, the weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended September 30, 2024 and 2023:

	2024	2023
Expected term	3.00	3.00
Volatility	100%	100%
Dividend yield	0%	0%
Interest rate	5.13%	5.13%

The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended September 30, 2024 and 2023:

	2024	2023
Expected term	3.00	3.00
Volatility	100%	100%
Dividend yield	0%	0%
Interest rate	5.13%	5.13%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

